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SUMMARY
1 /f 3
Carbenoxolone has been labelled with C and H. [ CjCarbenoxolone
administered as a positioned-release capsule to duodenal ulcer patients
1^f 3was shown to be readily absorbed. The fate of [ Cl- and [ Hjcarbenoxolone
administered orally to human volunteers has been investigated. Most of
the dose was recovered as carbenoxolone in the faeces, although a portion
(< 13$) was present as carbenoxolone-30-glucuronide. Peak plasma
concentrations indicated at least 30$ absorption of the dose. Less than
10$ of the dose underwent hydrolysis to enoxolone and succinate, in
contrast to the rat where extensive hydrolysis occurred after oral
1^ fadministration. [1,^ - C^lSuccinate was rapidly and almost completely
1*fmetabolised to respiratory CO2 in a human volunteer.
1 f^No significant hydrolysis of [ Cjcarbenoxolone occurred after 
administration to intact or biliary-cannulated squirrel monkeys. 
Carbenoxolone was excreted in the bile mainly as carbenoxolone-30-glucuronid 
Conjugation appeared to be a pre-requisite for biliary excretion and 
conjugates were excreted against a concentration gradient. A species 
difference in metabolism between primates (man and squirrel monkey) and 
the rat was attributed to the gastrointestinal microflora.
Carbenoxolone has been found to be highly bound to the plasma
proteins of man and common laboratory species. The binding was
investigated by a variety of methods to obtain quantitative and qualitative
7data on the interaction. Albumin had a very high affinity (k > 10 ) for 
carbenoxolone and was found to be the principal binding protein in human
plasma, although binding to globulins also occurred; carbenoxolone also 
induced a conformational change in the albumin. The distribution of 
[ C]carbenoxolone in the rat showed that it was confined largely to the 
gastrointestinal tract, liver and plasma.
Pretreatment of rats with carbenoxolone had no significant effect
on various hepatic microsomal enzymes concerned with the metabolism of
drugs and steroids. Neither did such pretreatment influence the biliary
3
and urinary excretion of [ Hjcortisol and its metabolites.
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When the Stranger says: ’What is the meaning of this city?
Do you huddle close together because you love each other? 
What will you answer? ’We all dwell together 
To make money from each other'? or 
'This is a community'
T.S. ELIOT.
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CHAPTER ONE
Carbenoxolone (3-0-|3-carboxypropionyl-11-oxo-l8(3-olean-12-en-30-oic 
acid, the hemisuccinate of l8f3-glycyrrhetic acid) is a drug used in the 
treatment of gastric and duodenal ulcer (Robson & Sullivan, 1968; 
•Langman, 1968). This chapter contains a brief review of its known 
chemical and biological properties, development as a therapeutic agent 
and a discussion of the scope of the present work. It is a triterpenoid 
known to have some corticosteroid-like properties and it is a good 
example of a drug that has been developed from an active principle of
vegetable origin. (Parke & Williams
1) Chemistry of Carbenoxolone
Fig 1-1 ' Formulae of Enoxolone,
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18P-GLycyrrhetic acid (approved name: enoxolone) is the parent
acid of carbenoxolone which is the hemisuccinate ester of enoxolone.
The metabolism of enoxolone and to a lesser extent carbenoxolone has 
recently been studied by Iveson (1968). Enoxolone is a triterpenoid 
of the P-amyrin series which is naturally occurring in the form of the 
diglucuronate glycyrrhizic acid, present in the root and stolons of the 
liquorice plant Glycyrrhiza glabra.
The isolation of glycyrrhizic acid from liquorice extract was 
first described by Tschirch and Cederberg (1907)« It is a white 
crystalline powder soluble in water and on hydrolysis with acid yields 
two molecules of glucuronic acid and the aglycone glycyrrhetic acid, 
a white crystalline compound insoluble in water. Glycyrrhetic acid 
has not been prepared synthetically. Carbenoxolone is prepared by 
refluxing anhydrous l8p-glycyrrhetic acid with succinic anhydride in 
pyridine. (Turner & Wotten, 1939? unpublished method).
The chemistry of glycyrrhetic acid and the p-amyrin series of 
triterpenes has been discussed by Simonsen & Ross (1937)• Ihe 
compound was first described by Tschirch & Cederberg (1907) who obtained 
it by hydrolysis of the glycoside which Vogel (18^ 3) had shown to 
occur in liquorice. Its chemistry has since been studied extensively 
by Ruzicka and co-workers (Ruzicka & Leuenberger, 1936; Ruzicka, et_al., 
1937; Ruzicka 8c Marxer, 1939; Ruzicka 8c Jeger, 19^ 2; Ruzicka, Jeger 
8c Winter, 19^ -3 ) and also by Bilham, Kon 8c Ross (19^ 2). Glycyrrhetic 
acid is known to exist in two interconvertible isomeric forms.with 
different configurations at C-18.
The two isomers are:-
COOH
COOH
Me
a -form (3-form
These two forms of glycyrrhetic acid have different pharmacological 
activities and a lot of the clinical evaluation of liquorice preparations 
has been of dubious value because of their unknown isomeric composition. 
The stereochemistry of the junctions of rings A, B, C and D is the 
same as in allopregnane.
Carbenoxolone is a weak dibasic acid (pk', 6.7; pk" 7»1) which
like enoxolone is insoluble in water and soluble in chloroform, ethanol,
methanol, n-heptane and a variety of other organic solvents. In common
with the structurally related sapogenins it appears to have some
-5surface-active properties for when a solution (10 M) of the sodium 
salt in water is agitated considerable frothing occurs,
Carbenoxolone labelled, with carbon-14 in the one and four 
positions of the succinate side chain, and also randomly labelled 
with tritium has been used in some of the studies undertaken and the 
preparation of these isotopically labelled compounds is described later.
2) Therapeutic Uses of Carbenoxolone
a) Topical Use of Enoxolone.
Early clinical work with the parent compound enoxolone involved 
its use as a topical anti-inflammatory agent when applied to certain 
skin conditions. It was introduced into dermatological practice by 
Adamson & Tillman (1955) and a number of trials claimed that it was 
useful in this respect (Evans, 1956, 1958; Annan, 1957> Chakravorti,
1957; Sommerville, 1957; Colin-Jones 8c Somers, 1957; Colin-Jones, 1957? 
1959, 1960) while other trials revealed no useful topical anti­
inflammatory effect (Warin & Evans, 1956; Bettley, 1956; Russel, 1956; 
McCallum, 1956; Hall 8c Jefferson, 1956; Wilson 8c Edwards, 1 9 5 8 ). As 
Colin-Jones 8c Somers (1957) pointed out the reason for the discrepancies 
in the various trials is likely to be the variable isomeric composition 
of the preparations used. Enoxolone has also been used as a dental 
paste in the treatment of dry socket (Fry 8c Goldman, 1958; Saunders, 1959) 
and it is currently formulated as an adhesive gel for treating mouth 
ulcers.
■V
b) Gastric and Duodenal Ulcer.
Liquorice preparations have been known to be useful, in the 
treatment of various gastric disorders for a long time. The beneficial 
effects of administering crude powdered liquorice extract orally to 
patients suffering from peptic ulcer was reported by Revers (19^ -6) 
and again by Revers (19^ 8). In the period following this,many 
publications appeared in the European, literature describing the clinical 
effects of extracts of liquorice and preparations of glycyrrhizic or
glycyrrhetic acid on gastric and duodenal ulcers and a variety of 
gastro-intestinal disorders. Some of these clinical investigations were 
badly designed, conducted.without proper controls and with patients 
suffering from ill defined ailments. The chemical composition of the 
drugs employed was generally unknown and the nature of the isomers of 
glycyrrhetic acid not appreciated. The results of these trials were 
often conflicting, some being favourable and others not. It was not 
until 1962 when Doll, et al. provided in a controlled clinical trial 
proper scientific proof that a derivative of a constituent of liquorice 
extract had benefit in the treatment of gastric ulcer.
While liquorice and its derivatives were being tested for their 
usefulness against gastric and duodenal ulcer the corticosteroid-like 
properties of glycyrrhetic acid (Card, et al., 1953; Finney, Somers & 
Wilkinson, 1958) stimulated a search for water-soluble derivatives with 
therapeutically useful anti-inflammatory properties. An early member 
of this series of derivatives was the disodium salt of 18(3-glycyrrhetic 
acid hemisuccinate (carbenoxolone sodium) and this showed promising 
anti-inflammatory activity (Brown, et al., 1959)- Carbenoxolone 
administered orally in tablet form was tested in the clinical trial 
by Doll, et al., (1962) and found to have a significant healing effect 
in the treatment of gastric ulcers but not duodenal ulcers. Carbenoxolone 
was administered either as the free acid or the water soluble disodium 
salt and no appreciable difference was observed in the results with the 
two preparations.
Since Dole's original clinical trial there have been a number of 
subsequent trials that have shown carbenoxolone to be efficacious in 
the treatment of gastric ulcer in outpatients (Doll, Hill 8c Hutton, 19&5;
Horwich 8c Galloway, 1965; Turpie 8c Thomson, 1965; Bank, et al., 19^ 7; 
Montgomery, Mehta 8c Lawrence, 1969; ^ d  see also Robson 8c Sullivan,
19&8). Carbenoxolone does not appear to provide any additional benefit 
to inpatients who are undergoing bed rest and have stopped smoking 
(Middleton, et al., 1965)- There appear to be only three measures, bed 
rest, cessation of smoking and administration of carbenoxolone that 
accelerate the healing of gastric ulcer (Langman, 1968). A recent 
preparation containing deglycyrrhizinized powdered block liquorice which 
contains not more than J>% glycyrrhizinic acid (Anon, 1970) has also 
been used to treat gastric ulcers (Turpie, Runcie 8c Thomson, 1969).
However at this limit it is possible that patients could receive 68. mg. 
of glycyrrhizin per day. Glycyrrhizin has been shown to be inactive in 
the treatment of gastric ulcer (Berndt, et al., 1968) but the extent of 
hydrolysis of glycyrrhizin by gastric acid to glycyrrhetic acid is not 
known.
Carbenoxolone in tablet form (trade name: "Biogastrone”) is
ineffectual in duodenal ulcer (Doll, et al., 1962) and becuase the drug 
is largely absorbed from the stomach (iveson, Parke 8c Williams, 1966; 
Downer, Galloway, Harwich 8c Parke, 1970) and assuming that carbenoxolone 
exerts a local action,insufficient drug may reach the duodenum to exert 
its healing effect. In an attempt to overcome this possible disadvantage 
a positioned-release gelatin capsule (trade name: "Duogastrone”) has
been made containing carbenoxolone and carbon dioxide producing excipients 
(tartaric acid and sodium bicarbonate). It is designed to swell with 
the production of carbon dioxide and rupture in the pylorus after 
peristaltic abrasion, liberating its contents into the pylorus and 
duodenum (Craig, et al., 1967). The first, double-blind placebo
controlled trial (Craig, et al., 1967) suggested that this capsule 
was of value in duodenal ulcer and this has been supported by two open 
trials in which the capsules were compared with anticholinergic and 
alkali preparations (Cliff, 1968 ; Lawrence, et al., 1968) .  However in 
another double-blind trial the preliminary results have suggested that 
the capsules were no more effective than the dummy preparation (Colin-Jones, 
et al., 1968) .  A recent trial in fifty-seven male service personnel 
(Cliff & Milton-Thompson, 1970) showed no advantage for carbenoxolone 
although review at three months and at six months revealed a slight but 
clinically insignificant trend in favour of the carbenoxolone group.
Amure (1970) in a smaller double-blind controlled trial of twenty-eight 
patients in Ibadan, Nigeria showed a marked clinical improvement in the 
carbenoxolone treated group. The long-term multicentre trial of this 
preparation that is now in progress may finally determine its efficiency 
in the treatment of duodenal ulcer.
Therapy with carbenoxolone may be complicated by fluid retention, 
resulting in hypertension and oedema, and electrolyte disturbances with 
sodium retention and hypokalaemia (Doll, Hill 8t Hutton, 1965; Horwich 8c 
Galloway, 1965; Turpie 8c Thomson, 1965; Forshaw, 1 9 6 9 ). It is not 
certain whether hypokalaemia is due to redistribution of the ion between 
the intracellular and extracellular compartments (Baron, et al., 1968 ) 
or to a loss of total body potassium (Mohamed, Chapman 8c Crooks, 1966 ) .  
Administration of a thiazide diuretic blocked these side effects and did 
not interfere with ulcer healing, however administration of the 
aldosterone antagonist spironolactone prevented the development of side 
effects but also blocked ulcer healing (Doll, Langman 8c Shawdon, 1968 ) .
It has been observed that spironalactone also inhibits the mineralocoticoid 
activity of liquorice (Salassa, Mattox 8c Rosevear, 1962) .  Reduction of 
the dose of carbenoxolone reduces the frequency of side effects
(Montgomery, 19&7) does not always abolish them (Turpie & Thomson, 19&5) 
and the ulcer healing rate also falls.
c) Miscellaneous Therapeutic Use
Enoxolone has been used in the treatment of Addison's disease 
(Card, et al., 1953; Pelser, et al., 1953) and was said to have 
antileukaemic activity in experimental rats (Logeman, et al., i960) 
though it does not appear to have been tested clinically for this activity. 
The dicholine salt of carbenoxolone has been shown experimentally to have 
antitussive activity (Anderson & Smith, 1961).
3) Pharmacological and Biochemical Properties
Many of the pharmacological and biochemical actions of carbenoxolone 
have recently been discussed (Robson & Sullivan, 1968) and Martin-Smith & 
Sneader (1969) have recently reviewed the biological activity of a large 
number of terpenoids, including carbenoxolone.
a) Anti-inflammatory Properties
The anti-inflammatory activity of carbenoxolone in experimental
animals after parenteral administration was originally reported by
Finney & Somers (1938) and further reports of this activity have appeated
(Finney & Tarnoky, i960; Tangri, et al., 1963; Khan & Sullivan, 1968).
Carbenoxolone has approximately one-third of the activity of cortisol
when measured by the cotton-pellet test (Khan & Sullivan, 1968).
Cygielman (1963) confirmed the results of earlier workers but could find
. *»
no structure-activity correlation in a'number of derivatives. Enoxolone 
has been found to be beneficial to patients suffering from Addison's 
disease but only in the presence of some functionally active cortical 
tissue and is inactive in bilaterally adrenalectomised patients (Hudson, 
et al., 193^ ; Hart, .1937)• agreement with this clinical finding is 
the claim that carbenoxolone has a stimulant effect on the rat adrenal 
cortex (Cygielman, 1963)- The anti-inflammatory activity is not dependent 
on the adrenals (Cristol, et al., 1966) but adrenalectomy decreases the 
anti-inflammatory activity and increases the toxicity of carbenoxolone 
(Robinson, 1963; Khan & Sullivan, 1968). Adrenalectomy is known to 
increase the toxicity of a number of drugs (Csaky, 1969)- Carbenoxolone 
still exerts its full anti-inflammatory effect in hypophysectomised rats 
(Khan & Sullivan, 1968) but there is conflicting evidence as to whether 
enoxolone acts on the pituitary axis (Kraus, 1962; Salassa, et al., 1962; 
Nikitina, 1966; Gupta, et al., 1969).
A number of anti-inflammatory drugs both steroids (Spiro 8c Milles, i 960 ) 
and non-steroids such as indopethacin (Rothermich, 1966 ) and 
phenylbutazone (Mauer, 1933) possess ulcerogenic properties but 
carbenoxolone appears to be unique in this respect in that it possesses 
both anti-inflammatory and ulcer healing properties. It has been shown 
that cortisone (Menguy 8c Masters, 1963)1 phenylbutazone (Menguy 8c 
Desbaillets, 1967 ). and indomethacin (Menguy 8c Desbaillets, 1967 ) cause 
a reduction of gastric mucus production in dogs and this may render the 
mucosa more susceptable to ulceration. The precise mechanism of this 
action is unknown but the composition of the mucus secreted is of great 
importance. Salicylates (e.g. aspirin) are known to cause considerable 
damage and bleeding to gastric membranes (Wood, 1963; Muir, 1963) and 
have been shown in vitro to have an inhibitory effect on glycoprotein 
biosynthesis in sheep and human mucosa (Kent 8c Allen, 1968 ) and to 
inhibit enzymes involved in mucopolysaccharide synthesis (Lee 8c Spencer,
1969). Salicylate and phenylbutazone administered in vivo to female rats 
were found to reduce the synthesis of glucosamine-6-phosphate in gastric 
mucosa (Sch8nh8fer 8c Eerrey, 1967) which in turn may impair mucoprotein 
formation. Ulcer producing agents may interfere with the production of 
sulphate-containing components of gastric mucus (Familiar, 1969) and 
phenylbutazone reduces the secretion of sulphated glycoproteins by rat 
gastric mucosa (Lambert, et al-., 1967)- Ragins 8c Wincze (1969) found that 
cortisone appeared to decrease the formation of new gastric parietal 
cells in the mouse. It is possible that a better understanding of the 
ulceration process obtained by using drug-induced ulcers as experimental 
models may suggest possible mechanisms of the ulcer healing action of 
carbenoxolone.
b) Steroid-like Effects of Carbenoxolone
Revers (19^ 6) found that sodium and water retention resulting in 
oedema occurred in approximately 20^ of his patients and Molhuysen, et al. 
(1930) showed that an active principle of liquorice extract was similar 
in its metabolic activities to deoxycorticosterone, a potent mineralo-cort 
icoid. Brief summaries of the undesirable clinical manifestations of 
ingesting liquorice preparations have recently been presented (Conn,
Rovner & Cohen, 1968; Hausmann & Tarnoky, 1968). Glycyrrhetic acid 
known to be present in liquorice extract was shown to have corticosteroid- 
.like properties (Card, et al., 1963; Finney, Somers & Wilkinson, 1938) 
and Doll, et al., (1962) reported the occurrence of oedema in 17$> of their 
patients treated with carbenoxolone. It is now recognised that therapy 
with carbenoxolone may give rise to fluid retention and that concomitant 
administration of a thiazide duiretic blocks these side effects and does 
not interfere with ulcer healing (Doll, Langman & Shawdon, 1968).
The effects of carbenoxolone on water and electrolyte excretion 
in experimental animals are somewhat variable depending on the species, 
route of administration and sodium intake (Khan & Sullivan, 1968). It is 
generally observed in rats treated with enoxolone and carbenoxolone that 
there is a dose-related antidiuretic effect with retention of water and 
sodium and a decrease in the urinary sodium/potassium ratio. (Finney & 
Tarnoky, 1960; Cristol, et al., 1966; Khan & Sullivan, 1968). These 
effects are similar to those of the mineralocorticoid hormones e.g. 
aldosterone. The presence of the adrenal gland was considered necessary 
for complete development of the mineralocorticoid properties of enoxolone 
(Cristol, et al., 1966) but Khan & Sullivan (1968) obtained almost 
identical results with carbenoxolone treatment on sodium and water 
excretion in adrenalectomised rats and dogs.
The clinical biochemical effects of carbenoxolone in patients 
with miscellaneous gastro-intestinal disorders were found to be: 
weight gain, rise in blood pressure, tendency to sodium retention with 
a rise in plasma sodium, a tendency to a fall in plasma potassium and 
excess urinary potassium excretion, and an increase in plasma bicarbonate 
(Hausman & Tarnoky, 1966). These results were supported by subsequent 
findings (Baron 8c Nabarro, 1968; Hausmann 8c Tarnoky, 1968). The effects 
of carbenoxolone on potassium metabolism in healthy adult males has been 
studied (Dymock, 1968) and although there was an increase in urinary 
potassium excretion there was no significant alteration in total body 
potassium. Baron, et al., (19&9) have studied a carbenoxolone treated, 
patient maintained on a restricted sodium diet and found that there was no 
retention of water, sodium or chloride. A subnormal urinary excretion of 
aldosterone occurred and it was considered that carbenoxolone may possess 
intrinsic aldosterone-like properties. It is interesting that the 
aldosterone antagonist, spironolactone antagonises the ulcer healing 
action of carbenoxolone (Doll, Langman 8c Shawdon, 1968). A preliminary 
report (Solymoss, Classen 8c Varga, 19&9) indicates that oral administration 
of spironolactone induces hepatic drug metabolizing enzymes in the female 
rat and if this is also the case for man, enhanced metabolism of 
carbenoxolone and/or endogenous steroids may interfere with the mode of 
action of carbenoxolone. ■ The mechanism by which carbenoxolone exerts its 
mineralocorticoid action remains obscure but work is in progress (Porter, 
1970; Humphrey- unpublished results) that may shed some light on this 
problem.
Enoxolone added to female rat liver homogenates in vitro inhibited 
the metabolism of progesterone and 11-deoxycorticosterone (Atherden, 1938) 
and it was postulated that enoxolone may inhibit steroid reduction in vivo.
Helbing & Bern.tsen (1963) found- that enoxolone partially inhibited the 
enzymic activity of commercial preparations of glucose-6-phosphate 
dehydrogenase and glutamate dehydrogenase and they suggested that 
enoxolone exerts its biochemical actions by interfering with general 
metabolic processes and not by a direct effect on steroid-metabolising 
enzymes. When enoxolone, administered subcutaneously as the acetate was 
screened for deoxycorticosterone, cortisone, estrogenic and androgenic 
activity it was found to be inactive (Wenzel & Emick, 1936).
6arbenoxolone does not appear to have any glucocorticoid activity 
in either rabbits (Finney & Tarnoky, i960) or humans (Fletcher, MacKay 
& Forbes, 1967) and this is somewhat surprising in view of the fact that 
anti-inflammatory action is a property of the glucocorticoids rather 
than the mineralocorticoids.
c) Action on Gastric Mucosa
The cause of gastric ulcers is not known but there is considerable 
evidence that mucus plays an important part in the protection of the 
gastric mucosa (Hollander, 1-93^ > Skoryna & Waldron-Edward, 1967) and an 
alteration of this mucus barrier may contribute towards gastric * 
ulceration. Hence a breakdown- in mucosal defence might be attributable 
to (1) decreased mucus synthesis, (2) decreased discharge of mucus,
(3) altered composition of mucus or (A) altered surface attachment of 
mucus (Johnson, 1968). The mode of action of carbenoxolone is not known 
but if it affects the defence mechanism of the gastric mucosa it may act 
through one or more of these processes. Since carbenoxolone 
administered as a tablet is effective only in the therapy of gastric 
ulcer (Doll, et al., 1962) and the major site of absorption is the stomach • 
(Downer, et al., 1970) it has been suggested that the drug has some local
action during its passage through the gastric mucosa (Downer, et al., 1970)* 
Macroscopic observation of tissue taken at gastrectomy from four 
carbenoxolone-.treated gastric ulcer patients suggested that either an 
increase in mucus production had occurred or the mucus present was more 
adherent (Goodier, Horwich & Galloway, 1967). Morphological examinations 
by conventional histology of these same tissue samples showed that 
<sarbenoxolone did not appear to alter the normal growth and repair 
processes of the gastric mucosa. A further twelve patients were studied 
(Goodier, 1968) and again healing appeared to follow the normal pattern 
with a possible improved production of periodate-reactive mucin.
Lipkin (private communication) measured the proliferation kinetics 
of cells of the gastric mucosa in mice using a ^H-labelled nucleoside 
precursor of deoxyribonucleic acid (DNA) and found that the turnover rate 
of gastric epithelial cells was decreased. The increased life span of 
the gastric epithelial cells may contribute to the ulcer healing action 
of the drug.
When carbenoxolone was tested experimentally in rats for a protective 
effect against ulcers produced by restraint or serotonin no such effect 
was apparent (Finney, quoted by Khan & Sullivan, 1968). A new technique 
using an electrocautery probe to produce ulcers in the ventral wall of 
the stomach close to the lesser curvature has been used and carbenoxolone 
administered orally after ulcer production caused a significant increase 
in healing rate (Khan & Sullivan, 1968). However the rat is not a 
suitable experimental animal in which to test the anti-ulcer action of 
carbenoxolone after oral administration since the drug is extensively 
hydrolysed in the gastrointestinal tract to enoxolone and succinic acid. 
(This hydrolysis is discussed more fully in section (d) and Chapter two). •' 
The extent of hydrolysis of carbenoxolone after oral administration to man
is far less than in the rat but patients receiving carbenoxolone will in 
fact be receiving small doses of enoxolone resulting from hydrolysis of 
carbenoxolone. It is not known whether enoxolone has an ulcer healing 
action in humans but this does seem likely in view of its close molecular 
similarity to carbenoxolone and early favourable, but inconclusive, 
reports about liquorice'preparations. Takagi, Okabe & Saziki (1969? 
found that the dipotassium salt of enoxolone exhibited significant 
repairing action on experimental ulcers produced in rats. These ulcers 
were produced by injection of 30% acetic acid solution into the rat 
stomach wall and on the second day after this operative procedure enoxolone 
(dipotassium salt) was administered orally in suspension for fifteen days. 
No observations were made on the mucus present in the rat stomachs after 
treatment.
It is pertinent here to comment on the usefulness and suitability 
of the animal experimental models used to test potential anti-ulcer 
compounds. At the present time there are several difficulties encountered 
when trying to evaluate such compounds experimentally, the experimental 
ulcers conveniently produced by stress, administration of various 
compounds such as serotonin, reserpine, acetic acid and steroids, or 
electro-cautery are of doubtful relevance of those found in human patients. 
Another factor to consider is that the fasting human stomach and proximal 
duodenum normally contains very few viable bacteria (Drasar, Shiner 8c 
McLeod, 1969) but the rat stomach usually contains large numbers of 
bacteria as a result of coprophagy. These gut bacteria are known to carry 
out a variety of metabolic transformations of foreign compounds 
(Scheline, 1968a, 1968b). Compounds that would normally be largely 
absorbed from the stomach in humans come into contact with an active flora 
in the rat stomach and may undergo metabolism to form inactive or toxic 
metabolites before absorption occurs. It has been suggested that a
change in the flora of the rat duodenum induced by indoraethacin may 
contribute to the production of small intestinal ulcers by the drug 
(Kent, et al., 1969)- A higher pH of the rat stomach may result in a 
smaller proportion of weakly acidic drug being absorbed from the stomach 
and a larger proportion absorbed from the small intestine, as compared 
to man. The absorption and metabolism of carbenoxolone in the mouse 
have not been investigated but since bacteria are present in the 
mouse stomach (Schaedler., Dubos & Costello, 19^ 5; Bubos , et al., 19&5) 
hydrolysis of carbenoxolone may occur similar to that in the rat and 
results for carbenoxolone from experiments in the mouse (viz. Lipkin) 
must be interpreted with caution. These biochemical and pharmacological 
properties of a drug which would indicate its potential usefulness in the 
treatment of ulcers are largely unknown but it seems likely that 
experiments with non-rodents such as the dog, pig or monkey would'be of 
greater value.
d) Absorption, Metabolism and Excretion of Enoxolone and Carbenoxolone
Tritium labelled glycyrrhetic acid was administered orally to four 
human subjects and it was considered to be poorly absorbed from the 
gastrointestinal tract as indicated by the percentage of the dose of 
radioactivity found in the blood at four hours (Carlat, et al., 1959)•
These workers found very low total amounts of radioactivity in the urine 
and blood of two subjects and in the bile of one of these subjects after 
four hours. The bulk (98$) of the administered radioactivity was 
recovered after one day in the faeces of two other subjects. In view 
of the previously mentioned side-effects observed in human patients after 
oral administration of liquorice and glycyrrhetic acid (Card, et al., 1953) 
it is hard to reconcile this with the findings of Carlat, et al., (1959 ) 
that glycyrrhetic acid is very poorly absorbed. The vehicle in which 
the drug was administered was not mentioned and as stated in their
discussion (Carlat, et al., 1959) the glycyrrhetic acid was of uncertain 
stereoisomeric structure and this may account for their findings.
Helbing (19&3) developed a spectrophotometric method very similar 
to that of Coleman and Parke (19&3) for the determination of enoxolone 
in biological material and using this method the excretion of enoxolone 
in the faeces of two patients after oral administration of enoxolone was 
measured. The enoxolone recovered from the stools represented 52. s^ nd 
60.8?o of the dose as compared with the 98% recovery of radioactivity by 
Cariat, et al., (1959)> The interesting possibility was considered that 
enoxolone might have undergone some chemical change during its passage 
through the gastrointestinal tract (Helbing, 1963) and an alteration of 
the 11-oxo-12-ene chromophore could render the compound undetectable by 
spectrophotometric methods. When enoxolone was incubated with a 
concentrated aqueous suspension of faeces for k days at 37°C, there was 
no significant change in the enoxolone content.
Parke, Pollock & Williams (19&3) using tritium labelled 1.80- * 
glycyrrhetic acid showed that after oral, subdermal and intraperitorieal 
adminstration (23mg/kg of body weight) to male and female rats most of the 
radioactivity was excreted in the faeces and only traces were present in 
the urine. However, when administered orally in arashis oil to female 
rats more than 70% of the dose of radioactivity was excreted in the bile 
in 2-3 days and after oral administration of aqueous suspensions to male 
and female rats an average of 53^ and 3Wo respectively of the dose of 
radioactivity was excreted in the bile in three days. An average of 
100^ of the administered radioactivity was excreted in the bile within 
12 hr. after intraperitoneal administration at the same dose level.
(Parke, Pollock & Williams, 19&3)- Three major metabolites were isolated
from the rat bile, one probably being a glucuronide conjugate and none were 
identical with unchanged enoxolone.
Iveson (1968) has further studied the metabolism of tritium labelled
enoxolone and carbon-labelled carbenoxolone and their metabolism has
been summarized (Parke, 1988). Enoxolone is a weak acid (pk 7-1 )*a
insoluble in water and very soluble in many organic solvents and therefore 
presumably lipid soluble and on theoretical grounds such a compound should 
be readily absorbed from the gut (Shore, Brodie & Hogben, 1957; Schanker,
196*f) as was in fact found by Parke, et al. (1983)- Further experimental 
evidence relating to the absorption of enoxolone has been obtained 
(iveson, 1968) who studied in detail the metabolism of ^H-enoxolone and 
of carbon-1^ - labelled carbenoxolone in rats. When enoxolone was administered 
orally and intragastrically to rats with pyloric ligation only 2-3^ of the 
dose of radioactivity was detected in the bile after 5 -8 hours, but 20-30^ 
of the dose was recovered from the liver indicating that considerable 
absorption had in fact occurred. When administered intraperitoneally or 
intraduodenally to rats with or without pyloric ligation, 80-9C$£ of' the 
dose of radioactivity was excreted in the bile within 5-8 hours. It was 
not certain from these experiments whether the stmach was the main site 
of absorption of an oral dose in the rat but ligation of .the pylorus 
inhibits gastrointestinal motility and may thereby have reduced gastric 
absorption, (iveson, 1988). The three metabolites present in the bile 
were identified by chromatographic comparison with synthetic derivatives 
(iveson & Parke, 1970) on® was enoxolone-3-sulphate, the second enoxolone- 
30-glucuronide and the third conjugate was almost certainly a diglucuronide, 
enoxolone-3,30-diglucuronide (iveson, 1988; Iveson & Parke, 1970).
When carbenoxolone labelled with carbon-1^ - in the C-1 and C-^ f atoms of
succinate side chain was administered orally in propylene glycol to intact
rats 60-75# of the isotope was excreted as respiratory carbon dioxide in
36 hours. After intraperitoneal administration to intact rats approximately
'l A
70% of the isotope was excreted as XO^ in 30 hours. A difference in rate
of excretion of CO^  dependent upon the route of administration was 
observed; administration by the oral route gave rise to rapid initial
14CO  ^excretion \Z0-J>3% in ^ hours) but after intraperitoneal injection, 
initial CO^ excretion was slow \S% in hours) but increased rapidly 
after four hours. An important difference was found in the elimination 
of radioactivity after oral and intraperitoneal administration to rats with 
biliary connulae. Following oral administration the bulk of the C was
1 if.
again excreted as respiratory CO^  (4-5-80^  in 30 hours) but after 
intraperitoneal administration the bulk of the radioactivity was excreted 
in the bile (50-60^ in 30 hours), only 6-2C$? in respiratory carbon dioxide 
and a significant amount of radioactivity remained in the liver, (iveson, 
1988). This suggests that hydrolysis of carbenoxolone is effected by 
enzymes present in the gastrointestinal tract and that these enzymes are
1/f
of bacterial origin. The C-labelled succinate that is released is
'\l\.
converted to respiratory CO^  via the tricarboxylic acid cycle. Only one 
metabolite of carbenoxolone was found in the bile of rats after intraperitoneal 
administration og carbenoxolone and this has been tentatively identified as 
the C-30 mono-glucuronide of carbenoxolone.
Thus, after oral administration to rats carbenoxolone undergoes 
hydrolysis in the gastro-intestinal tract before absorption occurs.
The enoxolone thus formed and the unhydrolysed carbenoxolone are then 
absorbed, metabolized and excreted in the bile as conjugates. The 
conjugates have been identified as enoxolone-3*-0-hydrogen sulphate, 
enoxolone-30-glucuronide and enoxolone diglucuronide together with the 
glucuronide conjugate of the unhydrolysed carbenoxolone. (Iveson, 1988). 
Since the conjugates of enoxolone and carbenoxolone are excreted in the 
bile the opportunity arises for intestinal reabsorption of hydrolysed 
conjugates with subsequent enterohepatic re-circulation and this has been . 
demonstrated experimentally in the rat (iveson, 1988).
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A similar pattern of enterohepatic re-circulation probably occurs 
in man for when Downer, et al., 0970) studied the absorption and 
excretion of carbenoxolone in human patients two peaks often occurred in 
the curve of carbenoxolone blood concentration and this was suggestive 
of enterohepatic re-circulation. Downer, et al., (1970) found that 
carbenoxolone does not undergo extensive hydrolysis in human patients and 
that after rapid absorption it is excreted in the bile as carbenoxolone-30  
glucuronide. This interesting species difference in the metabolism of 
carbenoxolone between man and rat is outlined in figure 1-2. As with 
the rat only very small amounts (2%) of the dose appeared in the urine 
(Downer, et al., 1970).
Downer, et al., (1970) administered an oral dose of carbenoxolone 
100 or 200 mg. in tablet form to patients and found that a peak blood 
concentration of carbenoxolone occurred 1-2 hours after dosing but when 
the drug was administered in a buffer (pH 8.5), to increase the pH of 
the gastric contents, extensive absorption was delayed until the pH of 
the gastric contents was <2. This evidence was considered to indicate 
that, the major site of absorption was the stomach (Downer, et al. , 1970)•
A second peak blood concentration of the drug occurred in a number of 
patients, indicating a probable enterohepatic re-circulation of the drug 
and in some cases thesecond peak exceeded the first. The high blood 
concentration of carbenoxolone (mean = 2k pg./ml. for the first peak), 
indicated that about 60% of the dose was present in the circulating blood 
and in one patient a concentration of 35 pg./ml. indicated that 
approximately 88% of the dose was circulating in the blood (Downer, et al.
1970)* When a large proportion of an administered drug is found
circulating in the blood it can be indicative of extensive plasma
protein binding (Martin, I965a)and preliminary experiments indicated that
carbenoxolone was highly bound to plasma proteins (Downer, et al., 1970).
From a consideration of its absorption characteristics and the fact 
that carbenoxolone in tablet form does not heal duodenal ulcers,
Downer, et al., ('1970) postulated that the absorption of carbenoxolone 
through the gastric mucosa was necessary for its ulcer-healing action.
e) Uncoupling Action of Carbenoxolone
Whitehouse and his co-workers have extensively studied the 
biochemical properties of a number of anti-inflammatory drugs and their 
findings have been reviewed (Whitehouse, 1968). These workers have made 
a number of interesting and important observations on the biochemical 
properties of carbenoxolone. Skidmore & Whitehouse (1966) found that 
carbenoxolone caused 85% inhibition of histidine decarboxylase activity 
in rat gastric mucosa. Whitehouse, Dean & Halsall (19^ 7) have shown that 
carbenoxolone, enoxolone and a number of similar triterperioids are fairly 
potent uncoup!ers of oxidative phosphorylation, i.e. they inhibit the 
mitochondrial biosynthesis of adenosine 3*-triphosphate without 
inhibiting mitochondrial respiration. The uncoupling ability of 
carbenoxolone was completely annulled in the presence of bovine plasma 
albumen and from this it was inferred that the drug was extensively 
bound to albumen thus reducing the concentration of free (unbound) drug 
below the level required for uncoupling activity. (Whitehouse, et al., 
1967)- This was probably the first report that carbenoxolone was bound 
to a3bumin. In line with the earlier observation (Skidmore & Whitehouse, 
1966) on carbenoxolone and other anti-inflammatory drugs-, Whitehouse,
Dean 8c Halsall subsequently showed that all, except three, of the 
triterpenoids studied inhibited the reaction of 2,A,6-tmitrobenzaldehyde 
with the albumin (lysl) e-amino groups and the degree of inhibition 
approximately paralled their uncoupling activity. This albumin-binding 
property appeared to be primarily a property of the 30-carboxyl group
but was enhanced by the hemisuccinate group. It was postulated that 
these triterpenoid acids uncouple oxidative phosphorylation by interaction 
with key lysl amino-groups participating in mitochondrial phosphorylation. 
Since neither enoxolone or carbenoxolone inhibited the thiol enzyme 
papain it was considered unlikely that they uncouple oxidative 
phosphorylation merely by reacting with.key thiol groups in mitochondria, 
(Whitehouse, Dean & Halsall, 19&7)*
k) Introduction to Present Work
In the previous three sections of this chapter the chemistry, 
therapeutic use, pharmacology and biochemistry of carbenoxolone and 
enoxolone have been critically reviewed. The purpose of this last 
section is to define the aims of the present work and discuss its 
relationship and relevance to previous investigations. A full introduction 
to each topic and a discussion of the results obtained is given in each 
chapter.
From the foregoing introduction a number of importance problems and 
questions arise. One such problem is that the rat is not a suitable 
animal for studying carbenoxolone after oral administration. It was 
therefore necessary to investigate the metabolism of carbenoxolone in the 
Squirrel Monkey to ascertain whether the biochemistry - i.e. the 
absorption, metabolism, distribution and excretion was of.a similar 
pattern to that in man. It has been advocated (Food & Drugs Administration) 
that primates such as the Squirrel Monkey should be used increasingly for 
the pre-clinical evaluation of drugs and this particular primate offers 
the advantage that it has not yet been found to carry the B-virus (Eosenblum 
8c Cooper, 1968), that is a potentially serious hazard to workers using 
other primates such as the Rhesus Monkey.
In addition it was necessary to investigate further the metabolism of 
carbenoxolone in the rat and in particular to ascertain the role of the 
gastrointestinal microflora. Further studies on the absorption, 
metabolism and excretion of carbenoxolone in man were also necessary 
because of the incomplete nature of Iveson*s work. These studies have 
been carried out using material labelled with carbon-lA and tritium and 
have been carried out in two human volunteers, and the absorption of 
^C-carbenoxolone as a positioned-release capsule ("Duogastrone") has
been studied in three duodenal ulcer patients. As an indication of its 
lipid solubility, an important factor for absorption, the partition 
coefficient of carbenoxolone has been- measured.
Following the observations of Downer, et al. (1970) there was 
an obvious need to investigate the plasma protein binding of 
carbenoxolone and this has been investigated in detail using several 
techniques: ultrafiltration, molecular sieve chromatography, electrophoresis,
spectrophotometry and fluorescence. Species differences in the plasma 
protein binding of carbenoxolone were investigated by ultrafiltration and 
binding constants for the binding to human serum albumin were determined 
by this technique. .
It is now believed that this protein binding property of a drug 
plays an important role in enhancing absorption, regulating its 
distribution and excretion (Schanker, I96A; Martin, 19&5 a,b; Goldstein, 
Aronow .& Kalman,1968). Furthermore there is a potentially serious toxic 
hazard of carbenoxolone as a potent uncoupler of oxidative phosphorylation 
by virtue of its binding to mitochondrial proteins and this toxic action 
is annulled by its binding to plasma proteins. Weinbach & Garbus (19&9) 
have postulated that uncoupling reagents interact with mitochrondrial 
proteins bringing about a conformational change and this is the basis of 
the uncoupling action. Hansch, Kiehs, & Lawrence (1965) studied a number 
of phenols of plant origin and found that they were highly bound both to 
serum albumin and -to hepatic mitocb ondrial protein. It was necessary 
to study this other aspect of the protein binding namely that concerned 
with carbenoxolone's toxic action and to this end the distribution of 
labelled carbenoxolone in rat liver subcellular fractions especially 
mitochondrial has been studied. An investigation of the effect of 
carbenoxolone cn the fluorescence of human serum albumin (HSA) was
included in the protein binding studies to try to investigate, 
any changes- in albumin conformation.
The mixed function.oxidases of the liver endoplasmic 
reticulum are considered to be involved not only in the metabolism 
of exogenous substrates (Mason, 1957; Conney, 1967; Gillette, 196?) 
but also, in the metabolism of endogenous compounds such as steroids 
(Kuntzman, ejt al., 196A; Conney, _et al, 1965; Conney, 196?;
Conney, _et al, 1968; Wada, et d, 1968), bilirubin (Billing & Black,
1969)? thyroxine (Stanbury, et d, 1960; Wynn, Gibbs. & Royster, 
1962), fatty acids (Stoffel, 1961; Marsh & James, 1962; Lu & Coon, 
1968; Das, Orrenius?& Ernster, 1968; Lu, Junk & Coon, 1969;
Orrenius & Thor, 1969)1 and detailed' reviews of these: microsomal 
enzymes have appeared*. (Mason, 1957; Conney, 1967; Gillette., 19671 
1969; Kuntzman, 1969)® Glucuronsyl transferase, enzymes are also 
present in the microsomal fraction of the liver and they are 
involved in conjugation processes for both endogenous and exogenous. 
compounds (Parke, 1968a). With these factors in mind the effect of 
carbenoxolone pretreatment on a number of enzymes present in rat 
liver, namely biphenyl-^-hydroxylase, glucuronsyl transferase and 
cytochrome P-A5 0, was studied. In conjunction■with this in vitro 
work hexobarbital hypnosis■times in vivo were measured.
Carbenoxolone has certain steroid hormone like actions, e.g. 
mineralocorticoid effects (see section 3(*>) above) but the mechanism 
of these actions is not known. Carbenoxolone may possess intrinsic 
hormone-like activity, it may stimulate the synthesis of new hormone 
or potentiate, the action of existing hormone by decreasing the
metabolic breakdown or displacement from Msilentn receptors.
The drug may enhance hormone-receptor binding or increase the.
synthesis of receptors. Cortisol, corticosterone and aldosterone.
Aare metabolised by reduction of the &  -double bond and the 3-keto
group, and cortisol also undergoes oxidation of the 17-ketol side
chain. It has been shown (Kumagai, et al, 1957) that glycyrrhetic
A
acid and glycyrrhizin inhibit the A  -3-ketone'reduction of cortisol 
by rat liver homogenates by 60;o and degradation of the 17-ketol side 
chain by Atherden (1958) found that enoxolone inhibited the
metabolism of progesterone and 11-deoxy-corticosterone by rat liver 
homogenate. To discover-whether carbenoxolone had any significant 
effect on cortisol metabolism in vivo the urinary and biliary 
excretion of radioactivity following a dose of [ HJcortisol was-, 
measured in rats that had been pretreated with carbenoxolone.
In summary the aims of the present work were as follows:-
i) to investigate the absorption, metabolism and excretion of 
carbenoxolone in the Squirrel Monkey and in human volunteers and 
patients and to correlate this with previous studies in the rat.
ii) To investigate the plasma protein binding and liver distribution 
of carbenoxolone with a view to determining their biochemical and 
therapeutic significance, iii) To determine the effect of 
carbenoxolone pretreatment on several liver parameters known to reflect 
the metabolism of both exogenous and endogenous compounds and,
_3 _
linked with this, to investigate [ H Jcortisol excretion in rats.
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1* Introduction to Drug Metabolism.
1
a) General Aspects
The food of man contains a large number and variety of 
compounds (many of natural origin) that have no apparent 
nutritional value and would almost certainly prove toxic if not 
eliminated from the body. Such compounds are frequently termed 
’foreign compounds' or 'anutrients' (Williams, 1939; Parke, 1968a)e 
In recent years with the increasing use of synthetic drugs, 
food additives and pesticides these man-made .foreign compounds 
have formed an increasing proportion of the anutrient content of 
the diet. It seems likely that the elimination of such foreign 
compounds in aquatic animals does not pose a difficult problem 
because compounds can be excreted passively through the gills into 
the vast volume of the surrounding water. However in terrestial 
animals, just as methods of conserving body water and electrolyte 
balance have evolved, active methods of eliminating and often 
’detoxifying* foreign compounds have also appeared. There is 
some evidence that fish, for instance, lack some of these 
methods (Goldstein, ejt al, 1988).
This section is concerned with ,a brief outline of drug 
metabolism and many.of the important discoveries in this field 
have been made while studying drugs or compounds of potential 
therapeutic interest, however the general principles of drug 
metabolism appear to apply to all foreign compounds. Because man 
is nov/ constantly introducing.new synthetic chemicals into the 
environment an understanding of the mechanisms available for 
their 'detoxication' and elimination is essential. It is also
important to1 obtain an idea of the limitations of these 
elimination mechanisms, for if they are overloaded by ingestion 
of large amounts of foreign materials undue toxicity may ensue.
Drugs may exert therapeutically useful pharmacological actions; 
but usually have no nutritional value and are treated by the body 
as a foreign compound. Most drugs undergo metabolic transformation 
in the body and therefore the study of drug metabolism has a 
twofold use. in that after discovering the action of the organism 
on the drug this may in turn throw light on the mechanism of drug 
action, i.e. the action of the drug on the body. The first major 
review on drug metabolism by Williams (1939) covered mainly the 
chemical aspects and following the subsequent increase in 
biochemical knowledge another important treatise has appeared 
which incorporates this new knowledge (Parke, 1988a). A number of 
useful reviews have also appeared (’Williams, 1980, 1984, 1983» 1987 
Maynert, 1981; Parke, 19 8 2, 1988a, b; Boyland 8c Booth, 1982; 
Shuster, 1984; Williams & Parke, 1984; Goldstein, Aronow & Kalman 
1988; Schreiber, 1970).
The most important feature of all the metabolic changes 
occurring in drug metabolism is that the products are more polar 
and less lipid soluble than the parent compound. The metabolites 
being more polar are less readily reabsorbed in the renal tubules 
and are excreted in the urine. The specific secretory processes 
for anions and cations in the proximal renal tubules and also the 
parenchymal cells of the liver act upon polar compounds (Schanker,
19^9) and a polar metabolite may be eliminated in this way in 
the urine or bile. Williams (1980) has classified the metabolic 
reactions of drugs and foreign compounds into two types - 
Phase I and Phase. II.
A phase, I reaction may be one or more of the following 
reactions: oxidation, reduction or hydrolysis. These reactions
generally increase the polarity of the compound, rendering it 
more readily excretable. A phase II reaction involves a 
synthetic step in which the compound is conjugated with an 
endogenous molecule usually glucuronic or sulphuric acid, but 
conjugation with amino acids or alkyl groups also, occurs.
Glucuronic acid can be conjugated with phenols, alcohols, carboxyli 
acids and aromatic amines to form glucuronides, which are water 
soluble acids which are more readily excreted. Dutton (1988) has 
presented a lot of the. information about glucuronides and their 
synthesis. If a drug does not possess, a. polar, group suitable for 
a phase; II reaction it v/ill usually undergo both phases of 
metabolism.
k) Factors Influencing the Metabolism of Drugs
The; duration and intensity of a drug's action is usually 
related to its rate of metabolism and excretion and frequently 
a drug cannot be excreted until it has been metabolised to a 
suitable form. The rate of reaction may therefore be an 
important rate-limiting step in the deactivation of drugs and a
number of factors have been discovered which affect the 
activity of hepatic microsomal drug-metabolising enzymes 
(Conney 8c: Burns, 1982; Fouts, 1983; Conney, 198?; Parke, 1988a, 
1988b). Many of these factors were discovered in the course; . 
of experimental work with; animals but it isi now believed that many 
of them have relevance to the human therapeutic situation.
These factors are: both physiological and environmental, in origin 
and include nutrition, circadian rhythm, sex, pregnancy, age, 
stress:, disease: and foreign compounds. These .will not be. 
considered here but factors such as the gastrointestinal 
microflora and species differences;in metabolism and excretion 
are relevant to the present work and will.be considered.
i) Species and. Strain
Species variation in the response to drugs is the central 
problem in their development and evaluation when results from 
experimental animals have to, be extrapolated to man. Part of 
this; variation is due to, differences, in drug metabolism and it is: 
hoped that a greater understanding of drug metabolism in a variety 
of species, will improve our ability to predict the biological 
actions, of a compound in man (Williams, 1987; Hucker, 1970).
The basic two phase pattern of drug metabolism can be
regarded as common to most animal species but v/ithin this basic
pattern tremendous species differences occur (Williams, 19&7)*
There is no apparent rationale for these differences which may be
both qualitative and quantitative as for instance with aromatic
hydroxylation which varies apparently haphazardly among species
(Williams, 1967)* Conjugation reactions can also vary and in man
and rhesus monkey the major urinary metabolite of sulphadimethoxine
1is sulphadimethoxine N -glucuronide while in the rabbit and guinea 
4pig N -aeetylsulphadimethoxine is the main metabolite and in the
dog the drug is excreted mainly unchanged (Bridges, Kibby, Walker &
Williams, 1968), However, in many instances results obtained from
drug metabolism experiments in monkeys have b.een of no greater
predictive value in man than those obtained from experiments in
dogs (Drug Research Board, 1969)* The deficient ability of the
cat to.form glucuronides is thought to be because of low levels
of glucuronyl transferase activity (Dutton 8c Greig, 1957)«<
In addition to in vivo studies species differences in drug
metabolism have been studied in vitro and Davies, Gigon 8c Gillette
(1969) have found species variations in both the K and V for  ^ * m max
the metabolism of ethyl morphine by liver microsomes of several 
common laboratory animals.
In addition to species differences in drug metabolism many 
examples of strain differences v/ithin a species have been recorded 
(Quinn, Axelrod 8c Brodie, 195$; Cram, Juchau 8c Fouts, 19^5»
Page 8c Vesell, 19^9)* Significant individual differences in
response to drugs sometimes occur in man and the study of these 
genetically determined differences is called pharmacogenetics*.
A number of genetic variants are now known which affect the 
metabolism of drugs (Parke, 1968b; Vesell, 1969)*
A. number orf other variables, excluding those in the external 
environment, may contribute to species differences in drug 
metabolism: differences in binding to tissue and plasma proteins
can occur (see Chapter 3) there may be species variations in 
the absorption and route of elimination of a drug and its 
metabolites. The pH of the urine influences the renal excretion 
of acidic and basic drugs. Acidic drugs are more rapidly excreted 
when the urine is alkaline and basic drugs more rapidly excreted 
when the urine is acidic. Amphetamine is a basic drug and it is ' 
excreted more rapidly in human subjects with urine of pH 5 than in 
others with urine of pH 8 (Beckett, Rowland 8: Turner, 1.9.65)• The 
renal excretion of salicylic and p-arainosalicylic acids and 
their conjugates is affected by urine pH, (Kakemi, Arita,
Yamashina & Konishi, 1962). It is known that the nature of the 
diet influences urine pH (Harper, 1969) and it is conceivable that 
the renal excretion of a drug could be affected in this way. The 
pattern of metabolism may also be dose-dependent (Hucker, 1970).
It is as well to remember as Rail (1969) bas pointed out that 
each species;has by definition some unique characteristics and it 
would be indeed surprising if some aspects of this uniqueness were 
not manifest in the response to drugs. Unfortunately it seems that 
at present our knowledge is insufficient to predict the metabolic 
fate of drugs in various species except in a few instances (Hucker-, 
1970).
ii) Biliary Excretion and Gastrointestinal Flora
The extent of biliary excretion of a drug and its metabolites 
and the nature of the gastronintestinal flora in an animal are 
two inter-related factors that can affect the overall pattern of 
metabolism of a drug. The physico-chemical characteristics which 
determine whether a compound is excreted in the bile are not fully 
understood but the molecular size and polarity appear to play an 
important role (Abou-El-Makarem, Millburn, Smith 8c Williams, 1967a, 
1967b; Abou-El-Makarem, Millburn 8: Smith, 1967; Millburn, Smith 8c 
Williams, 1967a, 1967b). These workers roughly classified the rat, 
dog and hen as good biliary excretors and the rabbit, guinea pig 
and rhesus monkey were relatively poor biliary excretors while 
the cat and sheep were in an intermediate category. Millburn (1970) 
in a review of this subject has suggested three chemical factors 
important for extensive hepatic excretion of organic anions by the 
rat :1) a minimum molecular weight of 325 + 5 0; 2 ) polar anionic
group and 3 ) certain type of molecular structure. The minimum 
molecular weight below which little biliary excretion occurs may 
vary with species and while it appears to be about 325 T°r the rat, 
dog and hen, it may be higher, in the range 500-6 0 0, for rabbit, 
guinea pig, rhesus monkey and man. These species may in fact be 
good biliary excretors of compounds having higher molecular weights 
(Millburn, 197 0). The characteristics predisposing towards the 
biliary route of elimination may be already present in a molecule 
or can be acquired during metabolism and although metabolism is 
not necessarily a prerequisite for biliary excretion it does 
appear to favour transport into bile (Millburn, 1970) and for 
example conjugation of bromosulphophthalein facilitates transport 
into bile (Whelan, Hoch 8: Combes, 1970).
A number of investigations have recently been made with 
regard to the effects on bile flow of- compounds known to affect 
microsomal drug-metabolising enzymes. Phenobarbitone, a. 
microsomal enzyme inducing agent, increased bile flow in male and 
female rats (Klaassen, 1969; Levine, Millburn, Smith 8c Williams,
1970) but other well known inducing agents such as 3»^—benzpyrene 
did not have any significant effect, (Klaassen, 1969)* Goldstein 8c 
Taurog (1968) found that treatment of rats with 3»^-benzpyrene 
increased the biliary excretion of thyroxine as its g3.ucuronide 
without altering bile flow. • Microsomal enzyme induction itself 
does not appear to result in increased bile flow (Klaassen, 1969) 
but increased biliary excretion of several compounds .following 
phenobarbitone treatment has been attributed to the increase in 
bile flow (Hart, Guarino 8c Adamson, 1969; Klaassen, 1970). It has 
been suggested that microsomal enzyme induction enhances only the 
biliary.excretion of compounds which undergo metabolism prior to 
excretion and that excretion of compounds which are excreted 
unchanged is unaffected (Levine, et al, 1970). Although the 
endoplasmic reticulum is involved in the metabolism of foreign 
compounds it does not appear to play a role in their transfer from 
liver to bile (Levine, et al, 1970-). Certain hepatic cytoplasmic 
organic anion-binding proteins (Levi, Gatmaitan 8c Arias, 1969) niay 
play a major part in the selective uptake by the liver of certain 
organic anions from plasma and pretreatment with phenobarbitone 
increased the amount of one of these hepatic proteins (Reyes, Levi, 
Gatmaitan 8c Arias, 1969)- While microsomal enzyme inducers may 
enhance biliary excretion ,an inhibitor of these enzymes,
diethylarainoethyl diphenylpropylacetate (SKF 525-A) has been 
found to depress the biliary excretion of stilboestrol and 
phenolphthalein as their glucuronides but did not influence the 
biliary excretion of phenolphthalein glucuronide (Levine, _et al, 1970).
As discussed above, differences in biliary excretion, whether 
innate or induced by other compounds, can be an important reason 
for species differences in drug metabolism and when biliary 
excretion is extensive enterohepatic circulation and metabolism by 
the gastrointestinal flora can result in further differences in 
drug metabolism. Metabolism by the gut flora of a biliary excreted 
compound to a form suitable for easy reabsorption would result in 
enterohepatic circulation and possibly accumulation of the compound 
with enhanced biological action. The importance of enterohepatic 
circulation when considering the potential toxicity of a novel 
compound has been emphasised (Williams, Millburn & Smith, 1965)*
A compound present in the gastrointestinal tract either as a result 
of poor absorption, excretion in the bile or pancreatic juice or 
enteric secretion is exposed to the action of digestive enzymes and 
perhaps more significantly?to the action of bacterial enzymes.
The metabolic activity of the gut flora is high and metabolic 
alteration by this flora may substantially alter the toxicological 
or pharmacological activity of a foreign compound (Scheline, 1968a, 
1968b). It is pertinent here to briefly review the nature of the 
gut flora in man and common laboratory animals and the ways in which 
gut flora can metabolise foreign compounds. Various factors may 
rapidly change the constitution of the gut flora and so affect the 
quantity and type of products of bacterial metabolism.
The gut flora of man has only recently been extensively studied 
and then usually in the diseased state and large variations have 
been observed (Drasar, Shiner ,8c McLeod, 1969)* With improvement in 
techniques for culturing strict anaerobes it has been recognised 
that in most animals the dominant bacteria of the intestines are 
members of the genera Bacteriodes and Bifidobacterium (Drasar, 1967)* 
The gut flora of common laboratory animals when fed on conventional 
'diets has been investigated (Smith, 19^5) and although the florae 
were qualitatively similar the numbers of micro-organisms in 
certain parts of the alimentary tract differed greatly between some 
of the animal species. Differences in diet may be the cause of 
some species differences in gut bacterial composition- and changing 
rat diet from the normal ^1B pellets to a pork infusion significantly 
altered the gut flora (Smith, 1965)- Rats have been observed to 
indulge avidly in the practice of coprophagy and this may also 
influence the gut flora (Smith, 1965)* Strain and age differences 
of the host animal can have an effect on the composition of the 
gut flora (Dubos, Schaedler & Stephens, 1963; Lubos, Schaedler & 
Costello, 1963)* Considerable species differences have been found ^ 
in the extent to which orally administered substances are metabolised 
.in the gut, for example quinic acid is aromatised by gut bacteria, 
in Old-World monkeys but not in New-World monkeys or in a number of 
other laboratory animals (Adamson, Bridges, Evans 8c Williams, 1970). 
Man differs from rats and mice in normally having very few bacteria 
in the jejunum and proximal ileum, whereas rodents have an abundant 
flora throughout the gut (Editorial, Lancet, 1970)* It is 
therefore apparent that great care must be exercised in choosing a 
species of test animal for metabolism studies when metabolism by 
the gut flora is suspected.
Scheline (1968a) has reviewed in detail the types of reactions 
which gut bacteria have been found to carry out. The reactions 
generally involve degradative processes with a reduction in 
molecular size and are therefore in contrast to reactions in the 
liver which tend to increase molecular size. The reduction in 
molecular size may considerably alter the physico-chemical properties 
of a compound, frequently with an accompanying increase in 
biological activity or toxicity and again this is in contrast to 
the general tendency of hepatic metabolism of foreign compounds 
(Scheline, 1968a). The metabolic reactions catalysed by 
microorganisms in the alimentary canal can be classified into three 
main groups 1) hydrolyses; 2 ) modifications of the carbon skeleton; 
3) removal of groups or their modification. The metabolism of drugs 
by the intestinal microflora has only been investigated to a limited 
extent and relatively few reports have appeared which correlate 
specific intestinal reactions with a specific bacterial species 
(Scheline, 1968a). With improvements in culturing techniques more 
information should become available. Germ-free rats are being 
increasingly used in this type of investigation and using such rats 
Scheline & Midvedt (1970) have shown that dehydroxylation of caffeic 
acid is a reaction carried out exclusively by the intestinal flora.
c) Metabolism of Carbenoxolone
The earlier studies of the metabolism of carbenoxolone were 
discussed in detail in chapter one. Previous work had suggested 
that there was a species difference between man and rat in the 
extent of hydrolysis of the ester bond and removal of the succinate
side-chain following oral administration. However, when 
administered intraperitoneally to biliary cannulated rats the 
hydrolysis was delayed and conjugates of carbenoxolone were 
excreted in the bile. Preliminary work in man showed a similar 
pattern after oral administration with only up to 20% hydrolysis 
of the ester.occurring (Iveson, 1968). The species difference after 
oral administration was attributed to differences in enzymes 
present in the gastrointestinal tract. These differences may arise 
in at least three separate ways. There may be differences in the 
integral enzymes of the gut mucosa v/ith hydrolysis occurring in 
the rat during absorption from the gastrointestinal tract.
Secondly the enzymes secreted by the mucosa of the rat may have a 
greater hydrolytic action and thirdly the species difference may 
reside in the different metabolic capabilities of the normal 
gastrointestinal flora of rat and man.
The metabolic activity of the gut flora seemed the most likely 
cause of the species difference and Iveson (1968) attributed the 
hydrolysis of the ester linkage, which occurs in rats following 
oral administration, to the gut flora. Carbenoxolone may be 
metabolised prior to absorption and further metabolism may occur 
following excretion of the conjugates in the bile. Scheline (1968a)- 
has reviewed the evidence which suggests that bacterial esterases 
may play an important role in the intestinal hydrolysis of esters 
and has also shown that the rat intestinal flora can hydrolyse a 
number of different types of compound including esters (Scheline, 1968c
Silboestrol ’glucuronide is hydrolysed by the gut flora (Fischer, 
Millburn, Smith & Williams, 1971; Clark, Fischer,Millburn, Smith & 
Williams, 1969) and hydrolysis of glucuronides is another very 
common reaction carried out by the gut microflora (Scheline, 1968a, 
1968c). Hydrolysis of carbenoxolone glucuronide conjugates occurs 
in the rat after intraperitoneal administration (Iveson, 1968) 
and also in man after oral administration (Downer, e_t al, 1970).
Other possible metabolic transformations of the carbenoxolone 
molecule that could be effected by the gut flora are decarboxylation 
in the C-A-1 and C-30 positions, aromatisation, particularly of 
ring A, or reduction of the 11-oxo-12-ene structure. .When 
carbenoxolone v/as administered rectally to three human volunteers 
no carbenoxolone was subsequently detected in their blood or
faeces but there was evidence of triterpenoids in the faeces which
did not contain the 11~oxo-12-ene structure (Parke, private 
communication). The obvious approach to the study of the role of
gut flora in the metabolism of carbenoxolone would be to use
germ-free animals but these were not available. Instead, experiments 
were done using rats which had been pretreated orally with a 
suitable mixture of neomycin sulphate and tetracycline hydrochloride 
to suppress the gastrointestinal flora.
The species difference in metabolism also meant that the rat
C'
was an unsuitable animal for further study of the biochemistry of 
carbenoxolone. The metabolism of carbenoxolone has therefore been 
investigated in the Squirrel monkey as a possible alternative species 
Administration of radioactively-labelled carbenoxolone to
human subjects has also been carried out. A new formulation
of carbenoxolone as a 1positioned-release capsule’ has been made
with the hope that if sufficient quantities of drug could be
delivered to the duodenum it would be effective in the treatment of
duodenal ulcers. An early trial of this capsule (Craig, jet al,
1967) indicated potential usefulness in the treatment of duodenal
ulcers. V/hen this preparation was first introduced it was believed
by some gastroenterologists that no significant absorption of
carbenoxolone would occur and that there was therefore no risk to
the patient of mineralocorticoid-like side effects sometimes
encountered in gastric-ulcer patients treated with the usual tablet
*1 Zj.
formulation of carbenoxolone. The absorption of[ C] carbenoxolone
following administration as such a capsule has been studied in
three duodenal ulcer patients, v/ith their permission,in collaboration
with Dr. D. Colin-Jones. A\ report of this work has been
published (Lindup, Parke & Colin-Jones, 1970). The absorption
and excretion of radioactively-labelled carbenoxolone has also been
studied in human volunteers. During the course of this work the
opportunity was taken to investigate the metabolism of 
14
[1 ,*f,- C^] succinate in a human volunteer since this would
provide information concerning the metabolic fate of any succinate 
arising from hydrolysis of the drug. It also appeared that very 
little experimental work in humans had been carried out with this 
fundamental biochemical substrate but intraperitoneal administration 
to rats resulted in 86/j of the dose being excreted as labelled 
carbon dioxide (Gould, Sinex, Rosenberg, Hollomon & Hastings, 19^9)*
2. EXPERIMENTAL
a) Materials
l8P-Glycyrrhetic acid, m.p. 284-7°, [a] + 1 6 3 + 1 °
(c, 1.0 in CHCl^); carbenoxolone, m.p. 312-7°C, [a]^^ + 132 + 1° 
(c, 1.0 in CHCl^) and other triterpenoids were donated by 
Biorex Laboratories Ltd.
The anaesthetic agents, phencyclidine hydrochloride.
(Parke, Davis & Co., Hounslow, London) and anaesthetic 
diethylether (British Drug Houses) were used in the animal 
surgical procedures and the antibiotics neomycin sulphate and 
tetracycline hydrochloride were used to suppress the animal gut 
microflora. All other chemicals and solvents were supplied by
B.D.H. and other usual laboratory suppliers.
Cannula.tubing: internal diameter 0.4 mm., external
diameter 0.8 mm., (Portex) was used for biliary cannulation.
Chromatographic materials were purchased from Merck, AG Darmstadt.
Scintillator chemicals, including napthalene; 2,5-diphenyloxazole
(PPO); 1,4-bis-2(4 methyl-5-*phenyloxazolyl) benzene (dimethyl
POPOP); "Cab-0-Siln; and radioactive standards were obtained
14from the Packard Instrument Co. [1,4- C^ ] Succinic acid (10.3 mg;
0.5 m Ci) and tritium labelled water (1 ml; 5*0 Ci) were 
obtained from the Radiochemical Centre, Amersham, Bucks.
1bi) Preparation of [carboxypropionyl-1,4- C^] Carbenoxolone
Carbenoxolone, labelled with carbon-1 -^ in the C-1 and C-*f 
atoms of the succinate side-chain was prepared by the following 
method (Dr. Turner, Biorex Laboratories Ltd.).
to a round-bottom flask by dissolving in a small quantity of 
methanol and then evaporating off the methanol. Non-radioactive, 
succinic acid (1 .1 8 g; 0 .01 mole) was added and the acid converted 
to. the anhydride with acetyl chloride (Fieser 8c Martin, 19^5)*
When all the acid had dissolved and then crystallised (1*5-2 hr.), 
acetic acid and residual acetyl chloride were removed under vacuum, 
and anhydrous l8j3-glycyrrhetic acid (^ -.5 g> 0 .0 9 6 mole) was added, 
followed by 15 ml. anhydrous pyridine. This mixture was refluxed 
overnight. Chloroform (bO ml.) was then added and the solution 
washed well with cold dilute HC1, then v/ith water. The solution 
was dried v/ith anhydrous Na230^ sulphate and most of the CHCl^ was; 
evaporated then acetic acid (60 ml.) v/as added. The solution v/as; 
concentrated, to about 25 ml. by boiling and left to crystallise.
The resulting yellow-brown crystals were filtered off, washed with 
aqueous acetic acid, then aqueous alcohol and dried in an 
Abderhalden pistol. Two further recrystallisations from glacial 
acetic acid were carried out to produce a v/hite crystalline material 
(2.0 g, m.p. 512-515°; specific radioactivity = 90 M-Ci/g.).
r 1 bA second batch of [carboxypropionyl-1 ,^f- C^J carbenoxolone was
obtained by adding unlabelled carbenoxolone (5*5 g) to the mother
liquors followed by recrystallisation (2 .5 g» specific radioactivity
= 50 HCi/g.).
Succinic acid (0.5 m Ci; 10.5 mg.) was transferred
•Z
ii) Preparation of [(l8j3-glycyrrhetic acid)G- Hi Carbenoxolone v
Platinum oxide catalyst (80 mg.) was placed in a pyrex glass 
tube. Glacial acetic acid (1.5 ml.) was added to the catalyst and 
the resulting suspension v/as shaken under hydrogen at 20 Ib./sq.in. 
pressure for 30 min. Thereupon the brown platinum oxide was: 
reduced to a fine suspension of platinum black. 3-0-Acetyl 
l8p-glycyrrhetic acid (1.2 g) was mixed with glacial acetic acid 
(2.5 ml) to form a:, slurry that was transferred to the pyrex glass 
tube. Tritium water (0.5 ml; 2.5 Ci) was added to the contents 
of the tube. The tube was cooled in an ice-water mixture, evacuated 
with a water pump and sealed. The sealed tube was placed in a 
screw-top tubular metal container and then heated at 127°0 for 
72 hours.
The tube was allowed to cool, opened and the tritium water 
and acetic acid removed by filtration. The 3-0-acetyl l8p- 
glycyrrhetie acid was dissolved in CHCl^ (10 ml.) and the platinum 
black removed by filtration. The CHCl^ was evaporated and water 
(5 ml.) and a solution of KOH in methanol. (135 ml; 5% U/v) v/as 
added. The mixture v/as refluxed under nitrogen for 2 hours and 
then 2M-HC1 was added to precipitate tritium-labelled l8p-glycyrrhetic 
acid. The [G - H] l8j3-glycyrrhetic acid v/as recrystallised from 
benzene as follows. [G-H] l8p~Glycyrrhetic acid (500 mg.) was 
suspended in benzene (5 ml.) and the mixture heated to boiling and 
methanol (^1.0 ml.) added dropwise until a solution was obtained.
The methanol was then boiled off and [G-^ H.] l8p-glycyrrhetic acid 
left to crystallise. The product appeared to contain benzene of 
crystallisation v/hich v/as removed by dissolving in ethanol, boiling
7
to remove benzene and the [G- h ] l8{3-glycyrrhetic acid precipitated 
with.water*
Yield: batch I = 792 mg, specific radioactivity = P-Ci/g;
batch II = 625 mg, specific radioactivity = 100 p,Ci/g. Two further
n
batches of tritium-labelled material were prepared using the same 
tritium-labelled water but the specific radioactivities obtained 
were low* The melting point, optical rotation and infra-red spectrum 
(see Fig* II-1) were identical with that of authentic l8p-glycyrrhetic 
acid. The infra-red spectrum v/as measured in a KBr disc (1 mg. l8j> - 
glycyrrhetic acid in 1^0 mg. KBr.) v/ith a. Perkin Elmer Infracord 
infra-red spectrophotometer.
7
[(l8p-glycyrrhetic acid)G- H] Carbenoxolone was prepared from
this [G- H] l8p-glycyrrhetic acid by esterification using
unlabelled succinic acid in the manner described above for the
1preparation of [carboxypropionyl-1, A— C^] carbenoxolone*
When the sodium salt of labelled carbenoxolone v/as required, 
slightly less than the theoretical amount of sodium hydroxide in 
1 ml. of water" v/as added to carbenoxolone (1 g.) suspended, in 
1-2 ml. of acetone. The neutralisation was completed v/ith sodium 
carbonate solution and then acetone was added to precipitate the 
sodium salt.
Radiochemical purity: the radiochemical purity of labelled
carbenoxolone, as opposed to the chemical purity, did not appear 
to have been adequately checked previously. (Iveson, e_t al, 1966).
A-compound present in minute amounts as a chemical impurity may 
make a significant contribution to radiochemical impurity
(Bayly & Evans, 1966), The radiochemical purity of the two batche
'[k 3of C-labelled carbenoxolone and H-labelled. carbenoxolone v/ere.
checked by thin-layer chromatography (section b) iii) using two
different solvent systems. The silica gel corresponding to known
intervals was removed from the plate and radioactivity
determined by scintillation counting. Thin-layer plates were also
scanned with a Panax Radiochromatogram scanner. Less than 1%
radiochemical impurity was detected in each of the batches of
labelled material. The radiochemical impurity present with
[carboxypropionyl-1C^] carbenoxolone appeared to be trace
amounts of [1»^ — succinic acid and this is known to be
radiochemically stable (Bayly Sc Evans, 19&7)*
iii) Animals
The rats used were the v/istar albino strain (body weight 
160-220 g) and were housed in the University’s animal unit and fed 
on diet 41B and water ad.lib.
The Squirrel monkeys (Saimiri sciurus) were obtained from 
Shamrock Farms (Great Britain) Ltd., Upper Horton Farm, Small Dole 
Henfield, Sussex. The experiments with these animals were 
performed at Biorex Laboratories where the monkeys were maintained 
on a diet of fresh fruit (banana, apple, orange) and rat diet A-1B. 
The co-operation and assistance of Dre J.B. Dekanski with these 
monkeys is gratefully recorded.
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b) Methods ’
i) Determination of Radioactivity
Radioactivity was determined by liquid scintillation counting 
and the three machines used in the course of this work were:
Packard Tri-Carb Spectrometer (model 321^) at St. Mary*s Hospital 
Medical School, Tracerlab Liquid Scintillation Spectrometer 
(model L.S.C. - 30) and Packard Tri-Garb Spectrometer (model 3320) 
at the University of Surrey.
Samples were counted in 20 ml. of one of two dioxan-based 
scintillators.
(A) Naphthalene (60 g), P.P.O. (^ -.0 g), dimethyl P0P0P (0.2 g), 
methanol (100 ml), 1,2-ethanediol (20 ml) in 1,A-dioxan to 
make 1 litre.
(B) A gel scintillator consisting of a 5% W/V suspension of 
nCab-0-Siln, a thixotropic gelling agent, in (A).
These dioxan-based scintillators can accommodate up to 10% 7/v 
of water without loss of efficiency but generally the sample volume 
counted did not exceed 3% V/v of the scintillator volume. Aqueous 
solutions and organic solvents were counted in scintillator (A) and 
samples containing protein or particulate matter such as barium 
carbonate, bile, plasma, silica gel, urine, tissue homogenates and 
faecal extracts were counted in the gel scintillator. Samples were
left in the counter for at least 2k hr. before counting to reduce.
o A-chemiluminescence and then counted at 0 G for 10 mins. or 10 count
Counting efficiency was determined by the internal standard
method for heavily quenched samples using a suitable dilution of
the [14C] toluene, [3H] toluene or [ ] water radioactive standards.
The channels ratio method of Bush (19&3) was used for most samples
and a suitable quench correction curve was prepared for each...
counter using either an appropriate biological material such as:
plasma, or chloroform which gave a wider range of quenching.
14-Counting conditions for doubly-labelled samples containing C 
3and H were determined by a method supplied by the Packard 
Instrument Co., based on the method of Bush (1964-). Counting 
efficiencies of each isotope were also determined by the use of 
internal standards. Corrections were made for the radioactive 
'decay of tritium.
All determinations were done in duplicate or triplicate and 
suitable blank and control vials were included for counting.
ii) Preparation of Samples for Liquid Scintillation Counting
Bile, tissue homogenate, material from chromatographic plates 
and urine samples were counted directly in the gel scintillator. 
Plasma was obtained by collecting blood into heparinised containers 
and centrifuging to deposit the erythrocytes. Samples were stored 
at ~10°C until radioactive determinations were carried out.
Tissues were homogenised in either water or 1M-NaOH to give 
an approximately 10% W/v homogenate. Faeces and any tissue that 
was to be examined for the presence of carbenoxolone and its 
metabolites prior to determination of radioactivity was homogenised
in water to’prevent the hydrolysis of the succinate ester group 
which occurs in strong alkali. Tissues such as the liver' and 
kidney were homogenised with a motor driven tissue grinder 
consisting of a Teflon pestle in a close-fitting glass mortar 
(Arthur H. Thomas Co., Philadelphia, U.S.A.). Other tissues such 
as the gastrointestinal tract which contain muscle and connective 
tissue were chopped with a scalpel and homogenised in water with 
glass beads using a; Waring blender. Prior to counting, samples of 
homogenate (3 ml.) were decolourised with an equal volume of 20 vol. 
hydrogen peroxide. Residual peroxide was destroyed by heating on a 
water bath, the sample made up to volume and an aliquot counted in 
the gel scintillator. Faeces were either extracted with methanol 
in a Soxhlet apparatus and the extract concentrated or treated in 
a similar way to the gastrointestinal tract.
14-Respiratory CO^ was collected by drawing the expired air 
through gas wash-bottles, fitted with sintered glass aerators, each 
containing an appropriate volume of 1M-NaOH. The contents of the 
wash-bottles were pooled after the collection period, an 
equivalent amount of solid ammonium chloride was added and allowed 
to dissolve and then 2M-BaCl0 was added to precipitate BaCO^
(Calvin, Heidelberger, Reid, Tolbert & Yankwich, 194-9)- The. 
precipitate was filtered through a Gooch crucible, washed with 
1% W/v NH^Cl solution and water and then dried. Samples of 
BaCO^ (200-300 mg) were counted in the gel scintillator. It has
14.
been found that Ba CO^ may be counted with an efficiency up to 
83% by this method (Turner, 1989)-
iii) Thin-Layer Chromatography
This technique was carried out by similar methods to those 
described by Coleman & Parke (19&3) and Iveson (1968). Bile, 
plasma, extracts of faeces and other biological materials were 
examined for carbenoxolone and its metabolites by ascending thin 
layer (0.25-1 -0 mm.) chromatography on plates of fluorescent 
silica gel (Kieselgel, HF 254-). The plates we re activated at 
100-120°C before use and samples were applied as spots or bands 
using a glass syringe (1 ml.) fitted with a fine needle. The 
plates were developed for 10 cm. in unlined glass tanks, suitable 
control samples of bile and other biological materials were 
chromatographed as well as carbenoxolone and other appropriate 
reference compounds. Solvent systems used were A: acetic acid -
butan-1-ol - 1,2-dichloroethane - water (4-:1:4-:1, by vol.); B: 
butan-1-ol - ammonia (s.g. 0.88) (5:1» by vol.). Compounds 
containing the conjugated 11-oxo-12-ene structure were detected by 
their absorbance of ultraviolet light (Hanovia Chromatolite lamp, 
^max = nm  ^an(^  pn £3-uorescen'k silica gel plates appeared as 
dark purple spots on a. green background. Three detecting reagents 
were used: (i) SbCl,_ (5% w/v in dry CHCl^) gave a 'brown colour
with enoxolone, triterpenoids and similar hydroxylated compounds 
when heated for 10 min. at 120°C; (ii) glucuronic acid and 
glucuronides were detected as violet spots by spraying with 
naphtharesorcinol (0.2% W/v naphtharesorcinol in acetone and 
H^PO^ 9% V v  in water; 5:1» by volume, mixed as required) and 
heating for 10 min. at 120°C; (iii) succinic acid was detected by 
spraying plates with a solution of 0.04- g. broraocresol purple in 
50% ethanol adjusted to pH 10 with 2M-NaOH, bright yellow spots on
a blue background were formed (Randerath, 196*0. Metabolites were 
eluted with methanol.
For determination of radioactivity serial strips of silica gel, 
corresponding to known R^ units, were scraped off the plate and 
counted in gel scintillator.
iv) Metabolism of [ij^-^C^] Succinate in a Human Volunteer
Experiment 1 
1*fThe C-labelled succinate for these experiments was obtained
r 14- i  ' r 14- nfrom the L CJ succinic anhydride used in the preparation of [ CJ
1carbenoxolone described earlier. [ C] Succinic anhydride (10*2 mg)
was mixed with 10% W/v Na_C0_ (0.1 ml.) and diluted to 25 ml. v/ith
v/ater and then warmed slightly to ensure conversion to sodium
succinate. A portion (20 ml; 4-.11p.Ci) was taken orally by a
subject (D.V.P.) on a fasting stomach at 10.00 a.m. Urine and
samples of expired carbon dioxide were then collected at intervals
for determination of radioactivity. Respiratory CO^ was collected
for 10 minutes at the times shown by bubbling the expired air
through two wash bottles each containing 1M-Na0H solution (500 ml)
1 *fand the 0 content determined as described above in section (ii).
The subject was able to breathe through a Douglas respiratory valve
v/hile expired carbon dioxide v/as being sampled. Blood v/as collected
ri4 i0.5 hr. and 2 hr. after the dose of’ L CJ succinate, heparinised, 
centrifuged and an aliquot (1.0 ml.) of plasma counted. The faeces, 
from days 1,2 and 3 after dosing were collected and counted as 
described previously. Normal eating and drinking were resumed 
three hours after dosing.
r 1^ iThe L ’C J urea present in the pooled urine samples v/as 
investigated as follows: Urea (2*0 g) was dissolved in an aliquot
(10 ml.) of urine and conc. HNO, (5 ml.) added to precipitate urea 
nitrate. The precipitate of urea nitrate v/as filtered off, 
redissolved in water (10 ml.), boiled for 1 min. v/ith charcoal, 
filtered and allowed to cool. The urea nitrate was reprecipitated 
with conc. HN0_ (5 ml.) and cooled well. The product v/as filtered 
off in a Bucher funnel, dried well, powdered v/ith a mortar and 
pestle and counted in gel scintillator.
Experiment 2
On a separate subsequent occasion a second similar experiment 
was performed with only respiratory CO^ samples being taken but 
at more frequent intervals. The [ TC J succinate (0.6*f p,Ci;
1.632 mg.) was taken orally in 19«5 ml. of aqueous solution. The 
sampling times (3 min. each), and results are given in Table II-3»
v) Partition Coefficient of Carbenoxolone
The partition coefficient of carbenoxolone was measured between 
chloroform and n-octanol and an aqueous phase which v/as either
0.1M phosphate buffer (pH = 7.^ -) or 0.1M-HC1. Both the organic 
solvents and the two aqueous systems were pre-saturated v/ith the
_1 if. ->
relevant aqueous or organic phase. [ Cj Carbenoxolone (90{iCi/g.)
was then dissolved at a concentration of 50 U-g/ml. in the chloroform
and the n-octanol. Aliquots (10 ml.) of the organic phases were
shaken in glass-stoppered tubes v/ith an equal volume of aqueous phase
for 1 hr. at room temperature (2A-°C) using a rotary mixer. The two
r1 ^  *1phases were separated and the concentration of [ CJ carbenoxolone 
in portions (0.3 ml.) of each phase determined by scintillation 
counting. All determinations were done in duplicate.
vi) Absorption of Carbenoxolone Administered Orally as a Positioned-
release Capsule
The absorption of carbenoxolone administered in a special 
capsule to three duodenal ulcer patients has been studied. This 
work v/as carried out in conjunction with Dr. Duncan Colin-Jones at 
University College Hospital, who performed the radiological 
examinations and took the blood samples.
r 1 ^  n
These experiments were performed using [_ CJ carbenoxolone 
sodium from the second batch of radioactively-labelled material 
(see section 2(a)(i), above) and this was used by Biorex Laboratories 
Ltd. to incorporate into three *positioned-release1 capsules
r 1O'Duogastrone1*). Each capsule contained [ C] carbenoxolone sodium
/iZj. .
(30 mg. equivalent to 2.0 pCi of C), 200 mg. Barium sulphate, 
and 13 mg. of sodium bicarbonate-citric acid mixture to generate 
carbon dioxide, in a specially hardened gelatin capsule. It v/as 
determined in previous experiments with three normal human 
volunteers that in similar capsules a minimum content of 200 mg. 
barium sulphate v/as necessary for radiological detection of the 
position and bursting of the capsule.
One capsule was administered orally to each of three patients: 
P.B. , a. man aged *f6, v/eighing 67 kg; W.C. , a man aged 311 
weighing 57 kg; and M.C., a woman aged 4-5, v/eighing 86 kg; each of 
whom had radiologically confirmed duodenal ulcers. The capsule v/as 
swallowed in the early morning after eight hours without food, one 
cup of tea v/as taken three hours later, and a normal lunch was 
eaten four to five hours after the capsule. Each patient v/as 
examined radiologically at intervals to ascertain the location and
time at which the capsule burst. Blood (6 ml.) was collected at 
intervals of 0.5 .to 2 hours, in lithium-heparin bottles, and 
centrifuged at 2,0b0 revs./minute for 20 minutes to separate the 
plasma.
The blood concentrations of carbenoxolone, and/or any of its
-i if
conjugates, were determined by measuring the total content of C 
of the plasma, since it has been shown that carbenoxolone present 
in human blood is associated with the plasma proteins (see: 
chapter three) and is reasonably stable, the G-label in the 
succinate side-chain being liberated to only a slight extent by 
metabolism of the drug (Parke, 1968). Samples (1.0 ml.) of the 
plasma were counted in gel scintillator.
/ - 
Pooled plasma from the patients v/as acidified and extracted
v/ith CHCl^ (2 x 15 ml.), the extract concentrated to 0.1 ml. and
chromatographed on thin-layer plates in solvent system B.
Heference samples of carbenoxolone and enoxolone were chromatographed
at the same time and after development the plates were examined under
TJ.V. light and sprayed for detection of glucuronides.
vii) Absorption and Elimination of f^cl- and f1-labelled
Carbenoxolone in Human Volunteers
r 1 Zf
The absorption and elimination of a mixture of [_ C J carbenoxolone 
*2
and [ H] carbenoxolone has been studied in two human volunteers.
The use of this mixture enabled both parts of the molecule to be 
traced and v/as /simpler and more economic than synthesis of doubly- 
labelled carbenoxolone. It was considered very unlikely that
significant mass effects due to the isotopic labels would occur
r 14 -| nsince the mass defect of [ CJ carbenoxolone was less than O.o%
and the [ H] carbenoxolone did not have the very high specific
activity of compounds which have revealed mass effects. It has
been reported by Benraad, Verwilghen & Kloppenborg (19^6) that
'lb
paper chromatography resulted in isotope fractionation of [ ‘C J 
aldosterone and [ ^H] aldosterone of high specific activities.
r l 4  n r 3  nHowever, no isotope fractionation of [ CJ- and [ H-J carbenoxolone. 
after thin-layer chromatography in two different solvent systems 
v/as detected.
14 3[ C] Carbenoxolone (90pCi/g; 27.8 mg.) and [ H] carbenoxolone
(34.6 p, Ci/g; 72 mg) were administered together in aqueous solution
(24 ml.) as their sodium salts. The solution, flavoured v/ith
orange juice, v/as taken orally by the volunteers (D.V.P. and D.H.)
on a fasting stomach in the early morning. Blood samples were
obtained by venepuncture 1,2,4 and 6 hr. after dosing and respired
carbon dioxide v/as sampled at convenient intervals for periods of
ten minutes as described for the succinate experiment (see 2(b)(iv)
above). Urine was collected for 24 hr. and faeces for 4 days after
dosing and these samples were kept frozen (-10°C) until analysed.
The radioactivity present in the samples taken v/as determined by
liquid scintillation counting as described in sections (i) and (ii)
above. Samples were examined for carbenoxolone and its metabolites
by thin-layer chromatography as described earlier in this section.
’ r *\k Tviii) Metabolism of | CJ Carbenoxolone in the Squirrel Monkey
rlij. -1
The metabolism of [ CJ carbenoxolone after oral administration 
has been studied in four intact squirrel monkeys and in three 
squirrel monkeys each fitted with a biliary cannula,
1, Intact Monkeys
Four squirrel monkeys (No.1, F, 600 g; No.2, M, 790 g;
No.3? M, k35 gj No.4-, F, 3S5 g) were dosed orally with ] 
carbenoxolone (90 jJ-Ci/g; 10 mg/kg). Each monkey was fasted
overnight but allowed water ad. lib, prior to administration of the:
drug in 0.1M-NaHC0^ solution (3 ml.) by stomach tube the following 
morning. The monkey was then placed in a perspex metabolism chamber 
and urine, faeces and expired carbon dioxide collected over a 
period of four days after dosing. Small blood samples were,
obtained within the first 2k hr. after dosing:, from two (Nos. 3 & ki)
of the monkeys. The expired carbon dioxide was collected by drawing 
the expired air through three gas wash-bottles, fitted with sintered 
glass aerators, each containing 1M-NaOH (230 ml.) and BaCO.. was
~~ 5
precipitated and counted as previously described. Six hours after 
dosing the monkey was allowed free access to food. At the end of 
the four day period in the metabolism cage blood v/as collected in 
heparinised tubes by cardiac puncture under ether anaesthesia.
The monkey v/as killed v/ith an overdose of ether and at post-mortem 
the adrenals, brain, spleen, lungs, liver, kidney, stomach and 
intestines were removed for determination of radioactivity.
2. Biliary Cannulated Monkeys
Three squirrel monkeys (No.5 * M, 900 g; No.6, M, 800 g;
No.7» M, 625 g) were used for these experiments. The monkeys were, 
starved overnight but allowed water ad. lib, and dosed orally in 
the morning with [ C] carbenoxolone (90p,Ci/g.) following biliary 
cannulation. The drug was administered in propylene glycol by 
stomach tube.
Ether and phencyclidine hydrochloride (Seal 8c Erickson, 19&9)
were used to produce surgical anaesthesia. Initially,.two doses
of phencyclidine hydrochloride (1 mg/kg, intramuscularly), were.-
administered, one just before cannulation and one an .hour later and
further doses were injected as required during the experiment. A
vertical midline incision was made and the common bile duct
cannulated with a polythene cannula (internal diameter = 0.4 mm,
external diameter = 0.8 mm). The cannula was exteriorised through
an incision in the abdominal wall made with a large gauge injection.
needle and bile v/as collected in graduated tubes cooled in an ■
r"l4 1ice-water mixture. The monkey was dosed with [ GJ carbenoxolone 
and bile collected hourly and during this time the monkey v/as.kept 
in a Restraining chair1 (see fig.II-2) as described by Lang (1968). 
At the end of the period of bile collection a blood sample was 
obtained under ether anaesthesia from the right ventricle by cardiac: 
puncture and collected in heparinised tubes. The monkey was killed 
v/ith an overdose of ether and at post-mortem bile remaining in the 
gall bladder and cannula was collected, the urine in the bladder, 
the liver, stomach and intestines v/ere removed for determination of 
radioactivity.
Fig.II-2 Restraining Chair for Squirrel Monkey.
(a) Side view
)_
(b) Frontal view 90°
10 cm.
6 cm.
30 cm.
ix) Metabolism of V c ]  Carbenoxolone by the Gastrointestinal Flora
of the Rat
(a) .Experiments in vivo
Three female V/istar albino rats were dosed orally with 
carbenoxolone (10 mg/kg; 90 l^ Ci/g.) in propylene glycol. Each rat 
was placed in a separate metabolism cage and the expired carbon 
dioxide, urine and faeces collected over a period of hours and
the radioactivity present in the excreta determined by liquid 
scintillation counting. The rats were then killed and the livers 
and intestines removed for determination of radioactivity.
Similar experiments were performed v/ith rats that had been 
pretreated with antibiotics. f^C ] Carbenoxolone (10 mg/kg;
90 PCi/g) in propylene glycol was administered orally to 2 female- 
and 2 male rats which had been previously treated twice daily for 
3 days with neomycin sulphate (100 mg.) and tetracycline hydrochlorid 
(30 mg) administered orally in 1 ml of aqueous suspension. The 
respiratory carbon dioxide, urine and faeces were collected and the 
radioactivity determined as previously described. During the 
antibiotic pretreatment period the rats were housed in separate- 
cages and the 'Steralit1 bedding for each rat was changed after 
each dose of antibiotic mixture, i.e. tv/ice per day. The faeces 
were shov/n by culture on plates of blood agar to contain very few 
viable micro-organisms.
(b) Experiments _in vitro
The metabolic effect of gut bacteria on carbenoxolone was 
examined by incubating the stomach from six rats (3 male, 3 female)
with carbenoxolone as follows: [ 14C] Carbenoxolone (1 mg; 901 Ci/g)
in ethanol (0.1 ml.) was incubated v/ith the contents from a rat 
stomach (1 g) in 10 ml. of nutrient broth made up in 0.1M phosphate- 
buff er (pH = 7.zO. The incubation v/as carried out under for 
12 hours overnight in side arm tubes which v/ere shaken in a.
Mickle Incubator. Duplicate control tubes which did not contain 
stomach contents were also similarly incubated. The incubated 
materials v/ere then acidified to pH 1 v/ith 2M-IIC1 and extracted 
three times with 0.5 vol. chloroform. The CHC1_ extracts were
j
bulked, washed v/ith water, dried (anhydrous Na^SO^) and the 
radioactivity of an aliquot (0.1 ml.) determined by liquid 
scintillation counting. The remainder of the CHC3--, extract v/as 
concentrated and examined by thin-layer chromatography. To 
determine whether the [_ QJ succinate arising from the hydrolysis
1 Zj. p 1
of carbenoxolone was metabolised to CO^, L CJ carbenoxolone
v/as incubated v/ith rat stomach contents as before and a current of
was drawn through the side arm tube and into 2M-NaOH contained
1 Z{.
in two wash-bottles. The trapped CO^ v/as then counted as
1 if. 1 Zj.
Ba C0_. The recovery of G from the incubates containing stomach 
5
contents v/as compared with that from the control tubes arid in this
r1^f i
v/ay the extent of hydrolysis of [ CJ carbenoxolone by micro­
organisms in the rat stomach v/as determined.
RESULTS '
Table U  - 1 Radioactivity Excreted in the Urine and Expired Air of a' •> " "" '
Human Subject after Oral [ CjSuccinate. (Experiment 1).
Time after • Urine Expired air
dosage 1
(hr.) Volume
14-Dose C excreted (% dose/1 0 min.
(ml) ($) sample)
0.5 — — 18.0
1 56 0.24- 12.0
2 38 0.19 3-0
3 k6 0 .16 0 .6
k 62 0 .12
5 14-2 0.05
7 138 0 .06
8 25 0.02
10 38 0.04- -<0.01
14- 210 0.18
16 162 0.05
20 212 0 .0 6
22 82 0.04-
24- 84- 0 .02
Total 1,295 1.23'
Faeces (day 1 and day 2 - 1.65$ of dose 
(
(day 3 - no detectable radioactivity.
Table II-2 Plasma Radioactivity in a Human Subject after
Oral L CJSuccinate. (Experiment 1).
Time after Plasma radioactivity Total plasma Dose in total
dosage (d.p.m./ml) radioactivity* plasma volume'^
(hr. ) (d.p.m.)
0.5 128 ,800 1.4-5
2 .0 114; 319 ,20 0 3 *6 0
* Assuming mean plasma volume = 4-0 ml/kg body wt. 
 ^ Total body weight = 70 kg.
Table II-3 Radioactivity Excreted in the Expired Air of a Human 
Subject after Oral l^cjsuccinate. (Experiment 2).
Time after dosage 
(min)
Dose
(50.
5 - TO 2 .0 3
1 5 - 2 0 8 .2 8
33 - 38 8.4-V
4-6 - 51 10.9T,
77 - 82 5*78
115 - 120 3*13
Total* 118 .00
* Estimated by graphic integration.
Table 11-k Plasma Concentration and Degree of Absorption of
r-1^* -iL GJ Carbenoxolone Administered Orally in 
Posltioned-Helease Capsules*
Patient Weight
(kg)
Maximum
plasma
conc.
(p,g/ml)
Time from 
capsule 
burst to 
max* plasma 
conc* (hr)
Plasma 
vol* * 
(1.)
Total
plasma C J 
curb e n oxolone 
(mg)
Dose in 
plasma.
m
P.B. 6? 9.1 1.5 2.7 2k.6 k9
M.C. 86 7.6 2 3*k 2 5 .8 52 • %
W.C. 57 5.2 >k 2.3 12.0 2k
* Assuming a mean plasma volume of ml/kg body weight*
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Fig.II-3 Plasma Concentrations of [^CjCarbenoxolone after Oral
Administration in a Positioned-Release Capsule.
The plasma concentration curves are for patients P.B., M.C. and W.C. 
Times of capsule when burst are indicated by the arrows.
8
6
2
W.C.
P.B. M.C.
6 82
Time after administration (hr.)
Table II - 3 Apparent Partition Coefficient of Carbenoxolone
Phase Concentration of [^C]C{
at
1.0
irbenoxolone (d.p.m./0.5 ml) 
PH:
7.4
CHC1
O
aqueous
CHCl -/aqueous 
P
5,345 5,373 
<4 <4 
>1,000 >1,000
3,152 3,010 
2,207 2,253 
1.43 1.34-
n-octanol
aqueous
octano]/ aqueous
4,122 4,010 
<4 <4 
>1,000 >1,000
' 4,147 4,025 
187 185 
22.18 21.76
14 3Table II - 6 Plasma Concentration of f C] f HiCarbenoxolone after 
Oral Administration to Human Subjects
Time after 
dosage 
(hr)
14 3Plasma Concentration of [ C] [ Il]Carbenoxolone
(pg/ml.)
Subject
D.V.P.
Subject 
. D.H.
1. Represents approximately 51$ of the dose circulating in the plasma*
2. Represents approximately 49$ of the dose circulating in the plasma*
Table II - 7 Excretion of Radioactive Carbon Dioxide in the Expired Air
r 14 nof Subject D.V.P. after Oral Administration of 1 C|~ and 
3r HlCarbenoxolone♦
Time after Rate of
dosage excretion $ Dose Cumimilative fo
(hr) (d.p.m./60 min)
0.5 2,574 0.05 0.05
1 1,767 0.03 0.08
2 8,970 0.16 0.24
3 5,628 0*10 0.34
4 1,428 0.03 0.37
5 1,626 0.03 0.40
6 1,122 0.02 0.42
7 14,550 0.26 0.68
8
; 137,046* 2.47 3.15
20
21 6,534 0.12 3.27
22 \ 18,600* 0.34 3.61
23 )
24 12,066 0.22 3.83
25 9,300* 0.17 4.00
26 6,246 0.11 4.11
27 \ 10,992* 0.20 4.31
28 1
29 4,746 0.09 4.40
30
|
i
122 ,064* 2.20 6.60
45
46 10,512 0.19 6.79
47 5,913* 0.11 6.90
48 1,314 0.02 6.92
71 0 0.00
Total 382,998 6.92 6.92
* Estimated rate*
Table II - 8 Excretion of Radioactive Carbon Dioxide in the Expired Air
r 14 -iof Subject D.H. after Oral Administration of | C]~ and
r3)l]Carbenoxolone .
-
Time after Rate of
dosage excretion *fo Dose Cnmnlative *fo
(hr) (dep.m./60 min)
1 11,460 0.21 0.21
2 1,692 0.03 0.24
3 2,712 0.05 0.29
4 11,742 0.21 0.50
5 13,594 0.25 0.75
6 8,544 0.15 0.90
7 7,482* 0.14 1.04
8 6,4-20 0.12 1.16
9 7,91^ 0.14 1.30
10 9,408 0 e 17 1.47
11i
1 | 82,800* 1.49 2.96
22
23 4,392 0.08 3.04
24 7,398 0.13 3.17
25 |
i | 248,424* 4.48 7.65
46
47 15,180 0.27 7.92
48 6,438 0.12 8.04
71 0 0.00 8.04
Total 44-5,600 8.04 8.04
* Estimated rate.
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Table 1 1 - 1 2  Recovery of Radioactivity in Urine of Human Subjects after
14 3Oral Administration of [ C~|- and f~ Hi Carbenoxolone
Subject Radioactivity excreted during 
8 hr. following dosing (d.p.m.)
Total radioactivity 
excreted
14 / Ratio: C/^
14C 3h (d.p.m.) *fo Dose
D.V.P, 5,010 4,980 9,990 0.009 1,0/
D.H. 5,524- 5,476 11,000 0.010 1.01
Table II - 3 5 Summary of Metabolic Fate of and [^H]Carbenoxolone
in Human Subjects
(a) Subject D.V.P.
Day
fo Dose excreted in
Urine Faeces Expired air Total
1
2
3
4
0.009 0
48.28 
J 38.59
J
3.83
3.09
<0.0/
3.84 
51.37 
| 38.59
Total 0.01 86.87 6.92 93.80
(b) Subject D.H.
Day
$ Dose exci-eted in
Urine Faeces Expired air Total
1
2
3
4
0.01 0
25.53
35.19
25.60
3.17
4.87
<0.0/
3.18
30.40
35.19
25.60
Total 0.01 86.32 8.04 94.37
Table II-1 4 The Excretion of Radioactivity in the Expired. Air
1 4after Oral Administration of [ Cj Carbenoxolone 
to Squirrel Monkeys. *
Me
no*
mkey
sex
% of do 
time (b 
0 -2
se excrete 
ir. ) after- 
2-4
14
d at CO. 
dosage:
4-6
at
6 -8
Total
1 F 0 .0 0 5 0 .0 1 0 0 .0 1 7 0 .0 3 0 0.052
2. M 0 .0 0 8 0 .0 1 6 0.024 0.023 0.071
3 M 0 .0 1 8 0.035 0.037 0 .0 5 6 0.146
4 F <0.001 0.004 0 .0 0 5 0 .0 3 0 0.039
Mean 0 .0 1 0 0 .016 0.021 0.035 0 .0 8 0
Table II-I^Excretion of Total Radioactivity following Oral
-14,Administration of [ C3 Carbenoxolone to the 
Squirrel Monkey.
ap Monkey 1
Day Percentage dose in Total
Expired air Urine Faeces
• 1- 0.21 0.05 43 43
2 ' <0 .0 5 <0.01 15 13
3 <0.05 <0.01 2 2
Zf* <0 .0 5 <0.01 1 1
Total 0.21 0 .0 5 61 61-
* Plasma radioactivity at completion of the experiment was 
equivalent to 0.1 p,g/ml or 0«04/£ of the dose in the total 
blood plasma.
b) Monkey 2
Day Percentage dose in
Expired air Urine Faeces
Total
1
2
3
Zf*
Total
0.21
<0 .0 5
<0.05
<0.05
0.21
0.09
0.09
0.11
<0.01
0 .3 0
4°
4
1
0.5
46
40
4
1
0 .5
46
* Plasma radioactivity at completion of the experiment v/as: 
equivalent to 0 .0 6 p,g/ml, or 0.02/A of the dose in the total 
blood plasma.
c) Monkey 3
Day 1 Perce 
Expired air
sntage dose i 
Urine
n
Faeces
Total
1* 0 .1 5 1.1 33 56
2 <0 .0 5 0.07 13 13
3 <0.05 0 .0 3 6 6 ’
4+ <0 .0 5 < 0.01 0.5 0.5
Total 0 .1 5 1 .2 77 78
* Plasma radioactivity 24 hours after dosing was equivalent to
3®5 P-g/ml, or 1.5/6 of the dose in the total blood plasma.
 ^Plasma radioactivity at completion of the experiment was 
equivalent to 0 .0 5 iig/ml, (0.02/6 of the dose in the total 
blood plasma).
d) Monkey 4
Day Perce 
Expired air
'ntage dose i 
Urine
n
Faeces
Total
1* <0 .0 5 0.09 61 61
2 <0 .0 5 0.05 8 8
3 <0 .0 5 0.07 3 3
4* <0 .0 5 < 0 .01 2 2
Total 0 .21 74 74
* Plasma radioactivity 4 hours after dosing was equivalent to 
24.3 p-g/ml, or 9% of the dose in the total blood plasma.
 ^Plasma radioactivity at completion of the experiment was 
equivalent to 0.0 6 p.g/ml, (0.02/6 of the dose in total blood 
plasma)•
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Table II-16 Summary of the Metabolic Fate of [ C 3 Carbenoxolone
in the Squirrel Monkey.
Monkey oL/o of dose in
No. Sex Expired air Urine Faeces
1 F 0 .2 0 0 .0 5 6l
2 M 0 .2 0 0.50 46
3 M 0 .1 5 1 .2 0 77
4 F 0 .0 5 0 .21 74
Mean 0.15 0,44 65
Table II - 17 ^Excretion of Radioactivity in the Bile of the Squirrel
Monkey after Oral Administration of f^Cl Carbenoxolone 
14Squirrel Monkey5(male; 900 g): [ C]carbenoxolone (90|i Ci/g) administered
orally by stomach tube, 20 mg/kg, [^ 4C]Dose administered = 3,596,400 d.p.m.
 —    ■   - — ----  i ______
Time after 
dosing 
(hr)
Rate of [l4C] 
excretion 
(d.p.m./hr.)
^ Dose
Cumulative rate 
of [14C], excretion 
(d.p.m.)
Cumulative 
fo Dose
1 4,476 0.12 4,476 0.12
2 11,508 0.32 15,984 0.4-4
3 2,824 0.08 18,808 0.52
4 0 0.00 18,808 0.52
5 0 0.00 18,808 0.52
6 10,704 0.30 29,512 0.82
7 22,800 0.63 52,312 1.45
8* 5,990 0.17 58,302 1.62
* Bile obtained post-miortem from gall bladder and cannula at 7 hr. 10 min.
Terminal plasma radioactivity was 4,200 d.p.m®/l.O ml = 20.2pg carbenoxolone^
ml.
Table 11-17 Excretion of Radioactivity in the Bile of the Squirrel 
Monkey after Oral Administration of T^C]Carbenoxolone
Squirrel Monkey6 (male; 800 g) : [44C]carbenoxolone (90p Ci/g) administered
orally by stomach tube, 5 mg/kg# £ ^ (fDose administered: 799,200 d.p.m.
Time after 
dosing 
(hr)
Rate of [14C] 
excretion 
(d.p.m./hr.)
$ Dose
Cumulative rate 
of [14C] excretion 
(d.p.m.)
Cumulative 
*fo Dose
1 303 0.04 303 0.04
; ■ 2 885 0.11 1,188 0.15
3 526 0.07 1,714 0.22
4 3,732 0.47 5,446 0.69
5 4,300 0.54- 9,746 1.23
6 5,225 0.65 14,971 1.88
7 6,656 0.83 21,627 2.71
7 hr. 35 min. 6,550 0.82 28,177 3.53
Terminal plasma, radioactivity was 1,820 d.p.m./ml = 9*1 J1S
carbenoxolone/ml.
Table II ~ 18 Excretion of Radioactivity in the Bile of the Squirrel Monkey
r14 Tafter Intraperitoneal Administration of | C |Carbenoxolone
Squirrel Monkey7(male , 625 g) : [^C]carbenoxolone (90j^l Ci/g) administered
intraperitoneally, 20 mg/kg. [^ 4C]Dose administered: 2,497,500 d.p.m.
Time after 
dosing 
(hr)
rl4Rate of [ C] 
excretion 
(d.p.m./hr.)
$ Dose
Cumulative rate 
of [14C] excretion 
(d.p.m.)
Cumulative
Dose
1 32,376 1.30 32,376 1.30
2 116,900 4.68 149,276 5.98
3 254,657 10.20 403,933 16.18
4 167,959 6.73 571,892 22.91
5 121,716 4.87 693,608 27.78
6 129,654 5.19 823,262 32.97
7 79,779 3.19 903,041 36.16
8 36,992 1.48 940,033 37.64
9 23,499 0.94 963,532 38.58
Terminal plasma radioactivity was 4^,090 d.p.m./ml = 250.5
carbenoxolone/ral.
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Table II-23; Percentage of Dose found in Tissues and Excreta of
1Hats after Oral Administration of [ G ] Carbenoxolone.
Rat Percentage dos3 in i Total
no. Sex Urine Faeces Liver Intestine Expired
air
1 F 7 . 6 1 1 . 8 0 . 0 ^ 8 . 8 7 2 .6
2, F i .^ f 3 . 5 0 . 0 1 3 . 6 kS.5 6 7 .0
3 F 2 . 3 0 . 0 3 . 2 5 7 . 3
Mean 3 . 8 6 . 6 0 . 0 7 .1 ^-8.2 6 3 .6
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Table 11-26
"1
Hydrolysis of [ C]Carbenoxolone after Incubation in vitro
with Rat Stomach Contents.
Ra
No.
t
Sex
Percentage of rad 
Carbenoxolone
.ioactivity present as: 
Hydrolysis products
1 F 65.6 34-.4-
2 F 77.0 23.0
3 F 81.6 18. 4-
Mean 7^ .7 25.3
k M 78.4- 21.6
3 M 78.6 21.4-
6 M 76.6 23.4-
Mean 77-9 22.1
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Fig. II-,5 Cumulative Excretion of CO^  after Oral Administration
of [^ClCarbenoxolone.
'IkThe rats & squirrel monkey received [ Cjcarbenoxolone 10 rag/kg.
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Discussion and Conclusions
The last part of chapter two is subdivided into several 
sections devoted to a discussion of the results and conclusions
to each set of experiments: the absorption and metabolism of...
"jif 1 h 3
C C ] succinate; absorption and metabolism of £ C ][ H]
"\bcarbenoxolone m  man; absorption and metabolism of [ CJ 
carbenoxolone in the squirrel monkey and the in vivo and in vitro
1 /f
hydrolysis of [ C J carbenoxolone. A further section discusses 
the species differences in the metabolism of carbenoxolone.
r1 n
The Absorption and Metabolism of L C JSuccinate in Man.
The pattern of excretion of radioactivity in the urine,
1faeces and expired air after oral administration of [ GJ succinate; 
is given in tables II-1, II-2 and II~3* During the first 2k hours 
after dosage only just over 1% of the administered radioactivity 
was found in the urine voided, and the volume of urine was; within 
the normal physiological range. The radioactivity present in the. 
urine was found by isotope dilution to be largely associated with 
urea. If it is assumed that the mean plasma volume of the subject 
is kO ml/kg (Altman & Dittmer, 196^) then the radioactivity 
present in the two plasma samples obtained revealed that only a 
very small percentage of the dose was present in the plasma after 
two hours (table II-2). The radioactivity present in the faeces 
passed on days 1 and 2 after dosage amounted to only 1*65/£ of the. 
dose and no detectable radioactivity was present in the faeces from 
day 3« The major portion of the administered radioactivity was
1 A- ■ .excreted in the expired air in the form of CCL,, The excretion
'lZf
of CO^ was very rapid and the time intervals between the sampling
periods of 10 minutes employed in experiment 1 were too large to
1Aaliov/ a reasonable estimate of the dose excreted as ^ 2* however,
the results (table II-1) do indicate the rapid rate of metabolism
*1 if ■'j Zj.
of [ C ]succinate to CO^ which is then excreted in the expired
air, A second experiment was subsequently performed with more
intensive sampling of the expired air for shorter collection periods*
To reduce the radiological hazard a much lower dose of radioactive
r”1^fL C]succinate was employed in the second experiment. The CO^
excreted in the expired air during the second experiment is given in 
table II-3. The total amount of C excreted in two hours was estimated 
by graphic integration to be approximately 1 *\8% of the administered dose. 
Thus it can be seen that almost all the [ C]succinate was metabolised 
to CO^. This is in accord with the results of the first experiment 
where only small amounts of the dose were found in the plasma and in 
the urine and faeces.
'\hThe high recovery of C obtained in the second experiment is
almost certainly a result of the errors and limitations inherent in
the method employed for sampling the expired air. Extrapolation of
iZf
the results to estimate the total amount of CO^ excreted must therefore
involve a degree of uncertainty. It was not feasible or acceptable to
carry out continuous collection of expired CO^ and so during the
second experiment expired air was sampled for 3 minutes at frequent
intervals. A Douglas valve was used to enable the subject to inhale
and then exhale through the gas-sampling bottles. Respiration
through the Douglas valve and gas-sampling bottles required the
expenditure of considerably more energy than is normally required for
qif
respiration in the resting state. Since it seems likely that the [ Cj
q Zf
succinate was metabolised to . CC>2 via the energy-yielding Krebs-citric
acid cycle, extra expenditure of energy, as for the sampling procedure itself
would lead to increased CO^ production. The results obtained would therefo
iZf
lead to an overestimate of the total CO^  excreted. Data obtained
during the first experiment indicated that the weights of Ba CO^ 
obtained during the sampling period were increased when the 
subject had taken moderate exercise, such as walking, just prior
i4to the sampling period. The site of metabolism of the [ C ] 
succinate is not known but since only a small amount of radioactivity
was found in the circulating plasma, it seems likely that
*\b 'Xboxidation of [ CJ succinate to CO^ would rapidly occur in the
mitochondria of the fasted stomach mucosa as well as in the liver.
*1 if.
The in vivo metabolism of [ C ] succinate in humans does not
appear to have been well studied. In rats, intraperitoneal
*]b tadministration of [1- C ] succinate resulted in a mean of 86% of.
•'j Zj.
the dose being excreted as 00^ within b hours (Gould, ejb al, 19^9)•
1 -^The excretion of CO^ by the rat may have been as high as 91# since
individual experiments varied by + 5% from the mean (Gould, .et al,
*119^9) a-^ d the amount of residual C in the body of the rat at
'lb .
post-mortem was very small. The dose of [ C Jsuccinate (O.l-O.;?
millimoles) administered by Gould, ejt al, (19^9) to the rat was
slightly greater than the amounts administered to the human
volunteer in these experiments. This: may account for the slightly
*\bslower overall rate of metabolism of C C] succinate in the rat as- 
compared to man. It is concluded that man metabolises orally
*\badministered [ C ] succinate in a similar manner to that found in 
the rat after intraperitoneal administration.
The Metabolism of Carbenoxolone in Man
The plasma concentrations of [ C 3 carbenoxolone aftor oral 
administration as a positioned-release capsule are given in 
table 11-^ - and fig® II~3® Radiological examination showed, that the 
capsules burst in the region of the pylorus in patient P.B® 1e5 hour 
after administration, and in patient M®C. after three hours® In 
the case of patient W.C® the capsule was not seen to burst and was 
intact after three hours but had disappeared (ruptured) after four, 
hours® The period of radiological examination was strictly limited 
to reduce the hazard from x-rays.
The plasma concentrations of carbenoxolone reached a maximum 
of 8 to 9 pg/ml. at 1®5 to 2 hours after rupture of the capsule in 
patients P®B. and M.C* (fig® II~3)» and subsequently slowly declined 
With patient WWC® the plasma concentration of carbenoxolone rose 
slowly and was still rising four hours after the capsule had , 
disappeared and had probably ruptured® This slow attainment of the 
maximum plasma concentration of. the drug, indicative of slow 
absorption, was probably due to dilution of the drug with food that 
was taken shortly after the capsule had burst®
In the case of patients P.B. and M.C® the maximum plasma 
concentrations were equivalent to approximately ^0% of the dose, 
present in the circulating blood (table 11-^)® With patient W.C® 
the highest plasma concentration, namely, that at the termination 
of the experiment, was equivalent to only 2k% of the dose in the 
circulating blood.
Thin-layer chromatography, as described in section 2(b)(iii) 
above, of the chloroform extracts of the plasma revealed the. 
presence of carbenoxolone only® The hydrolysis product, enoxolone 
was present in only trace amounts, and glucuronide conjugates of 
carbenoxolone and enoxolone were not detected.
In two (P.B. and M.C.) of the three cases observed the capsule 
was seen to rupture in the region of the pylorus within one to three 
hours of administration. In these two fasting subjects the released 
carbenoxolone was rapidly absorbed giving rise to high plasma 
concentrations of the drug after an interval of only one to two 
hours from the rupture of the capsule. The drug was absorbed 
largely unchanged, as only carbenoxolone was detected in the blood 
plasma. The extent of absorption of the drug in these two patients, 
as indicated by the plasma concentration, was comparable to that 
observed when carbenoxolone was administered orally as tablets 
but the time patterns of the plasma concentration did not show the 
marked second maxima characteristic of the gastric absorption of 
the drug (see Downer, et al, 19?0). This may be indicative of 
differences in the site or mode of absorption of the drug when given 
as the tv/o different preparations.
In the third patient (W.C.) the capsule v/as not seen to rupture, 
and although still intact at three hours after administration, had; 
disappeared at four hours. After ingestion the capsule adhered to 
the wall of the oesophagus for about one hour before entering the 
stomach. In this case the absorption of the drug was considerably
impaired, probably as the result of delayed rupture of the capsule 
and dilution of the drug with the meal which was taken after 
four hours. Thus a meal taken shortly after the rupture of the 
capsule is likely to delay absorption of the drug. It should be 
noted that the time taken for the capsule’to rupture is variable 
(1m5~k hours) in this study.
It is not possible in the present series to state with any 
certainty from which area of the gastrointestinal tract the 
carbenoxolone was absorbed, although in the tv/o cases in which the 
capsules v/ere seen to rupture in the area of the pylorus at least 
some absorption v/as likely to occur from the small intestines. 
However, as carbenoxolone has been shown to be readily absorbed 
v/hen administered as the capsule it is reasonable to suppose that 
this preparation of the drug could give rise to actions similar to 
those shown by the oral preparation. These actions would be the 
adverse mineralocorticoid-like effects of systemic origin and the 
therapeutic effect of increased gastrointestinal mucus biosynthesis, 
which is probably a * topical1 action occurring as the drug traverses 
the mucosa.
The gastrointestinal absorption of acidic drugs in general 
appears to be related to the lipid-solubility of the non-ionised 
molecule and to its acid dissociation constant (Schanker, 196^ -, 1969 
Kakemi, Arita, Hori & Konishi, 1967)* Carbenoxolone is a weak acid 
(pkr, 6*7; pkH, 7.1) and at the pH of the stomach (pH. 1.0) it 
would not be significantly ionised, however at pH &5/o of the
drug would be ionised® At pH 7*k the apparent partition coefficient 
for carbenoxolone at 2*f°C between chloroform and aqueous buffer is 
1.*f and for n-octanol and aqueous buffer is 22 (table II-5 )*
Whereas, at pH 1.0 the partition coefficients for both organic 
solvents are >1,000® Thus the non-ionised form of the drug is 
highly lipid soluble, a factor favouring absorption® It has been 
found by Downer, et d-} (1970) that carbenoxolone is well absorbed 
in man after oral administration. Administration of an alkaline 
buffer to increase the pH of the gastric contents above pH 2 greatly 
reduced the absorption of the drug (Downer, jet cOL, 1970). The drug 
is reasonably we11 absorbed after administration as a positioned- 
release capsule and although the site of absorption is not known 
with certainty it seems likely to be the pylorus or duodenum.
Another factor which may enhance the absorption of carbenoxolone is 
its binding to plasma proteins and this will be discussed later.
The results from the experiments involving the administration 
1*f 3of H ] carbenoxolone to human volunteers are given in
tables II-6 to 11-13 a^d figure II - I’he plasma concentration
of radioactivity after oral administration of the drug (table II-6 ) 
showed that the drug v/as rapidly absorbed with the peak 
concentrations occurring in both subjects approximately 2 hours 
after dosage. The peak plasma concentrations correspond to 
approximately 30% of the dose circulating in the plasma. This figure 
may be something of an underestimate of the amount of drug 
circulating in the plasma since the assumption of a mean plasma 
volume of *1-0 ml/kg. body weight (Altman & Dittmer, 196*0 is one- of 
the lowest estimates.
The possibility that the plasma radioactivity represented only 
'ik .[ C Jsuccinate or metabolites thereof can be excluded for several
1*f 3reasons. Firstly the ratio of CrH in the plasma did not
measurably change over the period of plasma sampling showing that.
both radioisotopically labelled forms were absorbed to a similar
14extent. Secondly the amount of GO^ excreted during the first six
hours indicated that negligible hydrolysis of carbenoxolone had 
occurred during this time. Finally, in the experiment when L C J 
succinate itself was administered even to a dose level of over ^ uCi 
it v/as found that at most only W  of the dose was present in the 
plasma after 2 hours.
Downer, ejb al, (1970) studied the absorption of carbenoxolone 
administered as tablets to gastric-ulcer patients and found that it 
was rapidly and extensively absorbed v/ith about of the dose
present in the blood at the peak plasma concentration. The present 
results with human volunteers although slightly lower are in good 
agreement and it is possible that enhanced absorption occurs in 
patients with gastric ulcer or other erosions of the mucosal wall. 
The high percentage of the dose circulating in the plasma suggests 
that carbenoxolone may be largely localised within the plasma. 
compartraent. This localisation can be indicative of plasma protein 
binding (Martin, 1965a) an(* an as described in the next chapter
this is the case. At therapeutic concentrations the drug is almost 
completely bound to plasma proteins and since the sensitivity of 
the ultrafiltration method depends upon the specific radioactivity 
of the [ C ]carbenoxolone, the amount of unbound drug ( <10 M)
was undetectable after ultrafiltration of whole plasma from these 
subjects*
The affinity of carbenoxolone for proteins may enhance its 
absorption from the gastrointestinal tract in two ways. A high 
degree of binding to plasma proteins would effect the equilibrium 
of the drug between the gastric contents and the blood so as to 
accelerate the absorption process, (see Chapter Three, fig. III-1)• 
Secondly, binding to the gastric and intestinal mucosa may be an 
important process in the absorption of some drugs and there is 
evidence that binding to the rat small intestinal mucosa is an 
important process for the absorption of barbiturates (Kakemi, Arita, 
Hori, Konishi 8c Nishimura, 1969; Kakemi, Arita, Hori, Konishi, 
Nishimura, Matsui 8c Nishimura, 1969)•
The surface active properties of some drugs may favour their 
gastrointestinal absorption. Anello 8c Levy (1969) found that low 
concentrations of a surface active agent significantly increased 
the absorption of 4-aminoantipyrine in goldfish by a direct effect 
on the biological membranes. Bile acids have surface active 
properties and these properties are considered to be important in 
the digestion and absorption of lipids, but the surface active 
properties may also be important, in promoting the absorption of 
bile acids themselves (Dietschy, 1969)* Aqueous solutions of 
carbenoxolone exhibit surface active properties and this may be 
another factor serving to aid absorption of the drug. Thus the 
absorption of carbenoxolone from the gastrointestinal tract may not 
just simply be governed by the pH-partition hypothesis but may be . 
influenced by the other factors just discussed.
The excretion of radioactive carbon dioxide in the expired
P14 3air of the human subjects who received [ C][ PI J carbenoxolone is
shown in tables II-7» II-8 and fig. II-5. The problems encountered
in sampling the expired air were the same as those described and
14discussed earlier for the [ C 3 succinate experimentso The hourly
'jZf.
excretion rate of COp .was calculated from the 10 minute sampling
14 .
period by simple multiplication® The rate of COp excretion during
sleep v/as estimated from the mean of the last, excretion rate
measured in the evening and the first excretion rate measured the
following morning® The total excretion rate was then estimated by
addition of the excretion rates determined experimentally together
14with the estimated COp production during sleep® The results
14indicate that in man the rate of hydrolysis of [ C 3-arbenoxolone
1 f^ ] 'to [ C] succinate is very low, for within 24 hours less than 4%
14of the dose of radioactivity had been excreted as COp and after
1 471 hours still less than 9% of the dose had been excreted as COp®
1 if
The COp excreted in the first hour after dosage may have arisen
1 4
from trace amounts of [ C ]succinate present in the drug®
Subsequently it appears that hydrolysis of the drug occurred
1h
continuously at a low rate® The pattern of metabolism of [ C 3
carbenoxolone metabolism in man is therefore in marked contrast to
the pattern found in the rat (Iveson, et al, 1971; and see
table II-27)« In the rat an average of of the dose was 
1 k . ^metabolised to COp in the first 24 hours, while after Jo hours
1471% of the dose was excreted as COp in the expired air.
The recovery of radioactivity in the faeces of the two
14 3volunteers after oral administration of [ C][ H.2carbenoxolone is
given in tables II-9 and 11-10® Unfortunately no stools were passed
by either subject during the first 24 hours after dosage® This is
probably a result of tv/o factors, one being the fasting before the
start of the experiment and the other a psychological one related
to the slightly inconvenient method of stool collection® The total
amounts of radioactivity recovered from the faeces of subject
14D.V.P. and subject D.H® were 78% and 79% respectively for C, and
for ^H.the total recoveries were 95% and 9^% respectively® The 
14
recovery of C is lower than that for tritium and this is probably
12|.
due to hydrolysis of the drug to [ C] succinate and subsequent loss
14 14of the radioactivity as . COp® Since the experiments with [ C]
14
succinate showed that the method employed for estimating COp
1excretion in humans tended to give an overestimate of COp excretion,
14at least in the short term, it is unlikely that the figures for COp
14excretion after [ C-J carbenoxolone are low® Therefore it is likely
14
that some loss of radioactivity as COp occurred by hydrolysis 
in vitro while the stool samples were stored prior to radioactive 
counting® A. certain amount of drug v/as probably also undergoing 
enterohepatic circulation and would have been excreted in the faeces: 
on days 5 nnd 6 after dosage®
14 3
In subject D.V.P® the C: EL ratio of radioactivity in the.
3
faeces showed that EE v/as in a small excess which v/as to be expected
14 14since C was being lost as respiratory COp. Similarly for subject
14 3D.H. the C: H ratio on days 2 and J after dosage shows a small
3 i 14-excess of H^. On day 4 the slight excess of G in the faeces
is probably due to excretion of endogenous substrates labelled
14 14
with C derived from the small amounts of [ C Jsuccinate produced.
Thin-layer chromatography of faecal extracts v/as carried out
to try and determine the nature of the radioactivity present in the
faeces. Chromatography in solvent system A revealed a large
number of spots giving the colour reaction for glucuronides. The
silica gel was cut into strips corresponding to R^ intervals of 0 .1
and the material counted. The larger proportion of the radioactivity
ran with the solvent front but a small proportion (14% for D.V.P.
and 10% for D.H.) was located at R^ , O.85. An ultra-violet light
absorbing spot v/as present at this R^ value and it also gave a
positive result when sprayed with the naphtharesorcinol reagent and
negative result with the Sb Clj_ reagent (table 11-11). It had the
same Rvalue as the 30-glucuronide of carbenoxolone (Iveson 8; Parke,
1970) and v/as therefore probably a glucuroiiide conjugate of
carbenoxolone with the 11-oxo-12 ene structure still intact. The
radioactive material present at the solvent front had identical
properties to authentic carbenoxolone. Chromatography in solvent
3system B revealed trace amounts ( <0.1%) of [ H ] enoxolone but no
14
detectable amounts of [ CJ succinate. There v/as no evidence of 
reduction of the 11-oxo-1 2 ene structure of the carbenoxolone molecul
The radioactivity recovered in the faeces of the two subjects 
14 3
who had taken [ C][ II 3 carbenoxolone represented largely free drug
together v/ith a small amount of carbenoxolone-30-glucuronide.
Downer, et al, (1970) administered unlabelled carbenoxolone to 
cholycystectomised patients fitted with biliary drainage T-tubes 
and found that carbenoxolone was excreted in the bile as one 
major metabolite with the chemical characteristics of 
carbenoxolone-30-glucuronide. The percentage of glucuronide 
conjugate found in the faeces in the present study v/as lov/er than 
that found by Downer, crt al, (1970) but since 'the drug has been 
shown to be absorbed to a considerable extent and is not markedly 
excreted in the urine, it must have been excreted in the bile*
It is therefore probable that the drug was excreted in the bile of 
the tv/o subjects largely as the glucuronide which subsequently 
underwent considerable hydrolysis by the gastrointestinal flora- 
during passage down the intestine. Hydrolysis of the conjugate to 
the aglycone and glucuronic acid followed by reabsorption of the 
aglycone would result in an enterohepatic re-circulation of the 
drug and account for the- second maximum blood concentration of the 
type observed by Downer, et al, (1970).
The excretion of radioactivity in the urine is given in
table 11-12. The amount excreted in the urine was very small and
only 0.01% of the dose was excreted during the first 8 hours after
dosage, and for this reason further collection of urine v/as
discontinued. Because of the small amount of radioactivity present
it was not possible to determine the nature of the metabolite(s)
14
present in the urine. The results from the [ CJ succinate
14 i4
experiment indicated that [ C J urea, derived from [ C J succinate,
would probably have been present. The rat only excretes a small 
percentage of the dose in the urine after oral or intraperitoneal 
administration of carbenoxolone (Iveson, et al, 1971; table 11-2 3) 
and faecal contamination of the urine may artifactually increase 
this percentage. Thus it appears that man and rat are similar in 
the extent to which they excrete carbenoxolone and/or its metabolites 
in the urine. The very low excretion in the urine is further 
indirect evidence that carbenoxolone is highly plasma protein bound. 
Normally, unless actively excreted, the amount of a xenobiotic 
present in the urine is a direct reflection of the amount of 
compound unbound in the plasma and therefore available for 
filtration at the glomerulus. In the case of carbenoxolone this 
appears to be very small since the amount excreted in the urine is 
small.
Metabolism of Carbenoxolone in the Squirrel Monkey
Y/hen [ C ] carbenoxolone (10 mg/kg.) v/as administered to the 
squirrel monkey only a small amount of radioactive carbon dioxide 
v/as subsequently detected in the expired air of each monkey 
(table II-14; fig. II-5). During the first 8 hours after dosage 
less than 0.2% of the administered radioactivity was excreted as 
respiratory carbon dioxide and after the initial 24 hour period 
no radioactive carbon dioxide was detected in the expired air.
This result is in sharp contrast to findings in the rat where the
14 ^4
metabolism of [ C ] carbenoxolone to COp occurs rapidly and
extensively after oral dosage (table 11-22)* It would appear that
this difference is due to differences in the gastrointestinal
microflora with the microflora of the monkey being unable to
hydrolyse carbenoxolone to any significant extent.
The total excretion of radioactivity is tabulated for each 
monkey in table II-13(a), (b), (c) & (d). The amount of . 
radioactivity excreted in the urine of each monkey v/as small 
(<2.0% of the dose) and the nature of this radioactivity v/as not
14 ']4
determined but the £ C ] succinate experiment indicated that [ C] 
urea would account for a part. The monkey is similar to rat and
man with respect to the low excretion of the drug in the urine.
It suggests that in the squirrel monkey too the drug is highly 
plasma protein bound. It was not possible to obtain a plasma sample 
from each of the monkeys within a few hours of dosage but a 
sample obtained 4 hours after dosing from monkey 4 contained 
radioactivity equivalent to 24.3 p,g/ml. of the drug. Plasma
radioactivity in monkey J at 24 hours after dosing v/as equivalent
to 3*5 jig/nil. Reliable data for the plasma volume of the squirrel
monkey does not seem to be available and so the mean plasma volume
of the rhesus monkey, 36 ml/kg* body weight (Altman & Dittmer, 1964)
v/as used to calculate the approximate amount of drug circulating
in the plasma. The amount of carbenoxolone circulating in the
plasma of monkey 4 was therefore about of the total, dose
4 hours after dosage and in monkey 3» 24 hours after dosage about
1.5%« Four days after dosing a small amount, up to 0.04% of the
drug, was present in the total plasma of each monkey. Thin layer
14chromatography showed [ C 3 carbenoxolone as being the only 
radioactive material present in the plasma and no glucuronide 
conjugates were detected.
Four days after dosing the monkeys were killed and at
post-mortem the brain, lungs, liver, spleen, kidney, adrenals,
stomach and intestinal tract v/ere removed for determination of
radioactivity. It v/as found that these organs contained no
14measurab3-.e amounts of [ C 3 carbenoxolone or its metabolites. The 
absence of drug in the brain indicated that it was unlikely that 
carbenoxolone had crossed the blood-brain 'barrier' to any 
significant extent. Drugs that are highly plasma protein bound 
do not generally readily penetrate the blood-brain barrier. 
(Goldstein, Aronow & Kalman, 1968).
Most of the recovered radioactivity (46-77%) v/as present in 
the faeces and the excretion on days 1,3 and 4 followed a 
similar pattern in all four monkeys (table 11-15),® On ^ay 2 only 
4% of the administered radioactivity was recovered from monkey 2, 
possibly indicating some accidental loss of faecal material.
The recovery of radioactivity in the faeces was low, probably as 
a result of the unfortunate design of the floor of the perspex 
metabolism cage. The floor had a large number of small holes 
designed to permit easy collection of urine but the recovery of 
faecal matter from this floor was a difficult process.
The nature of the radioactive material present in the faeces 
was examined by thin-layer chromatography. Determination of the 
radioactivity of the silica gel showed that 96.^% (monkey 1),
93•7% .(monkey 2), 95*2% (monkey 3) and 95«8% (monkey 4) of the 
radioactivity was associated v/ith the material having the same 
chemical characteristics as carbenoxolone. The remaining 3-6% of 
the radioactivity was associated v/ith a glucuronide having an of
O.8O-O.8 5 in solvent system A and by comparison v/ith synthetic 
material (Iveson & Parke, 1970) this was almost certainly
14carbenoxolone-30-glucuronide. No [ C 3 succinate v/as detected in 
the faeces of these monkeys.
These experiments have established that in the intact
14squirrel monkey [ C 3 carbenoxolone is absorbed from the 
gastrointestinal tract v/ithout appreciable hydrolysis. Moreover 
drug that remains unabsorbed in the gastrointestinal tract does
not undergo hydrolysis. This suggests that the intestinal flora 
of the squirrel monkey is different from that of the rat in its 
metabolism of carbenoxolone. Reduction of the 11-oxo-12 ene 
structure of carbenoxolone did not appear to occur.
Following the experiments involving the metabolism of [ C3
carbenoxolone in inta.ct squirrel monkeys the biliary excretion of 
the drug and its metabolites after oral and intraperitoneal 
administration v/ere investigated. Monkey 5 excreted 1.5/° of the
dose during the 7 hours after dosage (table II-17(a)). The reason 
for this low biliary excretion appears to be due to the fact that 
at the end of the experiment a large proportion of the dose 
remained unabsorbed and was recovered from the stomach and 
intestines (see table II-19)» As can be seen from table 11-19, 
less than Z5% of the dose v/as absorbed in the two monkeys dosed 
orally. The dose present in the plasma at the end of the 
experiment was 3.6% for monkey 5 aa<3- 6.6% for monkey 6.
14The poor absorption of [ C] carbenoxolone was surprising 
in view of its rapid absorption in rat and man. During these 
cannulation experiments the stomachs of all three monkeys became 
distended v/ith gas presumably as a consequence of the anaesthetics 
used. Anaesthetic ether causes profuse mucus secretion and 
stimulates the sympathetic nervous system causing a decrease in 
motility and tone of the gastrointestinal tract with contraction 
of the sphincters, (Bowman, Rand 8: West, 1970). The pharmacological
actions of phencyclidine in this respect do not appear to have 
been reported. It has been found by Ochsenfahrt 8c Winne (1 9 6 8 ;
1969) from in vivo experiments in the rat that the absorption rate 
of an undissociated lipophilic drug was closely related to the 
blood flow. When the blood flow was increased from low to high 
values increased absorption of unionised, but not ionised, drugs 
occurred. Thus diminished drainage of the gut mucosa which would 
occur with stimulation of the sympathetic nervous system may at
'jZf
least partially account for the reduced absorption of [ CJ 
carbenoxolone found in the cannulated squirrel monkey. If bile 
salts are involved in the absorption of carbenoxolone their absence 
in the cannulated monkeys would reduce absorption of the drug.
It is possible that the lower absorption of carbenoxolone is a 
species difference since such differences in the absorption of 
drugs have been observed as for instance with digoxin which is 
better absorbed in the rat than the guinea pig (Greenbergers 
MacDermott, Martin 8c Dutta, 1969)-
1 h-After intraperitoneal administration of [ C ] carbenoxolone 
to a squirrel monkey (table II-18) the drug was reasonably rapidly 
absorbed and excreted v/ith 39?^ of the administered radioactivity 
appearing in the bile within 9 hours after dosage. This 
demonstrated that the low biliary excretion by monkeys 3 and 6 was 
not as a result of a poor ability of this species to conjugate
and excrete carbenoxolone. At a dose level of *f0 mg/kg. the rat
/ 1 was found to excrete 20% of an intraperitoneal dose of [ C ]
carbenoxolone in the bile in 9-5 hours (Iveson, 1968), whereas
excretion by the squirrel monkey at half the dose level was nearly
double the rat’s. The rate of excretion is therefore similar in
the two species after intraperitoneal administration. The plasma
concentration of drug in monkey 7 at the end of the experiment was
equivalent to k0% of the dose circulating in the plasma (table 11-1 9)•
14
The excretion of [ G ] carbenoxolone and its metabolites into the 
bile is an active process with the bilerplasma ratio exceeding 
unity (Table 11-20). The bile:plasma ratio appeared to depend on 
the plasma concentration, the lower-'the plasma concentration of drug 
the higher the relative excretion in the bile. As the plasma. 
concentration increased, the bile:plasma ratio decreased indicating 
the excretory process probably had a limited capacity.
The bile samples for each monkey were pooled and the pooled 
samples examined for metabolites in the usual way. Control samples 
of bile were chromatographed for comparison. The distribution of 
radioactivity on the chromatograms is shown in table 11-21 and 
fig. The bile from each monkey was found to contain one
major metabolite (30~^7/<> of the total excreted), a glucuronide 
conjugate, which appeared to be carbenoxolone-30-glucuronide. There 
was evidence of another U.V.-light absorbing conjugate (up to 
of the total) of carbenoxolone which gave a positive reaction with 
the naphtharesorcinol reagent (table 11-21). This conjugate was 
most evident in the bile of monkey 6 (fig. II-4(b)). Although 
conjugation with two glucuronic acid moieties is rare (V/illiams,
1939; Miliburn, 1970) it is conceivable that this minor 
metabolite may be a double conjugate of carbenoxolone. The best, 
known double glucuronide conjugate is that of bilirubin and other 
double conjugates are also known (Miliburn, 1970).
It seems that despite careful precautions considerable.
hydrolysis of carbenoxolone glucuronide conjugates occurred since:
at most only 31^ °f the dose was present in the bile in the.
3
conjugated form. After intraperitoneal administration of [ H. 3
enoxolone to the. rat examination of the bile showed that the drug
was excreted largely as. conjugates and very little unchanged drug
1 A-was present. To try and determine whether [ C]carbenoxolone: was: . 
excreted unchanged in the bile to any significant extent the drug 
(20 mg/kg) was administered intraperitoneally to three male rats fitted 
with biliary cannulae under urethane anaesthesia and the bile 
collected for k hours. More than 30% of the radioactivity excreted 
in the bile, when freshly examined, was found associated with the 
glucuronide in each rat. The bile samples that were obtained from 
all three, monkeys after dosing contained more glucuronic: acid than 
the control samples obtained prior to dosage. A glucuronic acid 
residue in the -^! position is likely to be unstable (Iveson & Parke,
1970) and this may account for the extra glucuronic acid present 
in the bile after dosing.
Small samples (0.3-1 *>0 ml) of urine were obtained from the
bladder at post-mortem but less, than 0m0k% of the dose was found
1in the terminal urine. The low urinary excretion of [ G ] 
carbenoxolone was in agreement with the findings in the intact
squirrel monkey. The brain of each monkey was homogenised and 
1^fexamined for £ C] carbenoxolone and its metabolites but none
were detected. The plasma protein binding; of the drug in the
terminal blood samples was studied by ultrafiltration and no . ..
unbound drug was detected in the plasma from either of the monkeys.
Chromatographic examination of the plasma samples did not reveal 
lif
any [ CJ succinate or carbenoxolone conjugates. Low urinary 
excretion of a drug and poor penetration of the blood-brain barrier’ 
is indirect evidence that such a drug is highly plasma protein 
bound and this is confirmed by the experimental evidence of the 
ultrafiltration experiments.
In view of the fact that both enoxolone and carbenoxolone 
are excreted largely as conjugates by the rat it is probable that 
carbenoxolone has to undergo conjugation in the squirrel monkey 
prior to excretion. Carbenoxolone is therefore probably one of a 
large group of drugs which requires conjugation before marked 
excretion can occur. However, even unconjugated carbenoxolone 
itself fulfills the criteria for good biliary excretion by the rat 
and also for the monkey (Miliburn, et; al, 1967a; Miliburn, 1970; 
Abdel Aziz, Hirom, Miliburn, Smith 8c Williams, 1971)-
Bromosulphophthalein also is a compound which fulfills these criteria 
but is nevertheless excreted largely in the conjugated state. It 
is now considered by a number of workers that conjugation rather 
than excretion is the rate-limiting step in the delivery of a 
compound into bile (Schenker, Goldstein 8c Combes, 1 9 6 5 ;  Levine, 1970 
Whelan, Hoch 8c Combes, 1970). Thus it seems likely that with
compounds which undergo metabolism (especially conjugation) prior 
to biliary excretion, the conjugate may be more efficiently
transported than the parent compound (Guarino & Schanker, 1968).
1Glucuronide conjugates of [ C 3 carbenoxolone have hot been 
detected in the plasma samples analysed and it seems likely that 
once the glucuronide is made it is rapidly excreted. Guarino & 
Schanker (1968) studied the biliary excretion of probenecid and 
drew a similar conclusion. The transport system for excretion into 
the bile is not understood but separate mechanisms may exist for 
the biliary excretion of conjugated and unconjugated compounds 
(Priestly & Plaa, 1969) and this may involve selective uptake by 
carrier proteins in the cytoplasm of the type' isolated by 
Levi, e>t al, (1969)*
Since the possibility existed that one of the metabolites 
of carbenoxolone was a double glucuronide it was of interest to 
try and isolate the conjugates in amounts sufficient for 
characterisation and further study with' regard to biliary excretion 
and protein binding. Iveson (1968) attempted to isolate the 
conjugates of enoxolone from pooled rat bile by several methods but 
was unsuccessful largely because of contamination with bile acids 
which have closely similar chemical characteristics to these 
triterpenoids. If forced excretion of the conjugates via the urine 
could be effected a better possibility would exist of isolating 
the conjugates from the urine where contamination with bile acids 
should be less. Rats were injected with [ C ] carbenoxolone 
(40 mg/kg) intraperitoneally after bile duct ligation then placed
in metabolism cages for collection of urine. Isolation of 
glucuronides was attempted by the method of Kamil, Smith & Williams, 
(195*1 )• During the first 2k hours less than 1G/o of the injected 
radioactivity appeared in the urine by which time bilirubin and 
other interfering bile acids were being excreted in the urine.
Similar experiments in two male rabbits were done, where a much 
greater amount of drug was injected, but again poor urine production 
resulted in a low recovery of radioactivity. Because of the high 
excretion of drug and its conjugates in the bile it seems likely 
that fractionation of pooled bile samples by. more sophisticated 
chemical techniques will prove useful.
The pattern of-metabolism of carbenoxolone in the squirrel 
monkey was found to be different from that in the rat. In the 
squirrel monkey absorption of the drug without prior hydrolysis 
occurs and the amount of radioactivity excreted in the expired air
*\kis very low. After oral administration of [ C Jcarbenoxolone to 
squirrel monkeys fitted with a biliary cannula the drug was slowly 
absorbed but this result may be misleading in that the anaesthetics 
and other factors discussed above may have caused malabsorption.
The plasma concentrations of drug found in the intact squirrel 
monkeys demonstrated that the drug could be absorbed in the squirrel 
monkey. After intraperitoneal administration at least two glucuronide 
conjugates of the drug were rapidly excreted in the bile. One of 
these conjugates appeared identical v/ith carbonoxolone-30rglucuronide.
There were trace amounts of another glucuronide conjugate in the 
bile but the nature of this was not known. However in intact 
squirrel monkeys much smaller amounts (3-6%) of the 30-glucuronide 
were detected in the faeces. Similarly examination of the faeces
'tZj. ~Z
of the two human subjects dosed with [ G J [ H 2 carbenoxolone 
showed that a slightly greater amount (1 0, 1 H-%) of this conjugate 
were present. Thus it appears that carbenoxolone is excreted in 
the bile of man and the squirrel monkey as one or more glucuronide 
conjugates which then undergo hydrolysis on passage down the 
gastrointestinal tract. It appeared that there v/as no species 
difference between rat, squirrel monkey and man in the rate of 
excretxon of unhydrolysed [ C ]carbenoxolone and its conjugates
'j/f -i if
m  the bile. [ G ]Carbenoxolone is hydrolysed to [ G jsuccinate
and enoxolone to about 8% of the dose in man and less than in
the squirrel monkey after oral administration. This is in marked
contrast to the rat where extensive hydrolysis (> ?0%) occurs after
oral administration. Experimental evidence from ultrafiltration
of plasma samples and indirect evidence, such as the low urinary
excretion and absence of the drug in brain, showed that carbenoxolone
has a high affinity for plasma proteins in the squirrel monkey and
investigation of the protein binding of carbenoxolone is described
in the next chapter. The remainder of this chapter is concerned
with the investigation of the species differences in the metabolism 
1^fof [ G Jcarbenoxolone between the rat and the primates.
14-
Hydrolysis of [ C J Carbenoxolone an vivo and in vitro
1 4*It was found that after oral administration of [ C] carbenoxolone 
to rats a large percentage (average 71 /0 of the dose v/as excreted
14-as respiratory CO^ in 30 hours (Iveson, 1968)* Further similar' 
experiments were therefore performed to show.that these findings 
were reproducible in later batches of rats and also to serve as:
12f
controls for comparison with the excretion of CO^ after
14-administration of [ C J carbenoxolone to antibiotic treated rats*
The excretion of radioactivity in the expired air of rats
iZj.
after oral administration of [ C] carbenoxolone is shown in
'I l>r
table 11-22 and fig. II-3* The rate of excretion of CO^ was rapid,
as found by Iveson (1968), and the maximum occurred at about
3-4- hours after dosage and by 8 hours over 4-0% of the dose had been
1 /j.  ^if.
excreted as CO^ (fig. II-3)* The cumulative excretion of CO^ 
represented 4-5% of the dose 24- hours after dosage. The recovery 
of radioactivity in the faeces, urine and intestine is tabulated 
in table 11 -23 and the findings are similar to those previously 
described.
) 14-Incubation of [ C J carbenoxolone with human blood and stomach 
contents and rat blood and liver homogenates did not cause 
significant hydrolysis of the. drug but after incubation v/ith rat 
caecal contents 32-4-0% of the drug was hydrolysed (Iveson, ejt al,
1971)* The contents of the rat caecum therefore possess glucuronidase 
and esterase activity sufficient to account for the hydrolysis of 
first the drug conjugates and then free drug that occurs after
intraperitoneal administration.. It therefore remained to 
demonstrate whether the microflora.of the rat stomach possessed 
sufficient metabolic activity to account for the rapid hydrolysis 
of carbenoxolone that occurs after oral administration*
-|if
V/hen n C] carbenoxolone* was administered orally to rats, 
which had been pretreated orally with a mixture of tetracycline-HCl 
and neomycin-SO^ administered tv/ice daily for three days to 
suppress the gut microflora, the rate of excretion of respiratory 
CO^ , was much lower than in normal rats (table II~2 f^; fig* II~5 )«
In these experiments an average of only 1.8% of the' dose had been
1 kexcreted as respiratory C0p in 8 hours and -in 2k hours less than
1 k
5% of the dose appeared as ^ 2* This was in marked contrast to.
the findings in normal rats not pretreated with antibacterials where
^ Lf.
k^% of. the dose had been excreted as respiratory 00  ^in ?.k hours* 
Administration of antibacterial agents therefore reduced the extent
1 k 1kof metabolism of [ C ]carbenoxolone to GO^ by more than nine-fold 
in the 2k hour period after dosing. The recovery of radioactivity 
in these rats pretreated with antibacterial agents is given in 
table 11 -25 and the major portion was recovered in the faeces (67%) 
and intestines (15%)* An average of 56/0 of the excreted radioactivity 
in the faeces v/as associated with carbenoxolone-30-glucuronide end
1 kthe remainder was [ C ]carbenoxolone (table 11-25)* The
1kunconjugated [ C] carbenoxolone present in the faeces is likely to 
have arisen from hydrolysis of the biliary excreted conjugates 
although it may represent unabsorbed drug since neomycin is known 
to cause a reversible intestinal malaborption condition (Jacobsen, 
Chodos 8c Faloon, 19&0; Rothfeld 8c Osborne, 1983)* The large doses
of antibiotics employed almost certainly caused liver damage 
(the appearance at post-mortem v/as abnormal) which v/ould impair 
the conjugating capacity of the liver, leading to the excretion of 
unconjugated drug.
Pretreatment of experimental animals with one or more 
antibacterial agents has been extensively used as a ‘means of 
elucidating the contribution of the gut flora to the metabolism of 
both foreign and endogenous compounds. Gingell (1970) k&s reviewed 
a number of such studies involving the pretreatment of laboratory 
animals with various antibacterial regimens. For example, oral 
pretreatment with neomycin alone has been shov/n to suppress the 
aromatization of oral quinic e,cid in the rhesus monkey. (Adamson, 
Bridges, Evans & Williams, 1970) and pre treatment of rats .-with a 
mixture of neomycin and tetracycline showed that gut bacteria were 
partly responsible for tryptophan metabolism (Weissb.ach, King, 
Sjoerdsma& Udenfriend, 1957)* The dose and combination of 
antibacterial agents used v/as largely empirical but the combination 
of drugs used had theoretically a wide range of antibacterial activity 
and coupled with the procedure for changing the bedding materials 
should have greatly reduced the number of viable'micro-organisms-, 
in the gut. Culture of the rat faeces from these experiments on 
plates of blood agar in vitro revealed very few viable micro-organisms 
although this does not necessarily ensure that the gastrointestinal 
tract was free of viable organisms.
1 Zf
V/hen £ GJ carbenoxolone was incubated in vitro under nitrogen
with a portion of the contents of either a male or female rat
stomach considerable hydrolysis occurred (table 11-26)* It was
found that between 1o and of the [ C 1 carbenoxolone (1 mg)
- 1added to the incubation mixture v/as hydrolysed and that the [ C ]
“\bsuccinate produced was metabolised to T -^ere was no
In­significant sex-difference in the extent of hydrolysis of [ C ]
carbenoxolone. These, in vitro experiments, with no optimisation of
the incubation conditions, showed that micro-organisms present in
the rat stomach are capable of causing considerable hydrolysis of
1 h-[ C] carbenoxolone and therefore can account for the rapid excretion
'jZj.
of CO^ after oral dosage. Therefore hydrolysis of carbenoxolone
1^foccurs both in the rat intestine, as shown by excretion of CO^ 
after intraperitoneal administration, and in the stomach.
It does appear therefore from the experiments reported here that 
bacteria present in the gastrointestinal tract of the rat are 
responsible for hydrolysis of both the succinate side chain of 
carbenoxolone and its glucuronide conjugates. In the rat hydrolysis
1 h r 1 ^  nof [ Cj carbenoxolone to enoxolone and u C J succinate occurs in
1 A-the gastrointestinal tract prior to absorption and the [ C 3 succinate
14is then rapidly metabolised to CO^ by the gut bacteria and
possibly rat tissues. The other hydrolysis product enoxolone is
absorbed and its conjugates excreted in the bile. After
1*fintraperitoneal administration the rapid excretion of CO^ is 
delayed for several hours (Iveson, 1968; Iveson, ejb al, 1971) and 
then proceeds at a steady rate as biliary excretion occurs, 
indicating that the small and large intestines contain enzymes
capable of hydrolysing the succinate side chain. In contrast to. 
the rat, hydrolysis of the succinate side chain only occurs to a 
small extent, <1/o and 8% for the squirrel monkey and man respectively. 
The greater extent of hydrolysis in man as opposed to squirrel 
monkey indicates differences in the intestinal flora of the tv/o 
species and possibly certain tissues in man such as the liver may 
have a low esterase activity. It has been shown that the amount of. 
conjugated carbenoxolone is much lower in the faeces of rat, 
squirrel monkey and man than in their freshly excreted bile. The.- 
free carbenoxolone is further hydrolysed in the rat while hydrolysis 
only occurs to a small extent in the faeces of the squirrel monkey 
(< 1/o) and man ( <8?o)® Rapid absorption of the free aglycone occurs 
in humans to produce the characteristic two-peak plasma concentration 
curve observed by Downer, e_t al, (1970)* This has not been 
investigated in the squirrel monkey but the mixture of conjugated 
and unconjugated carbenoxolone found in the faeces would lead to an 
enterohepatic re-circulation.
The rat indulges in copropha.gy and Smith (19&5) ^as shown that
wide variety of micro-organisms are distributed throvighout the
gastrointestinal tract of .the rat. Smith (19^5) also found the
stomach of the monkey (Macaca irus) to contain viable micro-organisms
but no information has been found in the literature on the gut
microflora of the squirrel monkey. In man the fasting stomach is
usually sterile and also there are few bacteria in the jejunum and
proximal ileum (Editorial, Lancet, 1970). Thus in the rat orally 
1^fadministered [ Cj carbenoxolone encounters an environment
containing metabolically active bacteria, many being derived by 
coprophagy from the large intestine where the greatest esterase 
activity is thought to reside (Scheline, 1968a) and this is 
supported by the _in vitro hydrolysis experiments (Iveson, ejt al, 1971)* 
The pH of the rat stomach, pH (Smith, 1965) would also result
in a slower absorption of the drug since Downer, et al, (1970) found 
that in humans no appreciable absorption occurred if the pH of the 
stomach contents v/as much higher than pH 2. I11 the squirrel monkey
stomach it is likely that viable bacteria are present but few 
should be of large intestinal origin and assuming that the gastric 
contents of the squirrel monkey have a similar pH to that found for 
Macaca irus (Smith, 1963) i.e. pH 2.8-4.8 the lower pH would result 
in lower metabolic activity in the bacteria and better absorption 
of the drug. Smith (1963) found that the pH of the small intestine 
in Macaca irus v/as in the range 5*6-6.0, proximal to distal end, 
while similarly that of the rat was pH 6.3-7*1 ©
The possibility existed from the results v/ith antibiotic 
treated rats that the stomach mucosa may have been responsible for
1 Zf
hydrolysis of [ C] carbenoxolone and that oral administration of the
antibacterial agents merely inhibited the enzymes- responsible.
However since the in vitro metabolic capacity of the micro-organisms
in the rat stomach is sufficient to account for the hydrolysis of 
1 fj-
[ G ] carbenoxolone the possibility that the stomach mucosa plays a 
significant part in the hydrolysis is unlikely.
An attempt v/as made to show that after oral administration
14[ CJ carbenoxolone was excreted intact as its conjugate and not 
as conjugates of enoxolone in the bile of rats pretreated with 
antibacterial agents. However a number of rats died during the 
cannulation procedure and others that were successfully cannulated 
survived for only a few hours after surgery and no satisfactory bile 
samples were collected. The dose of antibiotics necessary for 
adequate suppression of the gut flora evidently caused toxicity 
rendering the animals susceptible to the combined stress of the 
anaesthetic (urethane and ether were tried) and the surgical procedure
A. large number and variety of micro-organisms are present in 
the rats gastrointestinal tract and the task of isolating the 
organisms responsible for the hydrolysis of carbenoxolone would 
probably be a long one. So far few reports have been published which 
correlate particular intestinal reactions with a particular 
bacterial species (Scheline, 1968). However with the development of 
more satisfactory culture methods, as for instance that of Drasar 
(1967) for strict anaerobes, it will be possible to study the 
metabolism of endogenous and exogenous compounds by these bacteria. 
Y/illiams, et al, (1965) have pointed out the importance of 
enterohepatic circulation with regard to the biological evaluation 
of new compounds and prolonged circulation of a compound and its 
metabolites may lead to increased biological activity with possible 
untoward consequences. The metabolic alterations; produced by the 
gut flora may be of great significance since the metabolic processes 
carried out by bacteria generally result in a reduction of molecular
v/eight and an increase in biological activity or toxicity 
(Scheline, 1968a). Large species differences in metabolism by
'jif _
gut bacteria as found for L CJ carbenoxolone are not necessarily 
a result of a large phylogenic separation of the species concerned 
but can occur, as with the aromatisation of quinic acid (Adamson, 
et al, 1970), in closely related species. In time a detailed 
knowledge of the microflora may enable the investigator to predict 
the likely contribution, if any, of the gut rnicroflora to the 
metabolism of a.compound being evaluated in a laboratory species 
or man.
Specios Differences, in the Metabolism of Carbenoxolone
The species difference in the excretion of radioactivity after
oral administration of [ C 3 carbenoxolone is tabulated in
"I A-table 11-27* The patterns of excretion of in the expired air
after oral dosage- is shown in fig. II-5* For comparison the figures
<j/|.
of excretion of CO^ after oral administration of C C Icarbenoxolon
in table 11-27 cover only the initial period after dosing. As
1 ^can be seen by far the greatest amount of hydrolysis of [ C ] 
carbenoxolone occurs in the rat. Experiments in vivo with rats 
pretreated with antibiotics showed a similar extent of hydrolysis of
1A-[ C 3 carbenoxolone to that found in man. These _in vivo experiments 
together with the In vitro hydrolysis-experiments demonstrated that 
it is the differences in the nature and distribution of the 
gastrointestinal rnicroflora which is responsible for the species 
difference in metabolism. Excretion of radioactivity in urine was 
low in all four cases (table 11-2 7) being particularly low in man 
and the squirrel monkey and this indicates that the bile is the
major route of excretion. The radioactivity in the urine was
"Im­probably largely [ C 3 urea.derived from the metabolism of [ C3
succinate. The bulk of the recovered radioactivity was found in
the faeces except in the case of the normal rat when an average
of only 7% of the dose was recovered in the faeces since the major
'l/f
portion of the radioactivity was excreted as ^0 .^
When bile from rats (after intraperitoneal dosage) and squirrel 
monkeys after oral and intraperitoneal administration was examined- 
for metabolites only one major metabolite, carbcnoxolone-30- 
glucuronide was found. In the bile of the squirrel monkey there v/ere
traces ( k%) of a second conjugate and this v/as possibly a
double conjugate of carbenoxolone. Small amounts of carbenoxolone- 
30-glucuronide were found in the faeces of the human subjects 
studied and Downer, ejb al, (1970) also found carbenoxolone-30- 
glucuronide in the bile of human patients. It appears the pattern 
of excretion of drug and its metabolites is closely similar in the 
three species examined. The rate of metabolism and excretion was 
fairly rapid in all three species. The differences in the overall 
pattern of metabolism and excretion is thus a reflection of the. 
differences in the gastro-intestinal rnicroflora of rat and man.
In man and squirrel monkey an enterohepatic circulation of 
carbenoxolone occurs while in the rat hydrolysis of carbenoxolone. 
results in an enterohepatic circulation of the hydrolysis product 
enoxolone.
In the introduction to this chapter other possible routes of 
bacterial metabolism of carbenoxolone were discussed: decarboxylation
at the C-^ -1 and C-30 positions, aromatisation particularly of ring A 
and reduction of the 11-oxo-12-ene structure. However no evidence 
of any of these possible metabolites; was found in the experiments 
reported here.
Species differences in metabolism poses a large problem in the 
evaluation of new compounds and care should be taken to investigate 
the nature of the observed difference; whether it is a real 
difference or merely dose dependent, or due to the gut rnicroflora.
As shown in this chapter the species differences found in the 
metabolism of carbenoxolone are a result of microbial action.
Since the patterns of metabolism betv/een man and squirrel monkey 
are much closer than those between man and rat, the squirrel monkey 
would be the experimental species of choice for further 
investigation of the biochemistry and toxicology of carbenoxolone.
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CHAPTER THREE
1• General Introduction to Protein Binding
It has been known since the time of Paul Ehrlich (185^-1915) 
that drugs could enter into various forms of combination with 
proteins, and Bennhold (1938) suggested that the plasma proteins 
were a:transport mechanism for the regulated distribution of 
naturally occurring and medicinal substances throughout the 
body. This may be something of an overstatement but it is 
known that plasma proteins can interact with a great diversity 
of ions and small molecules. It would be interesting to see 
if the proteins of other tissues, little investigated in this: 
respect so far, are found to have such a diverse- binding.capacity.
Goldstein (19^9) presented an excellent and farsighted 
review:which surveyed and summarised in tabular form the 
literature on drug-plasma protein interaction published up to 
that time and also set forth the concept of a rational approach 
to the problem. He also pointed out that the interaction of 
drugs with plasma proteins is one aspect of the general 
phenomenon of drug-protein interaction that is readily available 
for experimental investigation. With the increased - awareness 
of the significance of protein binding a large number of 
studies have appeared since Goldstein's review and 
Meyer & Guttman (1968) recently presented a review also 
summarising in tabular form many of the experimental observations 
made since 19^9 together with a discussion of recent developments 
in this field. A number of general articles on this subject
have appeared (Scatchard, 19^9; Edsall & Wyman, 1958;
Brodie & Hogben, 1957; Brodie, 196^; Krieglstein, 1969) 
and several books include a considerable amount of information 
on this topic (Binns, 196*f; Desgres & Be Traverse, 1966; 
Goldstein, Aronow & Kalman, 1968). A large amount of work 
has been done using various dyes as convenient tools to 
investigate protein binding. The binding of endogenous small 
molecules such as hormones and vitamins has also received 
considerable attention and the review of Meyer & Guttman (1968) 
cites the main references to this work and that with dyes.
This brief introduction to the subject is concerned mainly 
v/ith the binding of drugs but most of the work on small 
molecule-protein interaction has been and- is concerned with 
answering one or jnore of the questions posed by Scatchard (19^9) 
namely 'How many? How tightly? Where? Why?’ and to these: 
may be added; 'What of it?'.
A large number and variety of ions and small molecules 
both exogenous and endogenous: are bound to plasma proteins in 
varying amounts. The forces responsible for the attraction 
between small molecules (ligands) such as drugs and proteins: 
may be ionic bonds, hydrogen bonds, London - van der Waal's 
forces or so-called hydrophobic bonds (Guillot, 1966;
Goldstein, ejb al. 1968). It is likely that for most drug- 
protein interactions more than one type of bond contributes to 
the binding, the primary attraction may result from ionic 
attraction which is the strongest force, but as the two molecule 
come closer together the weaker forces such as hydrogen bonding
can reinforce the primary attraction. Although individual 
hydrogen bonds are weak a number of such bonds may cause 
considerable binding of a drug, an example of their collective 
strength being seen with the hydrogen bonding of DNA. The 
interactions occurring in this way are reversible and are 
therefore considered to obey the lav/ of mass action,
i.e. it is a: dynamic process, otherwise most drugs would have; 
a.very long duration of action and persistence in the body.
A.covalent bond between drug and protein would result in 
irreversible binding with the drug persisting in the body for 
a considerable time. However, since the most commonly 
encountered drug-protein interactions are reversible only this 
type of binding will be considered here.
The interaction betv/een a ligand (D) and a protein (P) 
is a reversible equilibrium:-
P + D ^  PD 
and from the law of mass action
c m  cpi _ K
[PDJ
where [DJ is the molar concentration of unbound ligand9 
[Pi the molar concentration of protein and [PDJ the molar- 
concentration of ligand-protein complex. K.is the equilibrium 
or dissociation constant. This is the simplest form of the 
equation and it assumes a single binding protein with a single 
binding site but plasma in fact contains a large number of 
proteins each with a number of different possible binding sites 
and this is discussed later. /K is termed the association 
constant and is a measure of the so-called affinity of the
protein for ihe ligand. Strictly the activity coefficients 
should be used rather than concentrations, but since they are 
not readily ascertainable, concentrations are used and the 
'apparent1 association constant is determined. At equilibrium, 
for any given concentration of free ligand the molar concentration 
of bound ligand depends on (i) the affinity between the protein 
binding sites and the ligand i.e. on the association constant- 
and (ii) the concentration or number (n) of binding sites.
Thus, the extent of binding or fraction bound of a ligand at a 
given concentration is determined by both the association 
constants and number of binding sites.
. Plasma contains a large variety of proteins all of which 
could potentially interact with drugs,and Bennhold (1966) has 
calculated that 5 1* of blood contain plasma proteins having a 
minimum surface area of 130,000 sq.m. So far the Y-globulins 
have not been found to interact significantly with drugs 
(Goldstein, et al. 19&8). The a - and 0-globulins bind a large 
number of lipid soluble molecules including a large number of 
endogenous compounds such as hormones and vitamins and this aspect 
will be considered in more detail subsequently. Albumin is the 
principal plasma protein (^ 5®°/° of the total) and is the most 
important contributor to plasma protein binding of drugs 
(Goldstein, et al. 1968). Bovine and human serum albumin are: 
now well characterised (Putnam, 1965; Schultze & Heremans, 1966), 
and readily available in crystalline form and so are widely used 
for in vitro studies of drug-protein interaction. Albumin has a
molecular weight of about 69*000 and its isoelectric point is
at r>j pH 5 when it carries about 100 each of positive andv
negative charges. At plasma pH (7«A) it has ainet negative
charge but can nevertheless interact strongly with anions as-
well as cations and indeed acidic drugs are generally more?
avidly attracted. Phenylbutazone (pk = k) is a relativelya
strong acid but is bound to plasma albumin to the extent of 
at therapeutic plasma concentrations (Brodie & Hogben, 1957)*
The total number of binding sites for drug molecules per a-lbumin 
molecule is generally much lower than the total number of 
charged groups, but the number varies with the molecular 
structure of the drug. It is now known that a large number of. 
endogenous compounds such as bilirubin, fatty acids, and various 
hormones and vitamins are bound to albumin (Desgrez & De Traverse, 
1966).
/
Globulins also form an important group of binding proteins 
and a number of a- and 0-globulins have recently been isolated 
and found to have a high affinity but relatively low capacity 
for a variety of endogenous compounds. Muldoon & Westphal (196?) 
following the results of earlier workers isolated and 
characterised an -corticosteroid binding globulin (transcortin) 
from human plasma which was broadly similar to that previously 
described (Seal & Doe, 1962; Slaunwhite, Schneider, Wissler 8c 
Sandberg, 1966). Similar corticosteroid binding globulins 
have been isolated from rat serum (Chader 8c Westphal, 1968a) and 
rabbit serum (Chader & Westphal, 1968b). It is. thought that
these proteins act as a transport and regulatory mechanism for.' 
the biological activity of corticosteroids (Keller, Richardson & 
Yates, 1968) and it is considered that only the unbound fraction 
of hormone is biologically active (Desgrez, 1 96 6 ) .  Specific 
binding globulin proteins have been described for a variety of 
other endogenous compounds including testosterone (Kosner & Daakin
1968), thyroxine (Rail, Robbins & Lev/alien, 1-96^ ; Salvatore, 
Andreoli & Roche, 1986; Pensky & Marshall, 19^9)? vitamin 
(Retief, Gottlieb, Kochwa, Pratt & Herbert, 1967) and vitamin A 
(Kanai, Raz 8c Goodman, 1 9 6 8 ) .
Physiological changes in the plasma concentrations of these 
proteins may occur as for instance during,pregnancy when 
transcortin is present in increased amounts (Rosenthal, Slaunwhite 
Sandberg, 1969)* The administration of certain drugs may also 
effect changes and Laureir, Kullander 8c Thorell (196?) found that 
administration of a combined estrogen-progestin (5 mg. megestrol + 
0.1 mg. mestranol) contraceptive tablet brought about significant 
changes in the concentration of certain circulating plasma 
proteins, notably a decrease in orosomucoid proteins and an 
increase in transcortin and ceruloplasmin. Administration of. 
chlormadinone acetate did not affect the homeostasis of 
seventeen plasma proteins studied (Laurell, Kullander 8c Thorell,
1969)« The importance of these changes, both natural and drug 
induced, has yet to be decided.
Endogenous small molecules are therefore present in
plasma bound to both globulins and albumins, the globulins
having high affinity for small amounts e.g. the association
constant of cortisol with human corticosteroid binding globulin
at 37° was 2.4 x 10^ M ^ (Muldoon 8c .Vestphal, 19&7) f ° r  one
binding site. Albumin has a lower affinity for cortisol but a
higher total binding capacity (Florini & Buyske, 1961) for this
steroid. With increasing plasma cortisol concentrations.
transcortin binding sites become saturated and the cortisol is
then partially bound to albumin (Desgrez, 1966) and a similar
process is thought to occur with other hormones such as
thyroxine (Salvatore, Andreoli 8c Roche, 1966). It seems likely
that with many exogenous compounds the primary binding occurs
with albumin, rather than globulin, and only when albumin sites
are becoming saturated do drugs become extensively bound to
globulins (Goldstein, jet al. 1968).
✓
The nature of the binding sites of plasma proteins is not 
really known but table III-1 lists the titratable groups of 
bovine serum albumin and these are potential binding sites 
for charged molecules or ions.
Table III-1. n
Possible Binding Sites for Charged Molecules or 
Ions in Bovine Serum Albumin 
(After Tanford, Swanson 8c-Shore, 1955)»
Group No. of titratable Groups per
molecule (6 5 ,0 0 0 g»)
a-Carboxyl 1
p, y-Carboxyl 99
Imidazole 16
a-Amino 1
€-Amino 57
Phenolic 19
Guanidine 22.
Thorp (196^ -) considered that the N-terminal amino acid 
group (aspartic acid for bovine and human albumin) acts as a 
binding site for fatty acids, coenzymes such as pyridoxal 
phosphate and hormones such as thyroxine and steroid'sulphates 
or glucuronides. Whitehouse, Dean 8c Halsall (1967) have- 
suggested that the (*-amino group of lysine is a binding site 
for a number of triterpenoid acids including enoxolone and 
carbenoxolone•
However, there is considerable evidence to indicate that 
non-ionic or hydrophobic interactions between albumin and the 
bound molecule play a considerable role in the binding process-. 
The protein binding of phenothiazine and derivatives was
considered to be mediated by hydrophobic interactions between 
the benzene rings of the drug and the protein (J&hnchen, et al.
1969)* Scholtan (1968) showed with a variety of drugs, including 
sulphonamides, antibiotics, cardenolides and steroid hormones 
that the affinity of the binding increases if the hydrophobic 
chara.cter of the drugs is increased by introducing hydrophobic 
substituents such as alkyl groups, halogen atoms and aromatic: 
rings* A model has been proposed for the primary albumin binding 
site of thyroxine and it suggests that the diiodophenolate portion 
of the thyroxine molecule fitted into a hydrophobic cleft in the 
albumin. O'Reilly (1967) carried out a detailed investigation 
of the plasma binding of warfarin and concluded the process: was 
largely non-ionic in character* A substituent constant, related 
to the partition coefficient, was proposed (Hansch, ICiehs & 
Lawrence, 1965) to estimate hydrophobic bonding and using this 
concept Bird & Marshall (19&7) have shown that the extent of 
binding of penicillins to human serum is dependent on the 
hydrophobic character of their side chains. The hydrophobic 
interactions between proteins and a variety of hydrocarbons has 
been studied (Mohammadzadeh, Feeney & Smith, 1969a, 1969b).
It may in fact be meaningless to talk about a. given number 
and class of protein binding sites per se because the very act 
of binding may make further sites available for binding 
(O'Reilly, 1967)* An increase in viscosity of albumin solution 
with addition of suramin or chlortetracycline suggested that the 
drugs were inducing a structural change in the albumin molecule
(Franz, JMhchen 8c Krieglstein, 1969)* The concept that 
bound molecules may induce conformational changes that 
facilitate further binding of drug molecules is similar to 
the 'substrate induced fit' idea' advanced by Koshland (1959) 
to explain the formation of enzyme-substrate complexes. Quite 
a number of ligands are now known to induce large conformational 
changes (unfolding) in proteins particularly long chain 
detergents (Steinhardt 8c Reynolds, 1969) anc* recent advances 
in optical techniques can detect small local conformational 
changes which probably occur v/ith the binding of many drugs at 
therapeutic concentrations. The nature-.of the binding process 
will be better understood when the significance of these 
changes can be interpreted.
a) Consequences of Plasma Protein Binding
The binding of a drug to plasma proteins is known to 
affect its absorption, distribution, elimination and, 
pharmacological action. A short discussion of the factors 
affected by protein binding follows but it should be 
remembered, as Meyer 8: Guttman (1968) pointed out, that it is 
probably only of practical importance with drugs that are 
highly bound.
i) Absorption
A. high degree of plasma protein binding may enhance the 
gastrointestinal absorption of a drug by rendering the 
concentration gradient favourable for further absorption.
It is particularly important with drugs poorly soluble in 
water since it affects the equilibrium between drug already 
absorbed and drug remaining in the gut both,dissolved and 
undissolved (see fig,III-l), For example the absorption of 
drugs with solubility characteristics of dicoumarol would not 
be possible without a high degree of binding (Brodie, 1966).
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Moreover many compounds are soluble in plasma at concentrations 
far exceeding their water solubility (Goldstein, 19^9) due to 
their binding to plasma protein and this prevents their 
precipitation and blocking of blood vessels.
It is generally accepted that the gastrointestinal
absorption of weak organic electrolytes is dependent upon the.
lipid solubility of the non-ionised molecule, and that only the
non-ionised entity can cross the mucosal barrier (Brodie &
Hogben, 1957; Schanker, 196^ -). The extent of ionisation of
the electrolyte is governed by the pk of the compound anda
the pH of the gastrointestinal contents. Some qualitative
Solid
drug
discrepancies in this pH partition hypothesis have been 
observed in rats with barbituric acid derivatives (Kakemi,
Arita, Hcri, Konishi, Nishimura, Matsui & Nishimura, 19&9) 
and it was suggested that the binding process to the mucosal 
surface was an important factor for absorption from the small■' 
intestine, .
ii) Distribution and Pharmacological Action
Plasma protein binding can also influence the distribution 
and pharmacological action of a drug. It is considered that 
only the unbound plasma concentration of a drug (as with 
unbound hormone) is available for transport to extravascular 
receptor sites and hence for exerting a pharmacological action,
Martin (19&5&) described the effects of protein binding 
on drug distribution by means of a simple model in which he, 
discussed the binding of four hypothetical drugs whose interaction 
v/ith albumin could be characterised by association constants (k)
h *5 6 7 —1of 10 , .10 , 10 , 10 L. mole respectively. From Martin’s
(1965 )^ theoretical plots it can be seen that protein binding
may have an effect on drug distribution in the body and
furthermore that the strength of binding and the dose of the?
drug may influence this effect. With a weakly bound drug 
A
(k s 10 ) the tissue distribution is not much affected by
7plasma binding, A strongly bound drug (k = 10 ) is located 
mainly in the plasma at low doses, but as the dose is increased 
the remaining available plasma binding sites become fewer with
the result that the drug may diffuse into the tissues and the 
fraction in the plasma is reduced* As a consequence of this 
as plasma binding sites approach saturation a small increase in 
dose will result in a large increase in unbound drug and hence 
in its pharmacological and toxic actions. The therapeutic dose 
range of a highly bound drug may therefore be critically narrow, 
Martin’s (1965&) treatment is highly simplified but nevertheless 
it does demonstrate the important effects of binding on 
distribution particularly on highly bound drugs. Meyer 8c 
Guttman (1968) discuss Martin’s work together with a number of 
experimental findings that indicate the influence of binding on 
drug distribution* The effect of plasma protein binding on 
distribution in vivo is complicated by a number of factors 
including binding to tissue proteins, partitioning into fatty 
compartments and distribution into various extravascular aqueous 
compartments such as cerebrospinal fluid. Until recently the 
influence of protein binding on the quantitative aspects of 
distribution has been neglected but Kriiger-Thiemer (1966, 1968) 
has remedied this using pharmacokinetic models solved by computer 
and relating this to experimental findings with drugs such as 
sulphormethoxine•
The unbound fraction of a drug only is available for 
exerting its pharmacological action, for example the antimicrobial 
activity of penicillins is proportional to the unbound concentration 
and not the total serum concentration (Kunin, 1967)* It is 
important with protein bound drugs to relate the dosage to the
unbound drug'concentration and not the total plasma concentration 
There is now evidence that one drug may displace another drug 
or endogenous compound from a common plasma protein binding site 
(Meyer & Guttman, 1968; Prescott, 1969)* Thus a drug may not 
exert a pharmacological action directly but only indirectly by . 
displacing another molecule from its binding site. For example 
administration of aspirin or phenylbutazone lowered, in a 
reversible way, the capacity of pl.asma proteins to bind uric 
acid (Bluestone, Kippen & Klinenberg, 1969) an(^  ^7 displacing 
albumin-bound urate these drugs augment its renal elimination.
It has been suggested (Whitehouse, Bluestone, Kippen & Klinenberg
1970) that albumin-bound phenylbutazone and aspirin may be. 
inactive as analgesics, antipyretics or anti-inflammatory agents 
but are useful uricosuric agents as a result of displacing bound 
urate. It has also been suggested (Brodle, 1965) that 
antirheumatic drugs such as indomethacin may displace endogenous 
corticosteroids which in turn exert a therapeutic action, but 
there is little other experimental evidence to support this*
The plasma protein binding of a drug can be a very useful 
feature of a drug in that bound drug acts as a 'depot1 of drug 
from which more drug is released by dissociation of the 
drug-protein complex. The concentration of unbound drug can be 
maintained at a useful therapeutic concentration for a 
reasonable period of time over a range of total plasma 
concentrations and the concentration of unbound (active drug) 
is not subject to drastic alteration after each dose. As unbound
drug is removed by distribution, metabolism and excretion more 
drug dissociates from the drug-protein complex thus maintaining 
the unbound concentration and in this v/ay binding can ’buffer* 
the unbound concentration of drug in biological fluids 
(Brodie, 196*0, With drugs that are potentially very toxic 
their binding to plasma proteins can reduce the unbound 
concentration below that required to produce toxic effects and 
render the drug safe for therapeutic use* -
iii) Metabolism
The present, generally held, view is that only unbound drug 
is available for metabolism* The very limited number of studies 
on-the kinetics of binding have been discussed by Meyer & Guttman
(1968) and there is general agreement that in most systems rates 
of association and dissociation are very rapid* Thus it is 
unlikely that a high degree of binding necessarily hinders the: 
rate of drug metabolism although the effect of binding appears 
to vary from drug to drug* . - - .
Newbold 8c Kilpatrick (1960) found that addition of plasma 
to the perfusion fluid of a perfused rabbit liver preparation 
reduced the rate of acetylation of two long-acting sulphonamides 
and that the rate of metabolism depended on the concentration of 
unbound drug. Anton & Boyle (196*0 and Wiseman 8c Nelson (196*0 
using in vitro and in vivo findings respectively reported a 
correlation between the rate of metabolism and degree of binding.
However^ there are a number of highly bound compounds that
are rapidly metabolised as for example sulphobromophthalein
n
with an apparent association constant (k) of-^.10 (Baker &
Bradley, 1966), Phenylbutazone is highly plasma protein bound 
(Brodie & Hogben, 1957) and with the exception of man is rapidly 
metabolised in several species. Bilirubin is a highly bound 
endogenous substance (Jacobsen, 19&9) anc^ r e a d i l y  metabolised.
It is difficult to see how the effect of plasma protein binding 
on the metabolism of drugs may be investigated in any series of 
analogues because changes of chemical structure may affect not 
only the extent of binding but also the nature and rate of 
metabolism.
A. number of binding proteins to which both endogenous and 
exogenous molecules are known to bind have been isolated from 
cells of various organs. Rat kidneys have been found to contain 
aldosterone-binding proteins (Herman, Fimognari;& Edelman, 1968); 
rat liver contains proteins that bind cortisol and corticosterone 
(Guidollet & Louisot, 1969) ar*d metabolites of cortisol 
(Beato, Biesewig, Braendle & Sekeris, 1969; Morey & Litwack, 1969)* 
Levi, Gatmaitan & Arias (1969) have isolated two hepatic cytoplasmic 
protein fractions, designated Y and Z, in a number of species 
which bind sulphobromophthalein, bilirubin and other organic 
anions, and the amount of Y was increased significantly in rat 
liver by phenobarbitone pretreatraent (Reyes, Levi, Gatmaitan &
Arias, 1969)* The function of these various binding proteins is
not known but' they may be involved in the uptake of small 
molecules from the plasma, intracellular transport or in 
mediating biological action in the case of hormones® Although 
the plasma protein binding of some drugs exerts a quantitative 
effect i.e. an alteration in the rate of metabolism, no 
investigators appear to have considered whether binding may exert 
a qualitative effect by affecting the type of metabolites produced©
iv) Elimination
As with metabolism, distribution and pharmacological action
it is generally considered that only unbound drug is available
for elimination in the urine after glomerular filtration® A
large number of observations have indicated that binding is an
important factor in the pharmacokinetic behaviour of a drug
(Meyer Sc Guttman, 1968)® As discussed in the previous section
/
protein binding can have an effect on the rate of metabolism of 
some drugs (Nev/bold & Kilpatrick, 19&0; Anton & Boyle, 1964-; 
Wiseman 8c Nelson, 196^) and so any reduction in the rate of 
metabolism of a compound is likely to reduce the rate of 
excretion®
Rieder (19&3) studied a number of sulphonamides but did not 
observe a correlation between binding and rate of disappearance 
from plasma or rate of renal excretion. Rieder (19&3) also 
pointed out that plasma protein binding would exert an appreciable 
effect on the rate of elimination of a drug if elimination 
occurred through glomerular filtration, but this effect may not
be apparent if significant tubular secretion and reabsorption 
occurred. Hence the persistence of a drug excreted unchanged 
in the urine after glomerular filtration can be influenced by 
the fraction bound of the total drug present in the plasma. 
Penicillin and p-arainohippuric acid are examples,even at 
concentrations where they are bound as much as 90% to plasma 
protein, the renal secretory mechanism clears them almost 
completely from the blood during a single passage through the 
kidney (Goldstein, e_t al. 1968), The order of urinary excretion 
rates of salicylic acid and four derivatives in rabbits and 
humans paralleled the order of the extent of binding, with the 
most extensively bound salicylate having the longest half life 
(Kakemi, Arita, Yamashina & Konishi, 1962),
Another factor to consider is that one drug may compete 
for renal excretion of another. Anton (1961) found that 
sulfinpyrazone displaced a number of sulphonamides from their 
plasma binding sites and also competed for their renal secretion. 
The net effect in vivo was a drop in plasma concentration of 
total drug and an increase in unbound fraction, resulting in an 
increased tissue concentration of sulphonamide (Anton, 1961). 
Martin (1965^)1 besides considering the effect of plasma binding 
on distribution, has considered the theoretical kinetics of 
elimination of drugs possessing high.affinity for plasma 
proteins, KrUger-Thiemer (1968) has made a considerable 
contribution to the understanding of the pharmacokinetic 
behaviour of plasma protein bound drugs, using models which he
subjected to rigorous mathematical analysis® The model 
proposed by Martin (1965b) was considered incorrect by 
Kriiger-Thiemer (1968) because of artifacts generated by the 
method of estimating plasma levels of the drug® Levy 8c Nagashimas.
(1969) have demonstrated the pronounced effect of protein binding 
on the distribution and elimination of bishydroxycoumarin®
A considerable number of drugs are eliminated unchanged or 
as metabolites via the bile (Williams, Millburn 8c Smith, 1965;  
Parke, 1968) and this route has received increasing attention 
in recent years but so far the effect of plasma protein binding 
on biliary elimination of drugs is largely conjecture® The rate 
of biliary excretion of a number of aso dyes has been shown to be 
a function of the ratio of binding with liver proteins to the 
binding v/ith blood proteins (Priestly 8c O’Reilly, 1 9 6 6 ) but the 
method used to measure protein binding was rather inappropriate 
in that it was a protein precipitation procedure® Osorio 8c Myant 
(1965) studied the relationship between the biliary excretion of 
thyroxine and its binding by plasma proteins in monkey and 
presented evidence to support the hypothesis that only unbound 
thyroxine in the plasma is extracted by the liver cells® However 
there appears to be an active transport process for the biliary 
excretion of certain anions (Sperber, 1959) and cations (Nayak 8c 
Schanker, 1969) and a number of compounds are secreted into bile 
against a high concentration gradient v/ith bile/blood concentration 
ratios often exceeding 50:1 (Goldstein, et al« 1968), The 
protein fractions that Levi, et al, (1969) isolated were suggested 
to have a role in the transfer of organic anions from plasma into
the liver* It does appear that a high degree of plasma protein 
binding, as with sulphobromophthalein used diagnostically to 
test liver'function, does not inhibit metabolism because of 
rapid dissociation of the drug-protein complex0
v) Species Differences
Goldstein (19^9) mentioned a number of reports of:1 different 
binding capacities for sera of different species, and apart 
from noting the apparent superior binding properties of rabbit 
serum towards various drugs, no consistent pattern was apparent* 
Since that time a large number of reports have been published 
concerning the binding of drugs to plasma, both whole and diluted 
and to certain plasma protein fractions, particularly bovine and 
human serum albumin. Unfortunately only a few of these reports
have been concerned with evaluating the inter-species variation
\
in the-plasma protein binding of drugs and no basis for 
prediction has emerged or seems likely to in the immediate future*
Sturman & Smith (1967) studied the binding of salicylate 
to plasma by sephadex gel filtration and found that the species 
investigated could be divided into two main groups* The first 
group comprising the baboon, horse, dog, rat, mouse and turkey 
exhibited a low protein binding capacity for the drug with only 
1 to 11% bound at a plasma salicylate concentration of 10 mg/1 0 0 ml* 
The second group consisted of the rhesus monkey, rabbit and 
guinea pig and was similar to man in possessing a much greater' 
capacity for binding salicylate for at the same total plasma 
salicylate concentration 60 to 80/S of the drug was bound*
Kucera & Bullock (1969)i concerned that differences in the total 
protein of plasmas amongst these species might have accounted in 
part for the striking apparent species differences found by 
Sturman & Smith (1967), investigated the binding of salicylate, 
in plasma samples adjusted to the same total protein concentration* 
The results of Kucera & Bullock (19&9) confirmed that man, 
monkey, rabbit and guinea-pig can be considered together as 
having a higher proportion of salicylate bound than rat and dog 
which have a lower fraction of salicylate bound at the same total 
plasma concentration. The lower affinity of rat and dog albumins 
for salicylate seemed the likely cause of the low binding observed, 
in the plasma of these species (Kucera. & Bullock, 1969)* V/itiak 8c 
Wh’itehouse (1969) noted species differences in the albumin 
binding of several acidic drugs and suggested that the rat may be 
an unrepresentative species as fap as drug binding to its albumin 
is concerned. Species differences in the plasma protein binding 
of desipramine, a basic drug, have been reported (Borga, Azarnoff & 
SjBqvist, 1968) and it was speculated that reported species 
differences in pharmacological effect of tricylic antidepressents 
could be related to the degree of protein binding. The inter- 
and intra-species differences that occur in plasma protein 
binding of drugs may account for some of the different and 
variable responses to drugs that occur and it seems likely that 
this will prove a fruitful area of research.
vi) Inhibition of Binding
When several drugs are administered concomitantly to ai 
patient then the possibility arises that if these drugs are 
plasma protein bound, inhibition of the binding of one drug by 
another may occur. Goldstein (19^9) reviewed a number of papers:, 
indicating that competition between drugs for binding sites could 
occur but although no clinical evidence of interaction was 
available he did forsee the dangers of a displacement episode.
Meyer & Guttman (1968) have discussed the more recent work on 
competitive binding and Brodie (19&5) an  ^Prescott (19&9) have: 
reviewed the therapeutic difficulties arising from competition 
between drugs for protein binding sites in plasma.
Competition for binding sites between endogenous and 
exogenous molecules falls into three broad categories. Firstly 
mutual competition may occur between endogenous substances such 
as steroid hormones (Keller, Sendelbeck, Richardson, Moore & Yates, 
1966) though the importance of this phenomenon remains to be 
ascertained. Secondly endogenous compounds may be displaced by 
drugs and a number of examples are now known. It has been shown 
(Odell, 1959a, 1959b) that sulphonamides can displace bilirubin 
from its albumin binding sites and this can produce toxic effects 
from the increased concentration of unbound bilirubin, particularly 
in premature infants with low plasma albumin concentration or in 
individuals v/ith an impaired capacity to metabolise bilirubin.
A.number of investigators have shown that a variety of drugs 
can displace bound thyroxine (Meyer & Guttman, 1968).
Brodie (1965) considered the possibility that some anti­
inflammatory drugs may act by displacing endogenous steroids 
and this is considered more fully in chapter four. The third 
type of interaction occurs when two drugs compete for the same 
plasma protein binding site. Phenylbutazone is highly bound and 
has been shown in vitro to displace the anti-coagulant warfarin 
(Solomon & Schrogie, 1967; Solomon, Schrogie & Williams, 1968) 
and a number of clinical reports (Aggeler, O'Reilly, Leong &
Kowitz, 1967; Eisen, 196^ f; Fox, 1964-) indicated that administration 
of warfarin and phenylbutazone or oxyphenbutazone potentiated the 
anti-coagulant action of warfarin and in some cases resulted in 
fatal haemorrhagic complications. After displacement more drug 
is'available for metabolism and excretion with the result that 
the biological half-life may be reduced (Aggeler, e_t al. 1967).
A number of other drug-binding interactions are now known and a 
number of highly bound acidic drugs 'can enhance the antibacterial 
activity of sulphonamides by displacement from plasma proteins 
(Anton, 1961); the hypoglycaemic activity of tolbutamide is 
increased by concurrent administration of phenylbutazone, 
salicylates and sulphaphenazole (Prescott, 1969)* Thus it can be 
seen that competition between two drugs or a drug and an 
endogenous compound can manifest itself clinically as a side effect, 
which is usually an undesirable one though it may be useful as 
with enhancement of antibacterial activity.
Meyer Sc Guttman (1968) suggested that in order to displace 
a strongly bound drug a competitor must be present in the system
at a relatively high concentration or have an affinity for the 
protein which is significantly greater than that exhibited by 
the drug. The effect of various drugs and fatty acids on the 
binding of warfarin and phenylbutazone to' human albumin in vitro 
has been studied (Solomon 8c Schrogie, 1967; Solomon, Schrogie & 
Williams, 1968) and the inhibition of binding was generally 
concentration-dependent and competitive in nature.
Chlorophenoxyisobutyric acid competitively displaced warfarin from 
albumin but the nature of the displacement depended on the 
concentration of acid. At a lower concentration of 
chlorophenoxyisobutyric acid a non-competitive type of displacement 
of the anti-coagulant was shown (Solomon 8c Schrogie, 1967 )  while 
at higher concentrations the displacement was competitive 
(Solomon, Schrogie & Williams, 1 9 6 8 ) .  Bttttner 8c Portwich ( 1 9 6 7 ) 
found that thylsulfadiazine and tolbutamide mutually displaced 
each other to the same degree from binding to albumin and the 
competition was concentration dependent. The influence of several 
drugs on the albumin binding of promazine and chlorprcmazine: has. 
been studied (Franz, Jahnchen 8c Krieglstein, 1969) and it. was 
found that promazine was displaced by acidic as well as basic- 
drugs and paradoxically highly bound drugs were not effective or- 
v/ere comparatively less effective as promazine displacing agents.
A more highly bound drug may not necessarily act as a better 
displacing agent because it may be bound primarily at a different 
site. It was also reported (Franz, ot al. 1969) that several 
drugs caused an increase of promazine and chlorpromazine binding 
to albumin. One explanation for this interesting phenomenon is
that the bound drug induces a conformational change in the 
albumin molecule and thus exposes more drug binding sites. It 
is thus apparent that competition phenomena: cannot be readily 
predicted and until there is a better understanding of the 
mechanisms involved great caution should be exercised when 
administering novel combinations of drugs known to be protein 
bound.
vii) Protein Binding and Uncoupling.of Oxidative Phosphorylation 
The work of Whitehouse, _et al. (196?) showing that 
carbenoxolone and related triterpenoid acids were potent uncouplers 
of oxidative phosphorylation was discussed in chapter one 
(section Now it has been postulated that compounds which
uncouple oxidative phosphorylation bring about a conformational 
change in the enzymes concerned v/ith oxidative phosphorylation 
(Weinbach 8c Garbus, 1969) • Hansch, Kiehs 8c Lawrence (1965) 
studied a number of phenols of plant origin that uncouple 
oxidative phosphorylation and found that they were highly bound 
both to serum proteins and to hepatic mitochondrial protein. If 
there is indeed a relationship between the ability to uncouple 
oxidative phosphorylation and protein-binding-induced 
conformational changes in mitochondrial protein ,it may be 
possible to use a simple in vitro test such as fluorescence- 
quenching, discussed later in this chapter, for detecting 
conformational changes.
b) Methods of Studying Protein Binding
Over the years a considerable variety of techniques have 
been employed to study the binding of small molecules to 
proteins and Goldstein's (19^9) review contains a critical 
appraisal of the techniques used up to that time, many of which, 
are still widely used. However the recently introduced methods 
based on gel filtration, fluorescence, nuclear magnetic resonance., 
optical rotatory dispersion and circular dichroism were obviously 
not discussed by Goldstein but have been summarised by 
Meyer & Guttman (1968). The book "Multiple Equilibria in Proteins" 
by Steinhardt & Reynolds (1969) contains a comprehensive chapter 
on methods for measuring ligand-protein complex formation but 
some of the methods listed depend on a ligand possessing certain 
physical or chemical properties and so are not generally 
applicable. Unfortunately no attempt was made to select or- 
recommend just a.few of the many methods as being the best or 
most generally suitable*
The aim of this section is to outline both the well 
established techniques and the most promising new ones* These, 
together with less frequently used methods, are summarised in 
tabular form at the end of this section. The major advantages 
and disadvantages of each technique, where known, are listed in 
the table and a small number of selected references are given 
to serve as an introduction to the method and relevant sources 
of information.
ij Dialysis and Ultraflltration
Equilibrium dialysis has been the most widely used method 
for studying the binding of small molecules to protein and a 
large proportion of the investigations based on this method 
have been concerned with bovine and human serum albumin. It ...
is considered the thermodynamic method of choice (Steinhardt &
Reynolds, 1969) an(^ is ideally suited for quantitative
measurements but it does have a number of problems and these
have been considered in detail by Go.ldstein (19^9) and 
Steinhardt & Reynolds (1969)* Briefly, the problems are that 
the Donnan effect must be considered, adsorption onto the 
membrane can occur and the time taken to attain equilibrium is 
very variable depending on stirring, pretreatment of the membrane, 
protein concentration, temperature, nature of the buffer and 
the volumes on both sides of the membrane (Steinhardt 8c Reynolds,
1969)* It has been found that many buffers used in in vitro 
experiments compete with the binding of ligands to bovine serum 
albumin and phosphate buffer appears to be the weakest competitor 
(Steinhardt 8c Reynolds, 1969)* Because of the length of time 
required to attain equilibrium (usually at least several hours) 
dialysis experiments should be conducted in a cold room to 
reduce the possibility of protein denaturation and bacterial 
contamination. Some ligands can be adsorbed onto the membrane 
and it is not easy to quantitate this effect by making 'blank’ 
measurements in the absence of protein since the presence and 
concentration of protein can affect the degree of binding to 
the dialysis membrane (Steinhardt 8c Reynolds, 1969)* Dialysis
experiments do not yield accurate information about the nature 
of an interaction occurring in whole plasma because, if the 
drug-protein combination is reversible, dissociation may occur 
when the water phase is diluted and neither the amount of 
drug bound per molecule of protein nor the fraction of the 
total drug bound will necessarily be the same as before the 
equilibrium was disturbed.
Ultrafiltration is in principle identical with equilibrium 
dialysis but a single solution, containing both protein and 
ligand in equilibrium, is used and from this is separated out 
by filtration a small volume of the protein-free phase which can 
be analysed for unbound ligand. Ultrafiltration employs the 
same type of membrane as used in dialysis and it is supported 
to withstand the filtration pressure which is provided by 
centrifugal force in a centrifuge, by vacuum or by gas under 
pressure. Because a dialysis membrane is used the results 
obtained by ultrafiltration are subject to some of the errors 
arising v/ith equilibrium dialysis and adsorption of unbound 
ligand onto the membrane may occur. However the technique is 
essentially simple and quick and does not interfere with the 
ligand-protein equilibrium by dilution, a severe disadvantage of 
dialysis. Goldstein (19^9) has pointed out that it approximates 
most closely to the physiological process of glomerular 
filtration since the hydrostatic pressures employed are usually 
of a magnitude comparable to the renal filtration pressure. This 
has been re-emphasised by Dixon, Booth & Butler (1967)-
Generally the data obtained by ultrafiltration has not shown 
serious disagreement from that obtained by equilibrium dialysis 
(Steinhardt 8c Reynolds, 1 9 6 9 ) *  Some disagreement exists as to 
whether when the volume of ultrafiltrate forms a relatively 
large proportion jpf the sample the equilibrium is disturbed.
Some workers consider that the volume of ultrafiltrate should 
not exceed 10-15% of the total sample volume (Tait & Burstein, 
196^; Sandberg, Rosenthal, Schneider 8c Slaunwhite, 1966 ; Kelle 
e_fc al. 1966; O'Connell & Welsh, 1966) otherwise the equilibrium 
will be disturbed by the increased protein concentration® 
However, Pearson, Keane oc Walker (1967) when studying cortisol 
binding found that ultrafiltration of up to 70% of the sac 
volume did not disturb the initial equilibrium and they consider 
this finding to be in accord with considerations put forward by 
Toribara, Terepka 8c Dewey (1957) based on mass action theory® 
Ultrafiltration has been widely used as a technique to study 
steroid-plasrna protein interaction (e.g. Keller, ejt al. 1966; 
Forest, Rivarola. 8c Migeon, 1968) and drugs (eeg. Meyer & Guttman 
1968).
When freshly taken plasma is left to stand it loses 
dissolved carbon dioxide and the pH of the plasma rises above 
that normally obtaining in vivo. Toribara, ejt al® (1957) in a. 
study of calcium binding in plasma published details of an 
ultrafiltration apparatus that enabled the plasma to be gassed 
with a carbon dioxide containing gas mixture just prior to
centrifugation to lower the pH to the physiological range.
The apparatus can be kept sealed during the centrifugation 
procedure to maintain constant pH. This apparatus of 
Toribara, ejt al. (1957) is of great value when it is desired 
to approximate conditions as closely to those in vivo as possible.
c
Some recent modifications of the dialysis and ultrafiltration 
methods have been discussed by Meyer 8c Guttman (1968) and these, 
workers have developed a dynamic dialysis method (Meyer 8c Guttman, 
1970a) which gave results for a number of compounds comparable 
to previously published figures or to results obtained by
independent methods (Meyer 8c Guttman, 1970b). A novel technique,
termed in vivo dialysis has been developed by McQueen (1968).
This technique involves the implantation of small dialysis 
tubing sacs, which contain an isotonic medium, into the 
peritoneal cavities of rats. The underlying theoretical 
assumption is that the unbound drug in the plasma is in 
equilibrium with drug in the interstitial fluid which in turn 
equilibrates v/ith the isotonic fluid present in the implanted 
sac. The amount of drug that has diffused into the sac can then 
be determined after a given period of 1 in vivo dialysis' and this
is considered to be equivalent to the amount of unbound drug
present in the plasma. This method has been used to study the 
protein binding of sulphormethoxine (McQueen, 1968) and the 
displacement of sulphormethoxine from serum proteins by 
phenylbutazone (McQueen, 1969) where the jln vivo technique gave 
similar results to those obtained in vitro. In vivo dialysis
appears to be a novel technique for studying the plasma protein' 
binding of small molecules and warrants much further investigation 
Recently a new semi-permeable membrane (”DiafloM, Amicon, 
Lexington, Mass., U.S.A.) has been produced which is designed 
for use in ultrafiltration methods using gas pressure in an 
ultrafiltration cell or a centrifugation technique. The technique 
is rapid (Paulus, 19&9) requires a special ultrafiltration
cell and does not offer any new significant advantages. Another.- 
interesting but very limited possibility is that of In vivo 
ultrafiltration performed on patients.,who are undergoing 
therapeutic haemodialysis for the treatment of renal insufficiency 
De Moor, Verberckmoes & Heyns (1968) studied plasma cortisol 
binding and the effect of oestrogen treatment in patients by 
this in vivo ultrafiltration method, the plasma ultrafiltrate; 
being obtained in vivo during the therapeutic dialysis.
If a very high centrifugal force, 100,000 x g or more is 
applied to a protein-ligand solution the membrane can be dispensed 
with and this technique is referred to as ultracentrifugation.
It seems likely that this technique will be widely used in the 
future with light-absorbing ligands since the necessary opticaj. 
accessories are now available (Steinhardt & Reynolds, 19&9)*
The disadvantage of this method is that complications arise if 
protein mixtures, such as plasma, are employed.
Treatment of Results obtained by Dialysis and Ultrafiltration 
The reversible binding of drugs to plasma proteins is a 
dynamic equilibrium which is generally considered to obey the 
law of mass action with sufficient accuracy to allow treatment 
of the data by methods derived from this law (Goldstein, 19^9; 
KrUger-Thiemer, 1968; Meyer & Guttman, 1968)* The adsorption 
isotherm method of Freundlich (1907) used by some authors applies 
only to ideal systems i.e. at infinite dilution and the equation 
has no thermodynamic validity (Goldstein, 19 9^; KrUger-Thiemer, 
1968). KrUger-Thiemer (-1.968)- considered that the law of mass 
action is sometimes identified incorrectly with the adsorption 
isotherm of Langmuir (1916, 1917) and although Goldstein (19^*9) 
considered the isotherm entirely equivalent to the mass law 
equilibrium, he also presented the then newly proposed treatment ' 
of Scatchard C19^9)•
There are two graphical methods of plotting exj^erimental 
data, the reciprocal plot (Klotz, W.alker 8c Pivan, 19^6) and that 
of Scatchard (19^9) which are both directly derived from mass-law 
considerations (Meyer 8c Guttman, 1968). Making certain assumptions, 
for a-, single class of sites reversible binding can be described 
by the equation.
n k D_
where v = moles of small molecule bound to total moles of 
protein in the system 
n =; number of binding sites
k = association constant for the binding of the small: 
molecule
ss concentration of unbound small molecule.
The assumptions made in equation (1) are that activities; 
can be represented by concentrations, that all sites within a^ 
class are equivalent in binding affinity.
Equation (1) can be rearranged:-
1 -  1 + -J—      (2)- n n k D  ............. .......
v f
'I
which is the basis of the reciprocal plot in which — is plotted
1 ^ • 
as. a function of — • Estimations of n and k are made from the
slope and intercept values of a reciprocal plot.
Scatchard (19^9) proposed a different form of equation (1)
~ = n k - v k   ............   (3)
where v is plotted as a function of v. Extrapolation to the
h
abscissa gives the number of binding sites n in a class, ana 
extrapolation to the ordinate allows estimation of n k. Curvatu] 
of such plots is usually indicative of the presence of more than 
one class of binding site (Meyer & Guttman, 1968).
The reciprocal plot heavily weights those experimental 
points obtained at low (Klotz, Walker & Pivan, 19^ -6; Meyer 8c
Guttma.n, 196$) and can lead to misinterpretations concerning 
binding at high D^ . The Scatchard plot does not suffer from 
this disadvantage and is therefore the graphical method of 
choice (Meyer 8c Guttman, 1968; Krieglstein, 1969) and is the 
one used in interpreting the present experimental data.
ii) Molecular Sieve Chromatography -
Gel filtration using columns of cross-linked dextran gel 
("Sephadex11, Pharmacia, Sv/eden) was introduced by Porath 8c Flodin 
(1959) and the first reports of its use in the context of 
ligand-protein interactions were by Hummel & Dreyer (1962) v/ho 
investigated the binding of cytidine 2 ‘-phosphate by ribonuclease: 
and Hardy & Mansford (1962) and Acred,, Brown, Hardy & Hansford 
(1963) who studied the binding of salicylate and several antibiotic
The cross-linked dextran is thought to act as a 'molecular 
sieve' with large molecules such as proteins being excluded 
from the internal volume of the gel and thus passing rapidly 
through the column. Small molecules enter the internal volume of 
the gel matrix: and migrate more slowly than the protein and are 
eluted from the column as a separate zone. Ligand that is bound 
to the protein is eluted from the column with the protein. A 
variety„of gels are now available having different exclusion 
characteristics suitable for proteins of differing molecular 
weight. The size of the gel column is determined by the size of 
the samples to be analysed and experiments can be carried out 
over a range of temperatures if the column is surrounded by a
thermostatically controlled water jacket. As a ligand-protein 
complex migrates down the column dissociation of the complex 
occurs giving misleadingly low binding values. This difficulty 
can be met (Hummel Be Dreyer, 1962) by applying protein-ligand 
mixture to a gel column previously equilibrated with a solution 
containing the same ligand concentration as the mixture, elution 
being carried out with the same solution. If the ligand is 
available in both radioactively labelled and unlabelled forms, 
the labelled drug can be used for the ligand-protein mixture 
while the column is equilibrated with the unlabelled drug and 
this method has been used by Clausen (1966) to study the binding 
of a sulphonamide. Results from this method have not been 
compared with equilibrium dialysis (Cooper & Wood,; 1968) although 
they are theoretically sound but the technique is extravagant of . 
drug. McArthur and Smith (1968) have used another interesting 
approach to overcome the possible dilution effects on gel columns
and they studied the binding of a drug on columns of known varying
lengths and by extrapolation of the results determined the 
binding on a column of zero length where no dilution should occur. 
This method has disadvantages in that some of the data obtained 
could not be extrapolated to zero .with certainty.
Other v/orkers have used gels in a batch method: a known
weight of dry gel is added to a solution containing known amounts 
of ligand and protein and the extent of protein binding is 
determined from the change of ligand concentration in the
external (prbtein solution) phase. This method is considered 
equivalent to equilibrium dialysis (Cooper & Wood, 1 96 8 ) but 
the composition of only the protein phase can be assayed with 
precision. Scholtan (1964 -) ,  who introduced this batch method 
has studied the binding of antibiotics, Pearlman & Crepy (1967) 
and Pearlman, Fong & Tou ( 1 9 6 9 ) the binding of testosterone and 
Kuschinsky ( 1 9 6 8 ) the binding of cardiac glycosides. The use of 
gels either as a column or batch method has the serious disadvantage 
that some ligands are adsorbed by the.gel but Cooper 8c Wood ( 1 9 6 8 ) 
have extended the method of frontal analysis chromatography on 
gel columns,that has been used for protein-protein interactions 
(Nichol 8c Winzor, 1964-) , to the study of- ligand-protein 
interactions. This technique appears to offer good agreement with 
equilibrium dialysis for a limited number of drugs (Cooper 8c Wood, 
1968).
Gel filtration appears to be a very useful technique for 
both the qualitative and quantitative investigation of binding 
but is inferior to other methods such as dialysis and 
ultrafiltration in the latter respect. Quite a large number of 
studies have now appeared and in addition to the examples quoted 
further references are as follows, Krieglstein 8c Kuschinsky
( 1 9 6 8 ) ,  Scholtan ( 1 9 6 8 ) ,  Franz, Jhhnchen 8c Krieglstein ( 1 9 6 9 ) ar.d 
the reviews by Meyer 8c Guttman ( 1 9 6 8 ) ,  Krieglstein (1 9 6 9 )
V/ood 8c Cooper (1970). Problems can arise if the ligand or protein 
is adsorbed onto the gel to any significant extent and bacterial 
contamination of the column can occur. However the disadvantages 
are generally far outweighed by the advantages, 'its simplicity
and speed, the introduction of new theoretical approaches and 
improved gel materials.
iii) Electrophoresis
Electrophoresis has been used to study the plasma binding . 
of a large number of drugs, hormones and vitamins (Goldstein, 
194-9; Desgrez & De Traverse, 1966; Meyer & Guttman, 1968).
The technique is relatively straight!orv/ard and gives qualitative 
information on which proteins in plasma are responsible for 
binding. It enables the relative percentages of ligand bound to 
individual proteins to be found but the precise quantitative 
relationship between drug concentration and molar binding ratio 
is not readily ascertained (Goldstein, 194-9)* This method has.: 
the advantage that only small samples ( 100 p.1) a.re required
but this does mean that a sensitive assay is needed for the 
detection and measurement of the ligand and so radioactively- 
labelled compounds have frequently been employed. If the 
radioactive compound is of sufficiently high specific activity 
immunoelectrophoresis combined with autoradiography can be used 
for precise loca.tion and identification of the binding proteins. 
Clausen (1966) has used immunoelectrophoresis combined with 
autoradiography to study in vitro the serum protein binding of 
-sulphamido-6-methoxypyridazine.
Electrophoresis does have a number of drawbacks, one being 
that with present methods the best separation of plasma proteins 
is achieved using buffers at a pH of approximately 8.6. This
does not correspond with physiological pH and the altered charge 
on the various plasma proteins will alter their binding 
characteristics and cause a re-distribution of the ligand bo 
occur, resulting in a binding pattern different from that 
obtaining in vivo at pH 7*4-. Dilution by the buffer may cause . 
dissociation and reduce the apparent extent of binding and 
competition effects are possible if a barbiturate buffer is 
employed. Competition for the ligand may occur between the 
support medium and the binding protein(s) and this problem has 
been encountered'with several ligands. Digitoxin has been found 
to bind to starch gel (Spratt & Okita, 1958; Lukas & De Martino, 
1969) with the result that it failed to migrate with the plasma 
proteins, but continuous flow electrophoresis on paper revealed 
that the glycoside migrated almost exclusively with albumin 
(Lukas & De Martino, 1969)* Similar distortion of the pattern of 
distribution of ligands among the plasma proteins by support 
material has been noted in the case of cortisol and transcortin 
(Daughaday, 1958) and with thyroxine binding (Robbins, 1956).
A number of modifications of the original electrophoretic 
apparatus have now appeared and probably one of the most useful 
is the continuous flow method which enables much larger plasma 
samples to be employed. O’Reilly (1967) studied the plasma protein 
binding of warfarin using this method and Lukas 8c De Martino (1969) 
studied the binding of digitoxin in a 100 ml. plasma sample.
Disc gel electrophoresis (Ornstein, 1964) does not appear as yet 
to have found much application to the study of drug-protein 
interaction.
iv) Fluorescence Methods
Fluorescence methods have been used to investigate protein 
binding and changes in the fluorescence spectrum of the protein, 
the ligand or sometimes both have been found when interaction 
occurs. Steinhardt 8c Reynolds (I969)have summarised a number of 
fluorescence studies of ligand-protein interaction particularly 
those of dyes and a number of other interactions involving 
serum albumin have been investigated. Attallah 8c Lata. ( 1 9 6 8 )  
studied the quenching of bovine serum albumin fluorescence.-by 
steroids and Spector 8c John (1 9 6 8 )  the quenching by fatty, acids. 
The interaction of thyroid hormones with proteins has been 
investigated by fluorescence quenching (Salvatore. Andreoli 8c 
Roche, 1966; Kocman 8c Hegedus., 1969; Tabachnick, Downs 8c 
Giorgio, 1 9 7 0 ) ,  and Winkler ( 1 9 6 9 ) has proposed a fluorescence 
quenching technique for investigating the binding site for • 
small molecules. Although listed in the appendix of methods 
in the review by Meyer 8c Guttman ( 1 9 6 8 ) the list of studies up 
to that time (table 1) did not- in fact include a reference to 
this technique but more recently this technique has been 
employed to study drug binding. Lukas 8c De Martino (1 9 6 9 )  
found that digitoxin caused quenching of human serum albumin 
fluorescence. Chignell (1969a), one of the pioneers of using 
optical techniques for studying drug binding, used dansylglycine: 
as a. fluorescent probe for the hydrophobic regions of proteins- 
to investigate the albumin binding of phenylbutazone. The 
binding of either dicoumarol or warfarin to human serum albumin
quenches the fluorescence of the protein (Chignell, 1970)* rfhe 
binding of warfarin is accompanied by a 7-fold increase in the 
fluorescent yield of the drug and a. shift of its fluorescence: 
emission maximum from 4-00 nm to 390 nm (Chignell, 1970) and is: 
an example of where the fluorescence spectrum of both the. 
protein and the ligand is altered.
Fluorescence methods have the disadvantage; at present tha.t 
a quantitative estimate of the strength of binding is difficult 
to obtain but Attallah & Lata (1968) did formulate a formation 
constant in an attempt to obtain a. quantitative estimate of 
binding, however this, was not the same as the commonly used 
association constants. The information that can be derived from
fluorescence studies is largely qualitative in nature with the
\
proviso stated by Attallah & Lata: (1968) that interaction may 
not necessarily result in an alteration of fluorescence, but 
it is assumed that if fluorescence does change., interaction has; 
occurred. As discussed earlier in this chapter it is considered 
that the binding of ax ligand to a protein can sometimes produce 
a conformational change in the protein which facilitates further 
ligand binding and the quenching of albumin fluorescence is 
thought to be indicative of a conformational change in the. 
albumin (Attallah & Lata, 1968; Lukas & De Martino, 1969)*
Hence fluorescence studies can serve to indicate whether a 
change in conformation results from the binding of a given 
ligand. This method also has the advantages that it requires:
only microquantities of materials and is carried out in a 
homogeneous system (Attallah 8c Lata, 1968).
v) Ultraviolet Spectrophotometry
Changes in the ultraviolet spectra of dyes had been observed 
by Robinson 8c Hogden (194-1) and Klotz (194-6) utilised these, 
changes to quantitate binding data*, More recent spectrophotometri 
experiments: with dyes-have been discussed by Steinhardt 8c Reynolds:
(1969)* Westphal (1961) initiated the use of this: technique; 
to study the interactions between steroids and proteins: and he:
a  4-found that the interaction of a £1 -3-ketosteroid with a:
protein was accompanied by a decrease of its ultraviolet
absorption, and in many instances by a slight shift of the;
absorption maximum to a, shorter wavelength. Westphal (1961)
studied a.number of steroids including cortisol, progesterone
and testosterone and investigated the effects of introducing
or removing functional groups such as hydroxy or methyl groups.
The extinction coefficient A  , observed in the presence of.
£
protein, was used by Westphal (1961) to quantitate his.. 
spectrophotometrie data.
where d and € are the molecular extinction coefficients of w p
steroid in protein-free phosphate buffer and in the presence, 
of protein, respectively. The work of Westphal has now been 
considerably extended and Ryan (19 68) and Ryan 8c Gibbs: (1970) 
have used a tandem-cell technique, expressing the results as
difference spectra, to study steroid-protein interactions. 
Spectrophotometric investigations of serum albumin binding have; 
been carried out with several small molecules, thyroxine 
(Tritsch, 1 9 6 8 ) ,  phenylbutazone (Chignell, 1969a )  and 
flufenamic acid. (Chignell, 1969b). This technique has similar 
advantages to fluorescence methods in that only microquantities 
of materials are required and the system is homogeneous but 
like all the new optical methods meaningful interpretation of 
the results is■extremely difficult. So far, investigation of 
the infrared region which should be more informative does not 
appear to have been explored.
vi) Optical Rotatory Dispersion - Circular Dichroism
In addition to ultraviolet absorption spectroscopy and 
fluorescence spectroscopy, optical rotatory dispersion and 
circular dichroism have now been used to investigate drug-protein 
interaction. Optical rotatory dispersion has been used to study 
the binding of sodium dodecylsulphate (Steinhardt 2: Reynolds,
1 9 6 9 ) but so far data obtained from circular dichroism studies 
has been more extensively employed in binding investigations 
and Greenfield & Fasman ( 1 9 6 9 ) regarded the use of circular 
dichroism as a: decided improvement over the use of optical 
rotatory dispersion for the evaluation of protein conformation. 
Chignell (1968), introduced the technique of circular dichroism 
to study drug-protein complexes formed by phenylbutazone and a 
number of its analogues. Further optical studies of the extrinsic 
(induced) Cotton effects arising from drug-protein interaction
have since appeared for such drugs as phenylbutazone (Chignell, 
1969a); flufenamic, meclofenamic and mefenamic acids (Chignell, 
1969b); warfarin and dicoumarol (Chignell, 1970). The 
circular dichroism spectra, of the complex of a sulphonate dye 
with bovine serum albumin have been investigated by Anderson (1969) 
and Jirgensons (1970) has compared the circular dichroism spectra. 
o:f a number of proteins of known and unknown conformation. The. 
study of small, molecule-macromolecule interactions by optical 
rotatory dispersion-circular dichroism methods is in its 
infancy at present but it seems a promising new approach and 
has recently been reviewed (Perrin & Hart, 1970).
vii) Nuclear Magnetic Resonance
Binding of a ligand to a protein usually results in an
alteration of the relaxation characteristics of one or more of
the hydrogen atoms of the ligand or of the protein, Selective.- 
broadening of some of the proton resonances: of the ligand is; 
always observed when it is bound to a. protein and this is. 
considered to indicate an intimate contact between such protons, 
or the groups to which they belong, and the macromolecule 
(Steinhardt & Reynolds, 1969)* Nuclear magnetic resonance is. 
finding increasing application to the investigation of 
pharmacological problems and several general articles describing 
its use have appeared (Cohen, 1969; Steinhardt 8c Reynolds, 1969;
and Burgen 8c Metcalfe, 1970).
Fischer & Jardetzky (19&5) have studied the binding of 
penicillin G and Jardetzky & Wade-Jardetzky (19&5) the binding 
of sulphonamides to bovine serum albumin and they concluded 
that the phenyl ring of penicillin and the p-aminobenzene 
sulphonamide. moiety of sulphonamides were the functional groups 
participating in the binding. Sykes (1970) has investigated the. 
binding of acetylsalicylic acid to human serum albumin by this; 
method and the binding of diphenhydramine and some methyl 
analogues' to bovine serum albumin has been found to be primarily 
as ai result of interaction with the dimethylamino group,
(van der Vlies, 1 9 7 0 ) .  Although this method is inherently 
insensitive, the development of computer techniques such as, 
signal averaging and Fourier transform spectroscopy can improve, 
the sensitivity sufficiently to make it relatively easy to 
study the smaller macromolecules (Burgen Sc Metcalfe, 1 9 7 0 ) .
It may soon be possible to use nuclear magnetic resonance, to 
determine not only which parts of the ligand are involved but 
also to determine whether hydrogen bonds or hydrophobic interactions, 
are involved (Steinhardt & Reynolds, 1969)*
viii) Summary of Techniques
Table III-2 summarises the well established techniques; for 
studying ligand-protein interaction and also some of the newer 
methods which are growing in importance. Table III-3 provides 
a list of miscellaneous and less used methods wliich have been 
used to study binding and the references quoted are to: provide
access to more information. Despite all the techniques that 
have been developed there is still no completely satisfactory 
way of measuring binding jLn vivo although perhaps jin vivo dialysis 
(McQueen, 1968) b^e method of choice for animal investigations, 
while ultrafiltration using the apparatus: of Toribara,, _et al« 
(1957) or similar is the best method for use with fresh human 
plasma samples.
The optical methods such as ultraviolet spectroscopy, 
fluorescence spectroscopy and optical rotatory dispersion- 
circular dichroism together with nuclear magnetic resonance are 
unfortunately only applicable to the in vitro situation.
However these techniques are starting to reveal important 
information about the mechanisms of binding at the molecular level 
which in turn should improve our. understanding of the _in vivo 
situation. It is now possible to investigate species differences, 
in binding in molecular terms with such methods and the effects 
produced on the absorption spectrum of a dye when it binds to 
human serum albumin have been found to be different from these 
produced by binding to the serum albumin of thirteen other- 
species (Baxter, 1963)*
It is perhaps regrettable, but at present the methods chosen 
to study the binding of a novel compound depends nod only on 
the type of information that is sought but also on the properties 
of the ligand. Conductivity and electromotive force measurements
are methods only applicable to electrolytes, and ultraviolet 
spectroscopy is only applicable to compounds that absorb 
ultraviolet light. However unpredictable problems arise 'which 
can eliminate a method as being unsuitable. For instance, a 
ligand that interacts strongly with dialysis membrane would 
exclude the use of dialysis techniques and several types, of 
ultrafiltration that utilise, dialysis tubing. O’Reilly (19& 7)  
found that warfarin was bound to dialysis tubing and he made: 
corrections for this but as discussed in the section above on 
dialysis, binding to dialysis tubing varies with protein 
concentration and is not easy to. correct for. Problems have been 
encountered with other, techniques.giving misleading results, some: 
ligands bind to dextran gel (Cooper & Wood, 1968) and an attempt 
to study digitoxin binding by starch gel electrophoresis revealed 
that the glycoside was bound almost completely to the starch 
gel (Lukas & De Martino, 19^9)* Thus it seems that no single 
method can be generally recommended and a combination of method (s') 
appropriate to the ligand and the information sought should be. 
used.
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Table III-3® Miscellaneous Methods for Studying Drug-Protein
Interactions
Method Reference
Goldstein (19^9)1, Biological action
2* Diffusion of dyes
3® Autoradiography
*f«. Physical properties, e»ge
osmotic pressure, vapour 
pressure, surface tension, 
viscosity electrophoretic 
mobility, sedimentation 
of protein
5o Adsorption of ligand
6. Solubility of ligand
7® Equilibrium partition of
ligand
8* Precipitation
9. Stabilisation
a) of ligand
b) of protein
1 0 . Conductivity 8c E .M .F .  
methods
11. Polarography
12. A  pH Method
13® Dielectric increment 8c 
dispersion
1*f. Refractive index
15. X-Ray diffraction
16. Heatburst microcaX.orimetry
Goldstein (19^9)
Meyer 8c Guttman (1968) 
Goldstein (19^9)
Goldstein (19^9); Heyns, 
van Baelen 8c De. Moor (1987)? 
Trapp 8- West (1969)
Goldstein (19^9)5 ■
Westphal (1961)
Goodman (1958); Spector, 
John 8c Fletcher.- (1969)
Goldstein (19^9); Priestly 
8c O'Reilly (1966)
a) Goldstein (19^9)
b) Mizushima 8c Kobayashi 
(1968); Colombo, Piliero 8c 
Grosso (1968)
Goldstein (19^9); Steinhardt 
8c Reynolds (1969)
Steinhardt 8c Reynolds (1969)
Scatchard 8c Black (19^ *9) 
Steinhardt 8c Reynolds (1969)
Steinhardt 8c Reynolds (1969)
Steinhardt 8c Reynolds (1969) 
Steinhardt 8c Reynolds (1969) 
O'Reilly, Ohms 8c Motley (1969)
c) Introduction to Plasma Protein Binding.of Carbenoxolone
Downer, et al, (1970) found that carbenoxolone was rapidly 
absorbed after oral administration and the high plasma, 
concentrations indicated that a large percentage of the dose:-was 
localised in the plasma:compartment. Localisation of a drug ih. 
the plasma indicates the possibility that the drug is extensively 
bound to plasma proteins (Martin, 1965a). A preliminary 
in vitro dialysis experiment indicated that this was the case. 
(Downer, et al. 1970). The structural similarity between 
carbenoxolone and the triterpenoid sapogenins had earlier, led 
Finney & Tarnoky (1960) to test carbenoxolone for a lytic action 
on erythrocytes but they observed haemolysis only at concentrations 
greater than 600 p,g carbenoxolone/ml. In retrospect this 
observation appears to have been one of the first indications: 
that the compound was bound to plasma proteins because the 
bound drug would be unable to cause lysis. The observation of 
Whitehouse, e_t al. (1967) that addition of albumin annulled the: 
uncoupling action of carbenoxolone on oxidative phosphorylation 
was also suggestive that the drug was bound to albumin. It was. 
therefore decided to investigate the plasma protein binding of 
carbenoxolone using several different techniques.
Following an investigation of the distribution of 
carbenoxolone in whole rat blood some preliminary dialysis 
experiments were carried out followed by more extensive 
ultrafiltration experiments. The ultrafiltration was first
performed using Toribara's apparatus (1957) when whole plasma 
was used but the experiments involving human serum albumin and 
buffer solutions did not require gassing to control the pH and 
so a simple more robust version of the Toribara tube has been 
developed. Dialysis and ultrafiltration yield quantitative, 
data but not qualitative data and it was hoped that a picture, 
of which plasma, proteins carbenoxolone was bound to could be 
obtained by gel filtration and electrophoresis. Carbenoxolone: 
has a slight structural resemblance to steroids and also certai 
steroid-like properties and since the drug absorbs light in the 
ultraviolet region it was decided that the spectrophotometric 
method of Westphal (19&1) would yield more information on the 
nature of the interaction between carbenoxolone and albumin. 
Fluorescence studies were carried out with albumin as a.model 
protein in an attempt to determine whether the drug did bring 
about a conformational change in the protein and hence whether: 
this mechanism could be a basis for its uncoupling action.
2. EXPERIMENTAL
(a) Materials
1/f
C CjCarbenoxolone (90 p,Ci/g) was the material synthesised as described 
in chaptertwo and unlabelled carbenoxolone was donated by Biorex 
Laboratories Ltd. Preparations of bovine serum albumin were purchased 
from Koch-Light Laboratories and human serum albumin (batch no. 16792) 
was purchased from Kabi Pharmaceuticals Ltd. Dextran gel, "Sephadex G 200" 
(lot no. To 3737) particle size A0-120 p, was obtained from Pharmacia Ltd. 
Cellulose polyacetate electrophoresis strips 2.3 x 17 cm, ("Cellogel") were 
manufactured by Chemetron, Milan, Italy and supplied by Horwell Ltd. The 
gas mixture CO^iN^ (3*93$) was obtained from British Oxygen Ltd. Other 
chemicals and reagents of the appropriate grade were obtained from 
British Drug Houses Ltd., Koch Light Ltd. or other usual laboratory suppliers.
The 0.1M phosphate buffer (pH = 7-^ ) a-nd Tris-HCl buffer (pH = 7«^ *) 
were both prepared as described in "Data for Biochemical Research" (1969)*
Eresh plasma samples were obtained as follows: from the dog by
venepuncture, from the cat, rabbit and rhesus monkey by venepuncture under 
ether anaesthesia and from the rat by cardiac puncture under ether 
anaesthesia.
(b) Methods
i) Distribution of Carbenoxolone in Whole Rat Blood
Before commencing plasma protein binding experiments it was decided to 
investigate whether any appreciable amount of carbenoxolone was 
associated with the erythrocytes. A method similar to that used by
-131Crispell & Coleman (1956), who studied the binding of I-thyroxine,
was employed.
Blood was obtained from rats (YftLstar albino strain) by cardiac puncture
under ether anaesthesia. Heparin (100 units per 10 ml. of blood) was used
as anticoagulant. The rat blood (1 ml.) was incubated with 0.5 nil of 
14E Cjcarbenoxolone in 0.1 M phosphate buffer (20 pg/ml; pH 7*^ -) for one 
hour at 57°C. The blood was centrifuged and the plasma separated. The 
erythrocytes were shaken gently with 0.9$? W/v saline (5 ml.) and
14recentrifuged. The supernatant was removed for determination of C Cl 
carbenoxolone by scintillation counting. The washing procedure was 
repeated twice and the washings retained for counting.
Erythrocytes (0.2 ml) were withdrawn after the first and third washes, 
haemolysed with distilled water (1.8 ml) and decolourised with alkaline 
peroxide (2 ml) for determination of radioactivity. Samples (0.1 ml) of 
whole plasma were taken for determination of radioactivity. Plasma proteins 
were precipitated from plasma (0.1 ml) by adding 2 M-phosphotungstic acid 
(0.2 ml). The precipitated proteins were washed with saline (1.0 ml) and 
the proteins separated by centrifugation. The materials were counted as 
solutions or suspensions in a thixotropic gel scintillator as described in 
chapter two.
ii) Ultrafiltration
The plasma protein binding of carbenoxolone in the dog, cat, rabbit, 
rat, monkey and man was determined by ultrafiltration of freshly obtained
14-plasma samples. A bicarbonate solution (0.5 ml) of [ Cjcarbenoxolone
(90 p,Gi/g) was added to each plasma sample (5-0 ml) and shaken for ten 
minutes to allow equilibration. It was determined by experiment that the 
amount of bicarbonate added had no measurable effect on the pH of the 
plasma. In subsequent experiments using either whole human plasma or 
buffered human albumin solutions the preparation of the sample for 
ultrafiltration was essentially the same as the method used by Keller, et al,
14(1966). An appropriate amount of [ Cjcarbenoxolone (90 -jiCi/g) dissolved 
in methanol was pipetted into each of six ground glass stoppered tubes and 
the methanol removed under reduced pressure using a rotary evaporator.
Plasma (6.0 ml) or a solution (6.0 ml) of human serum albumin in 0.1 M 
phosphate buffer (pH = 7«^ ) was added to each tube. The protein solutions 
were allowed to equilibrate for up to three hours on a rotary mixer. It was
14
found by experiment that solution of the [■ Cjcarbenoxolone was complete 
within this time. After equilibration,portions (5-0 ml) of the protein 
solution were transferred to bags of dialysis tubing prepared as 
described below. Aliquots (1.0 ml) of the original equilibration mixture 
were retained for scintillation counting.
Toprepare the bags of dialysis tubing lengths (20 cm) of tubing 
(24/32") were soaked overnight in distilled water and then for short periods 
in two changes of 0.1 M phosphate buffer (pH 7-^ )» The tubing was wiped 
dry with tissue and a knot tied carefully to avoid damage in one end. The 
unknotted end was opened and inflated by gently blowing into it. The 
previously equilibrated sample was then pipetted into the open end of the 
bag, taking care not to touch the side of the dialysis tubing. The 
cellophane bag was then collapsed to exclude as much air as possible and a
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second knot made in the open end in a similar way to the first knot. The 
hag was folded into a U-shape with the two knotted ends secured together 
with a rubber band and pushed down onto the sintered glass disc as shown 
in fig. XII-2(a), using a blunt instrument such as a glass rod. Care was 
exercised to avoid damaging the dialysis bag.
For ultrafiltration of whole plasma the apparatus of Toribara, ejb al, 
(1957} was used (fig. III-2(a) and this was supplied by Scientific Supplies 
Co. Ltd., Scientific House, Vine Hill, London, E.C.1. The apparatus was 
gassed with CO^:^ (9'95%) for five minutes when experiments were performed 
with whole plasma to stabilise pH and the apparatus could then be sealed 
by means of the flexible tubing shown. External control of pH was 
unnecessary when studying buffered solutions of human serum albumin and so 
because the Toribara apparatus was susceptible to breakage a simpler more 
robust version was developed (Fig. III-2(b)). This consisted of a sintered 
glass disc (porosity one) supported in a glass tube of suitable diameter to 
form a unit which fitted into a 90 ml transparent polycarbonate centrifuge 
tube (Measuring: & Scientific Equipment Ltd., 29 Buckingham Gate, London, 
S.W.1.). The sintered disc - glass tube unit was originally obtained from 
Scientific Supplies Ltd. but more robust units were subsequently 
manufactured by the University glass-blowers. This new apparatus had the 
advantage that the glass sinter could be removed from the centrifuge tube 
and this facilitated cleaning of both items.
The ultrafiltration of 6.0 ml samples was cariied out by centrifugation 
for 90 min. at 2,000 rev/min (MSE Magnum refrigerated centrifuge, head no. 
6872) at 20°C. For 3»0 ml samples the centrifugation time was reduced to 
60 min. This procedure was sufficient to produce an ultrafiltrate volume
approximately 10% of the initial sample, Carbenoxolone in the. 
ultrafiltrate and remaining in the sac was determined as previously 
described by liquid scintillation counting.
The unbound concentration of drug Jwas calculated as 
follows (after Keller, ejb al, 1966):
r T) *r _ r n 7 (net d,p.m./ml filtrate)
f “ ’ t' X (net d.p.nu/ml bag contents)
where [D.I is total drug concentration.
Molecular Sieve Chromatography 
Preliminary experiments were carried out using rabbit serum 
on a column of dextran gel (Sephadex G100)~ Serum (1.0 ml) from £u 
female rabbit v/as incubated with 20 p, g of [ Clcarbenoxolone in 
phosphate buffer (0 .1 ml) for one hour at 37°* fhe serum v/as then 
applied to a. column (60 x. 1,5 cm) °f sephandex G100, and eluted 
with phosphate buffer at 20°, and fractions of 5 nil being collected. 
The radioactivity and protein content of each fraction were, 
determined as described in chapter tv/o' and chapter four respectively.
Further experiments were carried out with human plasma (kindly
supplied by Mr. 2.F. Nunn, St. Francis' Hospital, Haywards Heath).
1APlasma was equilibrated with [ Clcarbenoxolone (100 p. g/ml) f or 
2 hours. A sample (1.0 ml) v/as applied to a column of Sephadex G-200 
(30 x 1.5 cm) and eluted with phosphate buffer at a flow rate of
0,2 ml/inin. Fractions (2 ml) were collected as before and 
carbenoxolone and protein content determined as above*
Electrophoresis of the protein-containing fractions was carried out 
as described below* Similar experiments were carried out in which 
the eluting buffer contained unlabelled carbenoxolone (10  ^M‘) in 
an attempt to minimise, any dissociation of the drug-protein complex. 
The columns were, checked for homogeneity using dextran blue
2,000 (Pharmacia).
iv) Electrophoresis-
1 A*Fresh, human serum (3 nil) was equilibrated with [ C Hcarbenoxolone 
(up to 500 pg/ml) for several hours. Electrophoresis of samples 
(^f pi) of this serum was then carried- out on cellulose acetate 
strips O’Cellogel") by the method of Kohn as described, in detail 
in Shandon monograph no.11, (1965)* The procedure was carried out 
in a.cold room at k°C using Shandon electrophoresis tanks and a 
Volkam power pack. A current of 0.A mA/cm strip width v/as used 
for a- protein separation of up to 5 cm. The buffer used was either 
0.05 M barbitone pH 8.6 or 0.05 M-Tris-HCl pH Six
electrophoresis strips per tank were run and the position of the 
serum proteins on two of these were located by staining with 
0.002% W/v nigrosin in 2% V/v CH^COOH. The unstained strips were 
cut into sections corresponding to the various serum protein
1 hbands located by staining and the G associated with the various 
protein fractions measured by liquid scintillation counting.
v) Ultraviolet Spectrophotometry
The method used was essentially that of Westphal (1961). 
Carbenoxolone sodium solution (5 ml) and human serum albumin (5 ml) 
both in phosphate buffer were mixed to give the required final 
concentrations of carbenoxolone and human serum albumin. The- ultra, 
violet absorption difference spectrum was measured in a 1 cm quartz 
cell with a Pye Unicam SP 800 dual beam spectrophotometer using 
human.'serum albumin solution as the reference.
The depression of the extinction coefficient,a , was. 
calculated from the equation
100 6W - *5? •A
c S/
where = molecular extinction coefficient of the compound in 
protein-free aqueous solution and molecular extinction
coefficient of the compound in protein solution. The depression 
v a l u e s , , refer to the wavelength of maximal absorption for the 
aqueous protein-free carbenoxolone solution and are expressed in 
percent.
vi) Fluorescence
The effect of carbenoxolone on the fluorescence spectrum of
human serum albumin and bovine serum albumin was studied. The
albumin solutions were made up in 0.05 M-tris-HCl buffer, pH = 7*^
—5at a concentration of 8 x 10 M. Protein solutions were not used 
for fluorescence studies until they were, at least 6 hr. old, to 
permit the fluorescence to stabilize (Attailah & Lata, 1968). 
Aliquots (5 ml) of albumin solution were pipetted into ground glass
stoppered tubes (10 ml) and appropriate volumes of tris-HCl buffer, 
pH =s 7 . ^  and/or carbenoxolone sodium in tris-HCl. buffer were 
pipetted into the tube* The solutions were mixed by inverting the- 
stoppered tubes and the excitation and emission spectra measured in 
quartz cuvettes (1 cm light path) using a Baird-Atomic 
spectrophotofluorimeter .(model SF-1)* The spectra were plotted 
manually*
vii) • Serum Turbidity
The effect of _in vivo- carbenoxolone pretreatment on the 
stability of serum proteins to heat was investigated by the serum 
turbidity method of Colombo, Piliero 8c Grosso (1968) and Piliero & 
Colombo (1969)» Male V/istar albino rats (225-250 g) were pretreated 
for 6 days with daily intraperitoneal doses of carbenoxolone 
(20 mg/kg) in propylene glycol* Control rats received the vehicle 
only* The rats were anaesthetized with ether 2^f hours after the last 
injection a_nd blood samples obtained by cardiac puncture* The blood 
was allowed to. clot and the serum turbidity of non-haemolysed samples 
investigated as follows* To serum (0.1 ml), 2*9 ml of 0*066 M. 
S/rensen phosphate buffer in saline at pH 5*2 was added and gently 
agitated* This mixture was allowed to stabilise at room temperature 
for 15 min. The serum-buffer mixture was then heated in a. constant 
temperature shaking water bath at 69° for 30 min. The samples then 
were immediately cooled in an ice-bath and the optical density 
measured at 6^5 nm with a Unicam SP500 series II spectrophotometer*
viii) Liver Distribution
1A[ ClCarbenoxolone in propylene glycol was injected intraperitoneally 
into male rats (200 g body wt.) at a dose level of 50 mg/kg. One hour 
after injection the rats were killed by a blow on the head, the livers 
quickly removed, weighed, cooled in ice-cold 0.1M phosphate buffer (pH 7*^ ) 
containing unlabelled carbenoxolone (10 ^ M) and homogenised as described 
later (chapter four, section 2c). The dilution of homogenate prior to 
fractionation was 1 g liver/A ml. The whole homogenate was’ fractionated 
by differential centrifugation at 0-A° as outlined below.
HOMOGENATE
I---------
PELLET
(Cell debris)
I- - - - - - - - - - - -
PELLET
(Mitochondria)
i---
PELLET
600 x g (10 min)
SUPERNATANT
10,000 x g (20 min)
SUPERNATANT
100,000 x g (60 min
 !
SUPERNATANT
(Microsomal fraction) (Soluble fraction)
ix) Tissue Distribution
The tissue distribution of C^CIcarbenoxolone in rats after 
intraperitoneal injection was investigated by whole-body 
autoradiography. The rats used were.- male V/istar albino rats
■  ^Zj. ■
(50-100 g body-weight) and [ CIcarbenoxolone (90pCi/g) v/as 
administered in propylene glycol at a dose level of kO mg/kg, 
Whole-body autoradiography was carried out as described by Powell, 
Curtis 8e-Dodgson (19&7) on rats killed at 30, bO, 120 and 240 minu 
after dosage*
At the appropriate time after dosing the rat v/as anaesthetize 
with ether and rapidly cooled by complete immersion in an acetone- 
solid 00^ mixture, at -78°, When frozen solid the carcass was
/ W  /embedded in a /v aqueous solution of acacia, gum contained in 
a metal syringe box at ~7o° and then the carcass was machined down 
to a suitable level using a 2n Surform rotary drum cutter attached 
to an electric power drill. The exposed surface v/as cleaned 
thorough3.y and placed in close contact with X-ray film (Kodak Ltd. 
and kept in the dark at -15° in a deep freeze for periods of time 
that were determined by trial and error. A minimum period of six 
weeks was required for the radioactivity to produce, adequate 
darkening of the film. The autoradiogram studied in conjunction 
with a colour photograph of the exposed rat surface enabled the 
localisation of the administered radioactivity to be studied.
RESULTS
"|2j.
Table III - Incubation of [ CjCarbenoxolone with Whole Eat Blood
Eat
1 Zf
°/o of H ClCarbenoxolone in
Plasma proteins Erythrocyte
1st
washings
2nd
Erythrocytes
Male , 99 2 <0.1 <0.1
97 2 <0.1 <0.1
96 3 <0.1 <0.1
Mean 97.3+0.9* 2.3+0.3
Female 97 2 <0.1 <0.1
96 3 <0.1 <0.1
96 3 <0.1 <0.1
* Mean • 96.3+0 .^ 2.7+0.3
___i
* + Standard error of the mean.
’ 'IkTable III - 5 Binding of [ CjCarbenoxolone to Plasma of Various Species
Species Sex Mean protein 
concentration 
(mg/ml.)
% of drug unbc 
concentre
^5-5 fig/ml.
>und at 
ition
91 «0 pg/ml.
Dog M 0 .0 (2) 0 .0 (2)
F 55 0 .0 (2) 0 .0 (2)
Cat M 57 1 .0 (1) 1 .0 (1)
F 56 1-5 W 1.5 W
Babbit M 72 0 .0 (2) 0 .0 (2)
F 70 0 .0 (2) 0 .0 (2)
Rat M *f3 0 .0 (3) 0 .0 (3)
F A-3 0 .0 (3) 0 .0 (3)
Rhesus M 5^ 0 .0 (2) 0 .0 (2)
Monkey F 53 0 .0 (2) 0 .0 (2)
Man M 70 0 .0 (2) 0 .0 (2)
F 69 0 .0 (2) 0 .0 (2)
The number in parentheses indicates number of experiments 
performed.
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1 - albumin
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14Fig.III-6. Scat'chard Plot of Data for Binding of C C]Carbenoxolone
to Human Serum Albumin.
Ultrafiltration at 20°; each point represents the mean of
six determinations.
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Table III - 7 Spectrophotometric Data for Carbenoxolone in the Absence
and Presence of Human Serum Albumin
Solutions made up in 0.1M phosphate buffer pH unless
otherwise indicated.
Carbenoxolone
conc.
. (M).....
Albumin
conc.
(M)
Amax
(nm)
Absorbance
2 .0 x 10~5 0 259 0.25
i O x  10"^ 0 259 0.k6
8 .8 x lo” 5 0 259 1.02
8 .8 x 10“5* 0 24-8 1.02
2 .0 x 10~5 x 10“ 5 2 5k 0.21
*f.O x 10~5 x 10~5 25^f 0 A 6
* Dissolved in dried methanol.
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Fig.III-7* Ultraviolet Absorption Spectrum of Carbenoxolone in 
Absence and Presence of Human Serum Albumin.
Solutions in phosphate buffer pH.7-^
_ c
A: carbenoxolone (2 x 10 J M)
-5 -5‘-Bi carbenoxolone (2 x 10 M) + HSA x 10 )
0.6
OA
0.2
300230223
-5C: carbenoxolone A  x 10 M)
-5 -5D: carbenoxolone (4 x 10 M) + HSA (A- x 10 M)
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.111-9* Ultraviolet Absorption Spectrum of Carbenoxolone in Aqueous
and Non-aqueous Solution.
0.8
o
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0.0
250 500
Wavelength (nm)
p
A: carbenoxolone (8 .8 x 10 ^ M) in 0.1 M phosphate buffer pH
- 259 nm.max
B: carbenoxolone (8 .8 x 10~^  M) in methanol. A  = 2^8 nm.''max
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Fig.III-10. Ultraviolet Difference Spectra of Carbenoxolone
0.5
O.k
0.2
0.1
>.im  ...
o.k
230223
Wavelength (nm)
-5 -3A: ©— carbenoxolone (2 x 10 M) & HSA x 10 M)
B: Zi— carbenoxolone x 10 ^ H) & HSA (k- x 10  ^M)
Difference spectra obtained by subtracting spectral values
obtained in aqueous buffer from thoss obtained in presence
of human serum albumin.
-5C: d—— a carbenoxolone (8 .8 x 10 ^ M) difference spectrum obtained
by subtracting spectrum in aqueous buffer from spectrum 
in methanol.
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Fig.111-11. Fluorescence Spectra of Human Serum Albumin in the 
Absence and Presence of Carbenoxolone.
HSA
HSA + carbenoxolone
)
j Protein & drug both k 
)
28
20
16
12
k
260 300 3A0 380
Wavelength (nm)
*f20
x 10
Excitation spectra - fluorescence control at 356 nm. 
Fluorescence spectra - excitation control at 296 nm. 
Quenching at 356 nm = 53•3$*
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Fig.III-12. Effect of Carbenoxolone on Fluorescence Emission /Spectra.of 
Two Bovine Serum Albumin Preparations
12
10
8
6
2
3603&0 390330
Wavelength (nra.)
Excitation A = 296 nm.
All concentrations: k x 10 M.
A: BSA (Cohn fraction v).
B: BSA (Cohn fraction v) + carbenoxolone.
C: BSA (crystalline).
D: BSA (crystalline) + carbenoxolone.
Table III - 8 Quenching of Serum Albumin Fluorescence in Presence
of Carbenoxolone
Excitation A  = 296 nm. Quenching measured at 358 nm.
All;
Type
>umin
Conc. (M)
Carbenoxolone 
conc. (M)
Eatio:
albumin
carbenoxolone
- ■
Fluorescence
quenching
(#)'
HSA • i^- x 10 ' k x ,:10“5 1.0 53-3
HSA k x 10"5 2 x 10“5 2.0 37.5
BSA* k x 10“^ x 10~5 1.0 42.9
BSA*^ k x 10“5 x 10“5 1 .0 ko.o
BSAf 2 x 10“5 k x 10~5 0.5 3
* Cohn fraction V preparation )
) both from Koch-Light Laboratories. 
 ^ Crystalline preparation )
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Fig dll-13. Effect of Carbenoxolone Pretreatment on Turbidity of
Rat Serum.
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Table III-9 The in vitro Distribution of [ CjCarbenoxolone in
Normal Rat Liver Cell Components One Hour after 
Intraperitoneal In,jection.
Livers (3) homogenised in 0*1 M phosphate buffer
. Q
containing carbenoxolone (10 M) at 0-'i G.
Fraction Mean
radioactivity
(d.p.m./mg protein)
% of total 
dose in 
liver
Cell, debris
Mitochondrial
Microsomal.
Soluble
(supernatant)
92 2 0 .3 (± 1-3)
160 22.9 ( + 1.8)
123 3.^ ( + 0 .^ )
83 51.^ ( + 3*8)
* Mean result (+ S.E.M.)
Fig.III-1^ -. Autoradiography of Rat Whole Body Section after
'[kIntraperitoneal Injection of [ CjCarbenoxolone.
(a) 30 minutes after injection.
Note: darkening of film indicates areas containing radioactivity.
1/2 Hour
Fig. Ill-1^- (continued)
(b) 240 minutes after injection.
s'
Note localisation of radioactivity in lumen of small intestine.
4 Hours
Discussion and Conclusions 
Distribution in Blood
'j Zj.
When [ C ]carbenoxolone was incubated with whole rat-blood 
between 96 and 99% of the drug was found, associated with the 
plasma proteins (table Examination of the erythrocytes
'I if
after washings revealed that the amount of [ C3carbenoxolone
associated with the cells was negligible; two washings contained
'2.5% and 0.1% of the drug respectively, and provided further support
for previous evidence, that carbenoxolone was extensively bound
to plasma proteins. Although the binding of drugs and foreign
compounds to plasma proteins has been studied by protein precipitation
methods (Goldstein, 19^9; Priestly & O’Reilly, 1966) this method
is open to criticism on two counts, namely (i) denaturation of
protein occurs and (ii) acidic drugs may be co-precipitated with
the plasma proteins. The recoveries of radioactivity in these
1^experiments indicated that no measurable hydrolysis of [ G 3
1Acarbenoxolone had occurred an plasma and that measurement of [ 0 3
14is also a measure of [ C3carbenoxolone.
1Binding of f~ C.3 Carbenoxolone to Plasma Proteins
*1 ii.
The binding of [ ‘C3carbenoxolone to plasma of various common 
laboratory animal species, as determined by ultrafiltration is 
shown in tcihle III-5* 'These results were somewhat surprising in 
that there appeared to be no detectable unbound drug at a 
concentration as high as 9 1 p 6/ml in all species investigated, 
except for the cat. This indicates that the amount of unbound 
drug was less than 0 .0 5 pg/ml, i.e. carbenoxolone is more than
99• 95% bound at a plasma concentration of 91 «0 jig/ml. The 
reason for the slightly reduced binding in the cat is not clear, 
it may represent a species difference or it is possible that 
the ether anaesthesia, used before venepuncture rnay have affected 
the binding, although it had no effect in the case of the rat, 
rabbit or rhesus monkey.
1^*The binding of [ CJcarbenoxolone in human plasma was further- 
investigated by ultrafiltration over a range of concentration of 
carbenoxolone up to 2^0 p,g/ml. Again the drug was found to be 
very highly bound over this whole range. In two experiments only 
a trace ( <0.1%) of unbound drug was detected but this may have 
been due to experimental error arising from damaged visking tubing. 
In all the other experiments (26) no unbound drug was detected 
(< 0„05%)o The possibility of binding to the visking tubing was 
checked by emptying the drug-plasma solution out of the bag, 
washing the bag once v/ith phosphate buffer to remove residual drug- 
albumin solution, then extracting the bag v/ith methanol and
1^f
counting the concentrated extract. No detectable [ CJcarbenoxolone 
was found to be .associated with the visking membrane. These, 
findings may at first sight suggest that the drug was irreversibly 
bound to some protein in the plasma, however this was examined by 
dialysing against a large external volume of phosphate buffer 
pH 7«A and the drug was readily removed showing that the binding 
was reversible. Moreover, since the drug is readily metabolised 
(see chapter two) it is unlikely that it would be irreversibly 
bound to plasma proteins.
The following reasoning may indicate why the drug is so
highly bound to plasma. If it is assumed that albumin is the main
binding protein and it has a molecular weight of 69»000 (Foster,
19^0) with an average plasma concentration of 3*5 g/100 ml. then
the molar concentration of albumin is about 5*1 x 10 M. The:
highest carbenoxolone plasma concentration found in human patients
—5was 35p g/ml (Downer, et al, 1970), i.e. 6.1 x 10 M with the
average concentration 2k p,g/ml being k.2 x 10 M. The highest
plasma concentration of carbenoxolone studied by ultrafiltration was 
*
250pg/ml ( k.k x 10 M) and this is far higher than any plasma 
concentration encountered in human patients and volunteers, but 
the albumin is still present in.molar excess.at this high 
concentration* Thus even assuming that each albumin molecule has 
only one high affinity binding site, then there will, be an excess 
of such sites available to the drug. In fact at the average plasma 
concentration of carbenoxolone found in human patients there would 
be an approximately tenfold excess or more of binding sites.
Brodie (1965) has similarly calculated that for an acidic drug with 
a molecular weight of 300 plasma albumin has a binding capacity of 
about 100-200 p,g of drug per ml of plasma, assuming that albumin
has only one or two binding sites.
Albumin frequently possesses more than one high affinity binding 
site for a ligand (Meyer 8c Guttman, 1963; Steinhardt & Reynolds,
1969) and since plasma is a complex mixture containing other 
proteins these may also contribute to drug binding. Hence it would
be difficult to accurately measure the amount of unbound drug in
1 -7plasma but it is below 10 M. Since these experiments had shown 
the drug to be very highly bound to plasma protein it was of 
interest to investigate which proteins were responsible for the 
binding of carbenoxolone and so sephadex gel filtration and 
electrophoresis were the methods employed in this study*
A quantitative measure of the affinity of carbenoxolone for
human plasma albumin was obtained by studying the binding in vitro
with the ultrafiltration technique in a range of dilute albumin 
*
solutions in buffer at pH 7®^ -® Many other drugs have been studied 
by this in vitro method which enabled the binding of carbenoxolone 
to be compared v/ith other drugs*
Molecular Sieve Chromatography
'I A
Gel filtration of rabbit serum containing [ CJcarbenoxolone
showed that the drug remained closely associated with the plasma
proteins during passage down the column (fig* III-3)® these
experiments no unbound, drug was detected in later fractions
collected from the column* Distinct separation of plasma proteins
was not obtained but the drug was largely associated v/ith the later,
albumin-rich fractions, rather than the early globulin-rich fraction
Further similar experiments were performed using fresh human plasma
1v/ith a higher concentration of [ Cjcarbenoxolone (100 p,g/ml) and
1A
the distribution of [ CQ carbenoxolone between the plasma proteins 
is shown in fig* III-A- and table III-6*
The nature of the protein in each fraction was examined by
electrophoresis. Taking experiment 1 as representative (fig.III-^ -), fractions
6-12 contained mixed globulins, while fraction 13 contained globulins and
albumin in the approximate proportion 1:3« A total of 17^ of the drug
was associated with the globulins. The major portion (82^ ) of the drug
was associated with the albumin-containing fractions (1^ -18). A small
amount (0.8 )^ of the drug had dissociated from the plasma protein during
passage down the column and was located in fractions 32-3^ • Similar
experiments were performed using eluting buffer containing unlabelled
-6carbenoxolone at a concentration of 10 M in an attempt to minimise 
disturbance of the drug-protein equilibrium. Clausen (1966) employed 
this approach in a gel filtration study of the plasma binding of a 
radioactively labelled sulphonamide. However, the results (table III-6) 
were not significantly different from those obtained with the non­
equilibrated column. This may be the result of competition between the 
unlabelled and labelled carbenoxolone for the protein binding sites 
resulting in displacement of labelled drug. However, the equilibrated 
column technique seems a good approach to solving the problem of 
dissociation of the drug-protein complex during passage down the column.
The main advantage may lie with the investigation of more weakly bound 
drugs.
The gel filtration experiments showed that the major binding 
protein in plasma for carbenoxolone at concentrations more than 
double those occurring therapeutically was plasma albumin. It is 
difficult to decide the true significance of the globulin binding 
of carbenoxolone: it may represent an artefact generated by the
technique or it may indicate a true binding of the drug by the
globulins. Any compound which has an affinity for protein such
as albumin will almost certainly show some binding v/ith globulins .
Gel filtration on sephadex G.200 has been used to study the
distribution of corticosteroid binding globulins in rabbit serum
(Chader Sc V/estphal, 1968b)and it was found that while progesterone
bound to both albumin said corticosteroid-binding-globulin (CBG)
cortisol was only bound to the CBG. The gel filtration results.
therefore raise the possibility that carbenoxolone may exert its 
*
anti-inflarams.tory activity by displacing endogenous corticosteroids 
from their plasma protein binding sites* This possibility was 
investigated and the results are discussed in chapter four. Gel 
filtration therefore affords not only a quantitative estimate of 
the extent of binding but also an assessment of the distribution 
of binding proteins.
Electrophoresis
1^fThe binding of [ C Jcarbenoxolone to human serum proteins 
was further investigated by electrophoresis on cellulose acetate: 
strips .'aid the results are shown in fig. III-5* As can be seen the 
drug was largely bound to albumin (70%) with smaller amounts, 1k% 
and 7% being associated with the and a ' globulins respectively.
A small amount of drug (2%) remained-at the origin and it is unlikely 
that this represents specific binding to the y-globulins and was 
considered to be due to binding to the support medium. The
1 if.
concentrations of [ C ^ carbenoxolone (300 pg/ml.) employed in this 
study were high in order to obtain measurable amounts of drug in
the very small samples (*f pi) employed v/ith this technique. 
Recoveries of drug averaged over 90/i?. The results show that at
-4high carbenoxolone concentration (8.8 x 10 M) , where the drug
is in excess, albumin is still the main binding protein although
binding to globulins does occur. The binding to the globulins
could also arise from a ’tailing* effect behind the migrating
albumin due to attraction by the support medium and also
electrostatic attraction to the cathode. However these results 
*
from electrophoresis are in good agreement with those, obtained by 
gel filtration and carbenoxolone appears to interact to a minor 
extent with the and globulins-
Pattern of Carbenoxolone-Binding Proteins
The pattern of binding of carbenoxolone to plasma proteins 
is similar to the general pattern of drug binding that has been 
observed over a number of years (Goldstein, 19^ 9; Goldstein, crb al, 
1988; Meyer & Guttraan, 1968). Albumin acts as the primary binding 
protein but carbenoxolone can bind also to globulins. Table 1 
of the review by Meyer & Guttman (19&8) summarises the results 
of binding experiments with a wide variety of compounds both 
exogenous and endogenous. It can be seen that for most drugs and 
foreign compounds albumin is the primary binding protein, although 
many drugs, e.g. penicillins, tetracyclines and chlorpromasine 
interact additionally with the globulins. Unlike drugs, the 
primary binding proteins for endogenous compounds such as hormones 
and vitamins tend to be or globulins. Certain globulin 
proteins have been isolated which exhibit a high affinity for
certain endogenous compounds and are thereby thought to act as
'specific binding' or 'transport* proteins* One of the best
studied specific binding proteins is transcortin (or CBG) and this
has been found to have a high affinity for corticosteroids but a
low binding-capacity, with only one or two corticosteroid molecules
being bound (Slaunwhite, ejb al, 1966; Chader & Uestphal, 1968a,b).
Florini & Buyske (1961) pointed out that albumin has a lower
affinity for cortisol than the globulins but a higher capacity
and as a broad generalisation this probably applies to quite a 
*
number of endogenous molecules with specific binding globulins*
It has been suggested that with increasing plasma concentrations 
of cortisol and thyroxine the specific binding proteins become 
saturated and these hormones then start to bind to albumin 
(Desgrez, 1966; Salvatore, ejb al, 1966)* Many hormones circulate 
in the plasma at very low concentrations and are therefore likely 
to be found only in association with specific binding proteins*
On the other hand, most drugs reach relatively high plasma 
concentrations and are therefore likely to be found largely in 
association with albumin* Hhis is the situation v/ith carbenoxolone* 
Although albumin binds a very diverse range of compounds, some only 
weakly, quite a number of compounds have been found to be bound 
strongly to albumin. Ultrafiltration experiments were therefore 
carried out to obtain a measure of the strength of binding of 
carbenoxolone to albumin.
Binding of Carbenoxolone to Human Serum Albumin
The ultrafiltration data for the binding of [ Clcarbenoxolone 
to human serum albumin at 20°G are shown in fig* III-6 plotted 
graphically after the method of Scatchard (19^9)* On the abscissa, 
v is the molar ratio of bound drug to albumin (number of micromoles 
of drug bound per micromole of albumin) and in v/l^ on the
J-
ordinate D_ is the concentration of the unbound fraction of thex
drug (see fig. 111*4 3) «■
kn
f.
v
Fig. III-19 Scatchard Plot
If all binding sites are equivalent and independent the
intercept on the ordinate when v = 0, v/D^ = kn and the intercept
on the abscissa when - 0, v = n which is the number of binding
f
sites. The quotient kn/n gives k which is the apparent association 
constant.
As can be seen the Scatchard plot of carbenoxolone binding
data is non-linear. This has been observed v/ith many ligands
and several interpretations of the reasons for curvature are
possible. (i) Curvature may result from significant electrostatic
interaction between the binding sites but the high ionic strength
of the phosphate buffer used v/ould have a screening effect and
this possibility is unlikely. For similar reasons the binding of
the first carbenoxolone anion is unlikely to affect the binding of
subsequent anions through appreciable alteration of the net charge 
*
of the protein-ion complex. (ii) Curvature may represent the 
binding of carbenoxolone in two different ionic states since the 
drug is a divcalent ion. (iii) The third, and most frequently cited 
explanation for this phenomenon is that at least two classes of 
binding site are present each with different association constants.
The Scatchard plot showed that the first class of binding 
site contained tv/o sites (n=2), but the value of the' apparent 
association constant was difficult to determine accurately since
the results could not be readily extrapolated to the ordinate but
7 8k,j was of the order of at least 10 l/mole and possibly 10 l/mole.
As pointed out by Steinhardt & .Reynolds (19&9) binding constants 
n
(k) of about 10 may be indistinguishable experimentally from 
others 10 to 100 times greater. The data suggest that a second, 
lower affinity class of binding site is present where n^ = k and 
k^ = 3 x 10^ 1/raole (see extrapolation in fig.III-6). It has been 
suggested that serum albumin has at least k classes of binding 
site for anions (Scatchard, Coleman Sc Shen, 1957) although with
carbenoxolone at therapeutic plasma concentrations only the first, 
high affinity class of sites would be involved in binding.
The shape of the Scatchard plot for carbenoxolone is somewhat - 
unusual in that the association constant for the first class of 
binding site was very high. As can be seen when v was less than two, 
v/D^ tended to become very large since at this molar ratio all the 
carbenoxolone appeared to be bound, i.e. becomes very small and
v
the intercept kn on the ordinate very large. The very high association 
constant for the interaction between carbenoxolone and albumin explains 
the in vitro results v/ith whole plasma reported in this chapter and 
also the in vivo results reported in the previous chapter. The molar 
excess of albumin in plasma would ensure complete binding of the drug. 
Only two similar cases of Scatchard plots of this type have been 
reported in the literature; bovine serum albumin bound A molecules of 
ethacrynic acid strongly (Ronwin Zacchei, 1967) and human serum 
albumin was found to have at least three binding sites with a very high 
affinity for the anti-inflammatory compound flufenamic acid (Chignell, 
1989b). No attempt was made to estimate association constants in these 
two cases. The plasma protein binding of another anti-inflammatory 
drug, niflumic acid, has been reported (Glasson, Benakis & Strolin- 
Benedetti, 1969) to 0^0°/° in ra"t plasma at concentrations of 195
and 220 ■j.ig/ml, but unfortunately no attempt was made to quantitate 
the strength of binding.
Carbenoxolbne is thus probably one of the most highly plasma protein 
bound drugs known. A number of other ligands have very high affinity for 
albumin and some selected data are shown for comparison in table 111-10.
It should be noted that in many cases large variations in binding affinities 
of human serum albumin preparations for various ligands have been reported,
for instance the k^  values reported for the binding of thyroxine have
5 6 ranged from 5 x 10 l/mole to 2.5 x 10 l/mole (Tabachnick, Downs, 8c Giorgio
1970). This emphasises the caution v/ith which all binding parameters
determined in this way should be interpreted because buffer solutions and
albumin fractions only provide at best a poor approximation to the
complexities inherent in plasma and tissue f3.uids.
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Optical Studies on the Interaction of Carbenoxolone with Human Seram
Albumin
The ultraviolet absorption spectrum of carbenoxolone in aqueous
solution in the absence and presence of human serum albumin is shown in
fig.III-7- The A ma, of carbenoxolone in phosphate buffer pH 7«^ was •
259 nm but in the presence of human serum albumin this underwent a blue
shift to 25^ - nm (fig.III-7 and table III-7)* There was a small decrease
of absorbance (0.02 units) in the presence of albumin at the lower
concentration investigated. The depression of the extinction coefficient
(A ) at 259 nm was calculated according to the method of Westphal (1961) c
and this is shown in fig.III-8 together with comparable data for
progesterone and cortisol (Westphal, 1961) although it should be noted that
the phosphate buffer used in the case of the latter two compounds was
-5pH 7.6. The decrease in absorbance (& ) due to albumin (A x 10 M) at
-5259 nm was 13-6% and 8.7% with 2 x 10 M and k x 10  ^M carbenoxolone 
respectively.
Westphal (1961) studied the interaction of a number of A 3-ketosteroids
with human serum albumin and found that a decrease in ultraviolet
absorption occurred which in many cases was accompanied by a slight shift
of the /l . to a shorter wavelength. The A values reported by Westphal max G
(1961) were in the range 5-^5% and Kyan (1968) has reported similar values
for similar steroids. Westphal (1961) has shown for a series of steroids
that there was a correlation between the value of A at the A  andc max
the binding affinity of the steroid for serum albumin. These spectrophotometr 
results for the steroids and for carbenoxolone suggest that the 
11-oxo-12.~ene structure of carbenoxolone is one likely site of interaction
with serum albumin. It has been found that much simpler a, P-unsatura.ted 
ketones such as mesityl oxide and isophorone also interact with albumin 
to produce A values of about 3-3% and 8.0^ respectively (Westphal, 1961).
Ryan (1968) and Ryan and Gibbs (1970) have extended the work of 
Westphal on the spectrophotometric study of steroid-protein interactions 
by expressing results as difference spectra (difference in absorbance in 
different solvents and in the presence of proteins), which were considered 
more meaningful. The difference spectra for the interaction of carbenoxolone 
with human serum albumin have been plotted (fig. 111-10). The difference 
spectra were obtained by subtracting the spectral values obtained in 
aqueous buffer from those obtained in the presence of human serum albumin.
The difference spectra obtained exhibit two peaks, one in the region of 
235 nm and a second in the 270-273 nm region. Ryan (1968) has observed - 
somewhat similar difference spectra for a number of steroids including 
progesterone and deoxycorticosterone. Ryan (1968) suggested that the peak 
at 233 nm may be an artifact due to light scattering, although this could 
also be due to changes in protein conformation (Glazer & Smith, 1961).
The difference peak in the 270-273 nm region may represent perturbations 
of tyrosine and tryptophan residues which have been observed under various 
conditions (Glazer & Smith, 19&1; Ryan, 1968).
The spectra of carbenoxolone in phosphate buffer pH 7«^ snd. in 
methanol are shown in fig.III-9 and their difference spectrum is included 
in fig. 111-10. A difference trough occurs in the 233-2^-0 nm region with 
a difference peak at 270 nm. Similar difference spectra between Tris buffer 
pH 8.0 and ethanol have been reported by Ryan (1968) for a number of steroids
such as progesterone, cortisol and deoxycorticosterone. In methanolic
solution the A  of carbenoxolone undergoes a blue shift from 259 nm to ' max °
2A8 nm (table 111-7), and a similar but smaller shift of the A. 5 frommax
239 nm to 23^ nm, of carbenoxolone occurs in the presence of human serum 
albumin. It seems therefore that there is a similar change in chromophor.e 
environment when the drug is bound to albumin or present in methanol.
This similarity of the difference spectra for protein addition and change 
of solvent (fig. 111-10) may be an indication, at the very simplest, that 
when carbenoxolone is bound to human serum albumin the chromophore is 
located in hydrophobic region of the albumin molecule.
Although the interpretation of difference spectra is in the very 
early stages of development at present these spectrophotometric studies 
have indicated several features of the carbenoxolone-albumin,interaction.
The 11-oxo-12-ene structure is probably involved in the binding process 
in addition to the V  and 30-carboxyl groups which are obviously involved 
in interactions with protein. During the binding process it seems likely 
that '11-oxo-12-ene group moves to a more hydrophobic environment and 
although the nature of the binding force is not known it probably involves 
hydrogen bond formation.
The effect of carbenoxolone on the fluorescence spectra on human serum 
albumin is shown in fig. III-11. Albumin excited with light of 296 nm 
shows a maximum fluorescence at 330-360 nm, and reduction in fluorescence 
(fluorescence quenching) by carbenoxolone was measured in the middle of this 
broad band, for convenience at 336 nm. Solutions of carbenoxolone alone
showed no significant light absorption or fluorescence at 296 nm or 336 nm, 
or over the whole region 270-A-30 nm. Carbenoxolone also had a similar 
quenching effect on the fluorescence of two bovine serum albumin 
preparations (fig. 111-12) and it can be seen that the Cohn fraction V 
preparation was more fluorescent than the crystalline whole bovine serum 
albumin. Differences in the fluorescence intensity of two albumin 
preparations have been observed previously (Lukas & De Martino, 1969) 
and reduced fluorescence, was attributed to the presence of fatty acid.
The results of the fluorescence quenching experiments are summarised in 
table III-8. As can be seen, considerable quenching of fluorescence, 
ranging from 3&% to was produced. At equimolar concentration of 
albumin and carbenoxolone the degree of quenching ranged from h-QP/o and 
A3% for the two bovine serum albumin preparations to 33% for the human 
serum albumin.
The suggestion that drug-protein binding may involve a conformational 
change in the protein was discussed earlier and Steinhardt and Reynolds 
(1969) have reviewed experimental evidence which suggests that this is the 
case with a variety of ligand-protein interactions. It can be speculated 
that at. low drug concentrations serum albumin has a limited number of 
binding sites but as the drug molecules progressively occupy these sites 
further binding sites are exposed by the conformational change. It may 
therefore be meaningless to talk about specific classes of binding site 
per se. Optical methods are being increasingly used to study small 
molecule-protein interactions and so fluorescence quenching was chosen as a 
suitable, technique to measure the influence of carbenoxolone on albumin 
conformation.
Chen (1966) studied the fluorescence spectrum of human, serum albumin 
and although most proteins having both tyrosine and tryptophan residues 
have emission characteristics only of the latter (Teale, i960) human serum 
albumin is an exception. This is because it possesses 17-18 tyrosine 
residues but only one tryptophan while bovine serum albumin is known to 
have two tryptophan residues. Hence Chen (1966) considered that human 
serum albumin was a specially favourable case for detecting changes in 
structure capable of influencing the emission of either residue. The 
fluorescence spectrum of albumin is derived from emission by the tyrosine 
and tryptophan residues in the molecules. The tyrosine residues are 
considered to be excited directly by the incident light whereas the 
tryptophan residue is excited both directly, and indirectly by energy 
transfer'from the tyrosine residues, and emits light at 3 3^-330 nm 
(Chen, 1966). With a conformational change in the albumin molecule, energy 
transfer from tyrosine to tryptophan decreases resulting in a decrease of 
tryptophan emission and a relatively greater contribution of tyrosine to 
the fluorescence spectrum, the overall result being decreased emission at 
3^3-330 nm (Chen, 1966). It seems likely that the conformational change 
wrought in the albumin molecule by carbenoxolone is unfolding since the 
changes in albumin fluorescence produced by carbenoxolone were similar to - 
those associated with the unfolding of human serum albumin at pH A in the 
region of its N-F transition (Chen, 1966). Carbenoxolone has surface 
active properties and the observation by Markus and Karush (1937) that 
the surface active agent sodium decyl sulphate caused partial unfolding 
or swelling of human serum albumin in the process of binding lends weight 
to the idea that carbenoxolone also causes unfolding.
In addition to quenching the fluorescence of albumin carbenoxolone 
tended to flatten the emission peak and move the centre of the peak 
to a longer wavelength. The significance of this is not known but may 
also be related to a conformational change in the albumin molecule.
Nature of the Carbenoxolone-Albumin Interaction
It seems likely that there are several forces operating in this 
interaction and they include ionic bonds, hydrophobic bonds and hydrogen 
bonds. Despite the fact that at pH 7-A albumin carries a net negative 
charge of 18 (White, Handler & Smith, 1968), anions can nevertheless bind 
very strongly to albumin. The binding of carbenoxolone to albumin can 
be considered similar to the binding of long-chain fatty acids, which have 
very high affinities for albumin in that ionic bonds and hydrophobic bends 
are involved. Association of fatty acids with albumin is thought to 
involve electrostatic attraction of the carboxyl group to cationic sites 
on the molecule of which there are a considerable number (table III-1).
The A*-and 30-carboxyl groups of carbenoxolone must therefore play a 
major role in the binding of carbenoxolone. Spector, at al, (^3^) found 
that the binding of fatty acids was decreased greatly when the carboxyl 
group was modified or removed. The work of Whitehouse, at al_, (1967) 
indicated that various triterpenoids possessing two carboxyl groups tended 
to be the most effective competitive inhibitors of the reaction of 
2 ,A , 6 trinitrobenzaldehyde with amino groups of bovine plasma albumin.
Hydrophobic interactions probably occur between the hydrophobic region 
of the carbenoxolone molecule and non-polar side chains of amino acids in 
albumin. The spectrophotometric and fluorescence experiments have thrown 
light on two aspects of the interaction. Firstly, when carbenoxolone is 
bound the 11-oxo-12-ene chromophore is involved in the binding process and 
is located in a less polar (i.e. more hydrophobic) environment. The 
interaction of the 11-oxo-12-ene group probably involves hydrogen bond 
formation. The location of the chromophore in a more hydrophobic
environment indicates that hydrophobic forces are also involved in the 
protein binding of carbenoxolone. These forces have been implicated in 
the binding of many organic ligands to albumin and Steinhardt & Reynolds 
(1969) considered that very powerful hydrophobic factors are involved 
in the binding of the larger aliphatic or cyclic hydrocarbons including 
steroids. Secondly, the optical studies indicated that a conformational 
change, which is probably unfolding, occurs in the albumin molecule when 
carbenoxolone is bound. This change affects albumin in the region of the 
tyrosine and tryptophan residues. Once the albumin ana carbenoxolone 
molecules have been brought into close proximity by the major attractive 
forces, short range forces such as van der Waal's forces may then 
contribute to the binding. .
Ronwin & Zacchei (19&7) considered that the reason for the very high 
binding of ethacrynic acid was that this molecule, although small contained 
a variety of potential binding groups. Carbenoxolone is a larger molecule, 
containing polar groups, groups capable of forming H-rbonds, and large 
hydrophobic regions. It thus offers the possibility of multiple contacts 
with albumin. The main forces involved in the interaction are likely to. 
be ionic, hydrogen-bonds and hydrophobic bonds with minor contributions 
from van der Waal’s forces. Another significant point made by 
Steinhardt 8c Reynolds (1969) which is pertinent to carbenoxolone is that 
compounds forming micelles are among the ions most tightly bound to 
protein. These two workers have also speculated that as yet unknown 
attractive forces contribute to the binding of many highly bound ligands.
Serum Turbidity
The effect of pretreatment for six days with carbenoxolone on the 
'serum turbidity' of male Wistar albino rats measured 2k hours after the 
last dose of drug is shown in fig. III-13* The period elapsing between 
the last dose of drug and collection of the serum sample was increased 
from 3 hours in the original method to 2k hours for the present work for 
reasons which will be explained below. The serum turbidity experiment 
involved a measure of the extent of denaturation of serum proteins after 
exposure to heat. As can be seen although carbenoxolone pretreatment 
brought about a marked reduction in the serum turbidity, from a mean of 
0.130 absorbance units to 0.100 units, the difference was not statistically 
significant (P > 0.03) because of a large standard error (+. 0.06). This 
may have been due to inadequate temperature control but in the work by 
Colombo, erb al, (1968) and Piliero & Colombo (1969) the standard errors 
reported were of the order of _+ 0.10 and _+ 0.0A units respectively. So 
although carbenoxolone pretreatment appeared to increase the heat 
stability of serum proteins this was equivocal and it seems unlikely that 
carbenoxolone had any significant effect on plasma protein biosynthesis.
It has been shown that a number of anti-inflammatory compounds can 
stabilise serum proteins, particularly albumin, against heat denaturation 
when added in vitro to serum proteins (Mizushima & Suzuki, 1963;
Mizushima, 1966; Brown & MacKey, 1968; Silvestrini & Catanese, 1968).
This is not a particularly surprising finding since most anti-inflammatory 
drugs tend to be fairly highly bound to plasma proteins and it has been 
known for many years (Goldstein, 19^ 9; Steinhardt & Reynolds, 1969) that
a great number pf ligands which bind with albumin can stabilise the 
protein against various denaturing agents, including heat. For instance, 
fatty acids can act as stabilising agents for plasma albumin (Goldstein, 
19^ 9). A modified in vivo heat denaturation method (Piliero 8c Colombo,
1967) was used to investigate the effect of various anti-inflammatory drugs 
separately and in cornbination with various stresses, on serum turbidity 
in rats using serum obtained only 3 hours after the last dose of drug 
(Piliero & Colombo, 1 9 ^7; Colombo, et al, 1968; Piliero 8c Colombo, 1969)- 
At three hours after the last dose of drug the plasma concentration of drug 
and metabolites is likely to be maximal and so measuring the effect on 
serum turbidity at this time amounts to a similar situation to the older 
in vitro method of Mizushima. The in vivo method would not reveal any 
changes in protein synthesis which would be expected to still be present 
after the drug had been eliminated. It was for this reason that the period 
of 2k hours after the last dose was chosen, so as to allow most of the drug 
to be eliminated. The experiment should therefore give an indication of 
whether plasma protein biosynthesis had been altered in any way towards 
synthesis of more stable protein.
Distribution of [ CjCarbenoxolone in Subcellular Fractions of Rat Liver
1AThe distribution of C Cjcarbenoxolone in subcellular fractions of 
rat liver one hour after intraperitoneal injection is shown in table III-9- 
Approximately 3% of the total dose injected was present in the liver at 
this time and the results in table III-9 indicate the distribution of this 
3% of the dose. The drug was associated with all fractions but just over 
30% was found in the soluble fraction. Subcellular fractionation by simple 
differential centrifugation provides a somewhat crude preparation of the
cellular organelles and may give rise to a somewhat distorted view of 
the situation obtaining in vivo. It is possible that disruption of the 
cell exposes new, normally unavailable binding sites for the drug and 
re-distribution of the drug amongst these sites may occur during the 
in vitro fractionation. However a more prolonged and complicated scheme 
is unlikely to improve the situation since this would increase denaturation 
of proteins and increase the in vitro opportunities for re-distribution to 
occur. A,fractionation scheme of the,type employed here is a widely 
accepted scheme for preparing subcellular fractions (Conn 8c Stumpf, 1966) 
and the estimation of certain key enzymes and other cellular components 
has served as a monitor to establish the efficiency of separation. The 
following have served as markers for instance: DNA as a nuclear marker,
succinic dehydrogenase for the mitochondria, mixed function oxidases as 
microsomal markers and NADP-linked isocitric dehydrogenase for the soluble 
fraction (Mahler 8c Cordes, 1971)* To prevent re-distribution of 
carbenoxolone to new sites exposed by homogenisation the livers were
-khomogenised in buffer containing unlabelled drug (10 M) to maintain the 
in vivo equilibrium. Studies of the tissue distribution of drugs are 
frequently performed but relatively few studies of the in vivo interaction 
of drugs and hormones with proteins at the subcellular level have been 
carried out. Most work on the subcellular distribution of drugs has 
involved addition of the drug to hepatic cellular fractions in vitro and 
it is hoped the present approach offers some improvement.
This investigation of the hepatic intracellular distribution of 
carbenoxolone was of interest from several viewpoints. As discussed earlier, 
carbenoxolone and related triterpenoid acids have the ability to uncouple 
oxidative phosphorylation (Whitehouse, at al, 1967) and so subcellular 
localisation experiments would show v/hether or not the drug was bound to
mitochondria after in vivo administration. Secondly the subcellular 
distribution of carbenoxolone may give an indication as to the mechanism 
whereby carbenoxolone is rapidly taken up by the liver and excreted in the 
bile as conjugates. As discussed in chapter two despite its high degree 
of binding the liver has the ability to concentrate the drug and the. - 
bile: plasma ratio exceeds unity.
The results indicate (table III-9)' that carbenoxolone does interact 
with the mitochondria in vitro and although no quantitative estimate of the 
strength of binding could be obtained, washing the resuspended mitochondria 
with buffer (20 ml) removed no more than 3% of the drug. This is indicative 
of a fairly strong association. Thus it appears that carbenoxolone does 
have the potential to interact with mitochondria in vivo. Whitehouse, 
et al, (1967) found that addition of bovine plasma albumin to an in vitro 
system reduced the ability of carbenoxolone and similar compounds to 
uncouple oxidative phosphorylation by between 30-70%, probably because 
the bovine albumin binds the triterpenoid thus reducing the amount 
available for uncoupling. Addition of albumin to in vitro systems has been 
shown to bring about a similar reduction of uncoupling with many other 
compounds (Weinbach & Garbus, 1969; Vaino, HMnninen & Puukka, 1971)*
Hansch, et_ al, (19&5) have correlated the uncoupling ability of a 
series of plant phenols with their affinity for bovine serum albumin and 
it has been observed by Weinbach & Garbus (1969) that many other uncoupling 
reagents combine avidly with serum and mitochondrial proteins. On the 
basis of this evidence Weinbach & Garbus (1969) have proposed a hypothesis
that uncouplers of oxidative phosphorylation induce conformational changes 
in mitochondrial proteins such as are shown by ligand interaction with 
soluble proteins. This hypothesis is supported by the fluorescence 
experiments which show that carbenoxolone produced a change in the 
conformation of albumin. The binding site of carbenoxolone on mitochondrial 
protein is not known but Whitehouse, at al_, (19&7) have suggested that, 
as v/ith plasma proteins, it is the c-amino group of lysine.
Generally speaking any compound which acts as a potent uncoupler of 
oxidative phosphorylation will exhibit very serious toxicity in mammals. 
However carbenoxolone does not show the toxicity expected. The reason for 
this is probably that in vivo the high affinity of carbenoxolone for plasma
proteins, albumin in particular, reduces the amount of unbound drug
—*7 —k —6(< 10 M) below the concentration required for uncoupling (10 -10 ).
Plasma protein binding of drugs is often held to be a useful feature since 
the bound drug can serve as a depot from which drug dissociates as unbound 
drug is removed by metabolism and excretion. In the case of carbenoxolone 
a high degree of binding is useful in that it serves to effectively 
eliminate the potential toxicity of the drug arising from its ability to 
uncouple oxidative phosphorylation.
The mechanism by which highly plasma protein bound compounds can be 
transferred to the liver and rapidly metabolised and excreted is obscure. 
Eaker & Bradley (1966) have suggested that hepatic uptake of 
bromosulphophthalein, a highly bound dye (see table 111-10), in man and 
experimental animals entails the transfer of the dye-albumin complex across 
the sinusoidal wall followed by uptake of the dye from the dye-albumin 
complex. They also suggested that dissociation of the dye-albumin complex
was augmented in some way by contact with the very large surface area 
provided by the hepatocellular microvilli within the perisinusoidal space. 
Carbenoxolone is a molecule which is almost exclusively excreted in the bile 
of man, monkey and rat (see chapter two) and it meets the criteria put 
forward by Millburn (1970) extensive biliary excretion, and yet the 
question as to the mechanism of this mode of excretion is unanswered.
As discussed in chapter two it seems to be a prerequisite for extensive 
biliary excretion that the drug has first to be conjugated and it has also' 
been suggested that a high degree of plasma protein binding favours 
biliary excretion (Braver, 1959)* In general the higher the molecular 
weight of an anion the larger the proportion that is excreted in the bile 
and also the greater the likelihood of its being extensively bound.to 
plasma proteins. It is therefore difficult to assess the relative 
contributions of molecular weight and protein binding towards influencing 
the extent of biliary excretion.
Russell and Burnett (19&3) examined the proteins in human bile 
qualitatively and showed that albumin and a variety of other plasma 
proteins are normally found in human bile. The possibility that the protein 
in bile may enhance the biliary excretion of protein-bound compounds was 
therefore considered.
In a single experiment, thin-layer chromatography of bile from a rat
1Adosed intraperitoneally with [ Cjcarbenoxolone revealed that > $0% of the 
radioactivity in the bile was present as carbenoxolone-30-glucuronide. 
Samples of the bile dialysed against buffer showed that approximately 70% 
of the total radioactivity of the bile was dialysable. It therefore seems
unlikely that there, is any significant binding of carbenoxolone arid its 
metabolites to bile proteins and hence protein-binding makes little 
contribution to the biliary excretion of carbenoxolone conjugates. The 
measured extent of binding (30 )^ may be erroneously high since conjugates 
associated with micelles formed by bile salt-pigment complexes may tend to 
behave as macromolecules. Examples of this phenomenon are known 
(Russell & Burnett, 1963)**
The work of Levi, et al, (1969) on two hepatic cytoplasmic protein 
fractions Y and Z and their possible role in the hepatic uptake of organic 
anions led to an interesting interpretation of the data on the subcellular 
distribution of carbenoxolone. The organic anions bilirubin, 
.bromosulphophthalein and indocyanine green were all found to be bound to 
these Y and Z proteins in the 110,000 x g supernatant, either in vivo or 
in vitro (Levi, et al, 1969)- Levi, et al, (1969) have shown that this 
supernatant-fraction protein is not albumin. Some carbenoxolone is 
located in the supernatant fraction, possibly as a result of binding to 
albumin, but it is surprising that more drug is not associated with the 
intracellular albumin which is known to be located in the microsomal 
fraction (Peters, 1962).
Carbenoxolone has certain similarities to bilirubin and the other 
compounds which have been found to associate with these Y and Z proteins; 
namely, it is an anion, highly plasma protein bound, lipid-soluble and 
rapidly eliminated in the bile after conjugation. It is therefore possible 
that carbenoxolone is present in the supernatant fraction as a result of 
association with the Y and Z anion-binding proteins.
1
Over the last few years a number of ‘proteins have been isolated from 
organs such as the liver and kidney which exhibit a high affinity for 
certain hormones and these proteins are thereby thought to have special 
receptor or transport functions. An aldosterone-binding protein has been 
isolated from nuclei of rat kidney (Herman, Fimognari & Edelman, 1968)- 
and found to be stereospecific for aldosterone and related mineralocorticoids 
(Swaneck, Chu & Edelman, 1970)- Similarly corticosteroid-binding proteins 
have been isolated from rat liver cytosol (Guidollet & Louisot, 1969;
Morey & Litwack, 19&9; Beato, Biesewig, Braendle & Sekeris, 19&9)- 
Proteins such as those isolated by Levi, et al, (1969) having a high 
affinity for anions would explain how highly plasma-bound compounds such 
as carbenoxolone can be transported into liver cells to undergo conjugation 
and excretion. It is possible that carbenoxolone may interact with the 
renal aldosterone-binding protein (Humphrey, Lindup & Parke; unpublished 
observations) and this may be a mechanism by which carbenoxolone does on 
occasion exhibit aldosterone-like activity.
' 1^f
Tissue Distribution of [ CJ Carbenoxolone
The technical quality of the rat whole-body autoradiograms 
was poor and for this reason only two are included (fig.III-14)«
The problem encountered was that of obtaining a, perfectly flat 
section of the wliole rat body without the use of a. whole body 
cryostat, so that good contact with the X-ray film was, difficult* 
Obtaining a. completely flat section with home-made equipment was- 
obviously a^ matter of considerable skill and practice* However a
■■ r - 1 4  acertain amount of information on the distribution of L CJ 
carbenoxolone was obtained*
The distribution was studied at 30,60,120 and 240 minutes.; 
after dosage and at no time, was there evidence of localisation of 
radioactivity in the brain, heart or lungs. The 30 minute 
autoradiogram showed a fairly diffuse, distribution of radioactivity 
in the peritoneum with no localisation except at the injection 
site. The. autoradiograms at 60,120 and 240 minutes showed 
darkening of the liver and at 120 and 240 minutes high concentration 
of radioactivity were present in the small intestine, almost 
certainly as a result of biliary excretion of the conjugated drug* 
Apart from the liver and small intestine, radioactivity did not 
appear to be localised in any other organs or tissues and the 
radioactivity present in the peritoneal cavity outlined these 
organs as white areas on the X-ray film.
During the course of the work described in chapter two the 
radioactive content of a number of organs of both the squirrel 
monkey and the rat was measured after administration of
[ C J carbenoxolone. The only organs with which radioactivity 
was associated were those concerned with its absorption, metabolism 
and excretion, namely the liver and gastrointestinal tract. These
results we re in c3-ose agreement with the- autoradiographic studies.
14 —[ C J Carbenoxolone found in the gastrointestinal tract almost
certainly represented some unabsorbed material in the case of oral 
dosing and after oral or intraperitoneal. administration it would 
be present as a consequence of biliary excretion. The possibility 
of some specific binding of carbenoxolone to the gastrointestinal 
mucosa;, cannot be excluded. Carbenoxolone present in the gut mucosa 
may also be undergoing glucuronide. formation since it is known 
that the gut can form glucuronides (Parke, 1968). If carbenoxolone 
undergoes conjugation in the gut mucosa a proportion of the 
conjugates, may diffuse back into the lumen of the gut as described 
by Barr & Biegelman (1970) for salicylamide glucuronide. Similarly 
it has been suggested that estriol-l6a -glucosiduronate can be 
transported into the. small intestine in the succus entericus- 
(I'noue, Sandberg, Graham & Slaunwhite, 1969)*
The tissue distribution studies indicated that carbenoxolone 
does not appear to be localised to any significant extent in organs 
other than the liver and gut. Presumably the plasma protein binding 
will tend to restrict the drug mainly to the plasma compartment 
and this would suggest that the therapeutic action of the drug is 
not centrally mediated.
Consequences of the Plasma Protein Binding of Carbenoxolone 
It has been shown in this chapter that carbenoxolone is 
highly plasma protein bound and that the main binding protein is 
plasma albumin although some binding' to. a - and a -globulins also 
occurs. It was suggested in the introduction to this chapter, that 
extensive protein binding is likely to promote absorption and 
carbenoxolone is we11. absorbed in human patients and volunteers- 
provided the drug is in the undissociated form, i.e. in an acid 
environment. The drug does not bind to erythrocytes' in vitro and 
this is probably as a result of its high affinity for plasma,proteins 
with which it binds preferentially. A potential toxic effect of 
carbenoxolone by causing haemolysis of erythrocytes, since closely 
related plant sepogenins and also neutral steroids cause haemolysis 
(Segal. & Milo-Goldzweig, 1971), is eliminated by plasma protein 
binding. Another potential toxic effect, the uncoupling of oxidative 
phosphorylation shown in vitro, is probably eliminated by the plasma 
protein binding. The plasma protein binding of the drug probably 
limits the distribution of the drug largely to the plasma compartment 
and the high plasma concentrations of the drug resulting after oral 
administration to patients and volunteers indicated that this was 
so.
Martin (1963a) has proposed a simplified model to describe the 
distribution of drugs which are bound to plasma proteins and this 
will now be considered in some detail with regard to carbenoxolone. 
Martin made a number of simplifying assumptions for calculating his
-Zf
model: albumin concentration was 5 x 10 M, with each molecule
having only one binding cite for drugs, the body weight was 70 kg
with a plasma volume of 3 1» and a total body water of kZ 1*
Distribution curves were then calculated for four model drugs
Zf q 5 7
having apparent association constants of 10 , 10 . 10 and 10 «,
For each drug he assumed a molar equilibrium concentration of 
unbound drug (D^ .) and bound drug (D^ ) in the plasma* Data, were then 
calculated from equation (k) below to produce a curve for each drug 
relating % of unbound drug in plasma to total plasma concentration*
„ v. CDfI 1/k.+ CDfIFraction unbound (a; = ^ 0***.
-[iy - v k +-'cV
v/here [£^2 = concentration of total, drug in plasma 
and £P 2. = molar concentration of total protein*
A. further three curves were calculated relating (i) total plasma 
concentration of drug (ii) percentage unbound drug in body and
(iii) percentage of drug in plasma, each in turn to the total 
amount of drug in the body* The equations (5)» (6) and (7) below 
v/ere used*
Amount of drug in body = kZ D ■ + 3D^  ...................(3)
k2Df
Percentage unbound =: 7-r-----", ■ x 1 0 0 ( 6 )
l l‘Z  1) £  +
3Df + 3Db
Percentage in plasma = 7-r-r---   x 100   (7)
f + 3i)b
The maximum daily therapeutic dose of carbenoxolone is 
300 mg (0 .3 2 m.raol) and frequently only 130 mg (0*26 m.mol) is 
given. If it is assumed that the total amount of carbenoxolone in 
the patients body does not exceed about 1„3 m.mols then on the 
basis of Martins calculations for a drug with an apparent association 
constant of 10 , less than 10% of the total drug in the body will 
be in the unbound state and more than 90% of the total drug-will: be 
localised in the plasma*
Martin's model is a greatly simplified picture of what is in
fact a complex situation, albumin has more than one binding site.
for carbenoxolone and the drug is also bound to globulins, neither
does the model allow for any tissue binding such as that in the
liver* However there is one very important point illustrated by
Martin’s model and this is that for drugs with a high affinity for
plasma proteins, there is a dosage range within which a small
increase in dose results in a relatively large increase in the.
amount of drug in the body which is unbound, i*e* not bound to
plasma protein. For example a model drug with an apparent association 
7constant of 10 exhibits a tenfold increase in the amount of unbound 
drug in the body when the dose of drug in the body increases from 
1 • Zf to 1*9 m.mols (an increase, of about one third) although the 
concentration of total drug in the plasma rises by only 10%,
(Martin, 1963a). Measurement of total and unbound drug concentrations 
in the plasma is therefore unlikely to reveal that such a change 
in binding has occurred.
It cannot be determined with any certainty over which dosa 
range- of carbenoxolone the total amount of unbound drug may 
increase dramatically in a similar fashion, but it is possibly 
within the 3-6 m.mols range i.e. within liimits of possibility if 
drug accumulation occurs. Curry (1970) has suggested that the 
fluctuation of chlorpromazine concentrations in plasma observed in 
dogs and man after intravenous administration could arise, from 
movement of the drug between tissue, and plasma stores. Theoretical 
calculations indicated that small changes; in the protein binding of 
drugs in plasma and tissues could cause redistribution of highly 
bound drugs between tissues and plasma and that redistribution would 
be greatest after changes in tissue binding of highly bound drugs 
(Curry, 1970).
Carbenoxolone exhibits mineralocor.ticoid side effects in a 
number of patients and the reason for this is unknown. The drug 
itself may possess intrinsic mineralocorticoid-like activity or it 
may potentiate the action of endogenous mineralocorticoids by 
influencing their metabolism and/or uptake at the receptor sites.
An explanation may arise from the plasma protein binding of 
carbenoxolone. It seems possible that in patients exhibiting 
side-effects the total amount of drug in the body has exceeded the 
range where most of the drug is bound and a.sharp increase in the 
amount of unbound drug results as discussed above. The extra 
unbound drug is then available to exert mineralocorticoid actions.
An increase in the amount of unbound drug or in the total amount 
of drug in the body may occur in several ways. A lowered
concentration or abnormality of the plasma proteins, especially 
albumin, may contribute to an increase in the amount of unbound 
drug* Impaired conjugation and excretion occurring either 
genetically or as a result of liver disease*v/ould tend to cause 
the drug to accumulate. Liver disease is frequently characterised 
by diminished plasma protein synthesis. It is significant that 
most of the patients with side-effects are over 60 years old and 
it is known that plasma proteins decrease with age and that liver 
function in general decreases with age. Enterohepatic circulation 
of the drug would also tend to cause accumulation and this would be 
exacerbated by slow bowel movement or constipation.
A recent st\idy of 2^0 in patients receiving prednisone revealed 
a correlation between the frequency of side-effects, the mean 
daily prednisone dose, and the serum albumin (Lewis, Jusko, Burke & 
Graves, 1971) and when the concentration of serum albumin was below 
2*5 g/100 ml the frequency of side effects was doubled. The binding 
of prednisolone, the active metabolite of prednisone, to albumin 
and transcortin was measured and a pharmacodynamic model developed 
to determine the effect of protein binding on prednisolone 
distdbution (Lev/is, et al, 1971 )• It was shown by Lewis, e_t al, 
(1971) that hypoalbuminaemia can result in increased amounts of 
unbound prednisolone in the body and at least partly explain the 
increased frequency of side-effects seen in such patients. Lewis, 
et al, (1971) suggested that the decreased binding in hypoalbuminaemi 
could also be linked with reduced metabolism by the liver. A 
practical suggestion that arises from this discussion is that patient
exhibiting mineralocorticoid effects during carbenoxolone therapy 
should be examined for hypoalbuminaemia.. and diminished liver 
function.
Since carbenoxolone interacts with the globulins,amongst. which 
the specific corticosteroid binding globulins are known to be. 
located,there is the possibility that carbenoxolone may exert its 
therapeutic action and side-effects through a. displacement of 
corticosteroids from their binding sites. The nuclear and cytosol 
aldosterone-binding proteins of rat kidney, duodenal mucosa, 
spleen, liver and brain have been isolated and on a quantitative 
basis the kidney and duodenal mucosa had the highest binding 
capacity in both nuclear and. cytosol fractions (Swaneck, Highland & 
Edelman, 19&9)* The most obvious site of action of carbenoxolone 
on mineralocorticoids would be the gut mucosa. The liver was to 
some extent exceptional in that of its aldosterone-binding
capacity was non-specific (Swaneck, ejt al, 19&9) and this is 
another potential site of interaction of carbenoxolone with the 
mineralocorticoids.
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CHAPTER FOUR
Introduction
(a.) Mineralocorticoid-like action of carbenoxolone.
Carbenoxolone and various liquorice preparations can have 
actions similar to those of the mineralocorticoid hormones such 
as aldosterone (see chapter one, section 3 (b))«. These 
mineralocorticoid side-effects are frequently manifest after.' 
administration of liquorice preparations but less frequently 
after carbenoxolone. Even so these side-effects may be so 
severe: as to necessitate 'withdrawal of carbenoxolone in some cases. 
(Doll/ Langman & Shawdon, 1968). The aldosterone-like effects are 
usually exhibited only by patients over 60 years and particularly 
those with hypertension and/or a heart disease (Doll, Langman &. 
Shawdon, 1968). Reducing the dose of•carbenoxolone from 100 mg 
three times per day to 50 mS three times per day lowers the 
incidence of side-effects but also reduces the healing action of 
the drug (Doll, et al, 1968). The incidence of this side-effect 
can be largely reduced by co-administration of a thiazide diuretic 
but concomitant administration of spironolactone, an aldosterone 
antagonist, antagonises the healing action of carbenoxolone 
(Doll, et al, 1968). Since this property of carbenoxolone can 
limit the use of the drug in certain patients the question arises 
as to how does carbenoxolone exert its mineralocorticoid side-effects 
Doll and his co-workers (1968) found no correlation between the 
rate of ulcer healing and fluid retention neither was the rate of 
ulcer healing reduced in patients given thiazide diuretics and so 
they concluded that fluid retention was not a necessary feature 
for ulcer healing to occur. Baron, jet al, (19&9) studied the
effect, of carbenoxolone administration on urinary aldosterone 
excretion in a female patient on a restricted sodium intake and 
found that aldosterone excretion was reduced* After considering 
the previous published results which showed that liquorice and 
glycyrrhizinic acid brought about normal or reduced aldosterone 
excretion Baron, e_t al, (1969) concluded that their findings were 
consistent only with the hypothesis that the mineralocorticoid 
effect of carbenoxolone is due to its possessing intrinsic 
aldosterone-like properties.
(b) Possible Interaction of Carbenoxolone with Hormones*
There are a number of ways in which-carbenoxolone may exert 
its mineralocorticoid action and of all the possible ways the 
following are most likely
(i) Carbenoxolone may possess some intrinsic mineralocorticoid
activity by virtue of its steroid-like structure and an 
11-carbonyl group. Carbenoxolone is "tri-polar" and 
Westphal (1961) has pointed out that most endogenous steroids 
with significant biological activity are at least "duo-polar"«
(ii) Carbenoxolone may increase the biosynthesis of
mineralocorticoid hormones by induction of adrenal cortex 
oxygenase enzymes responsible for the conversion of 
cholesterol to corticosteroids.
(iii) It may reduce the metabolic deactivation in the liver1
of these steroid hormones and thus bring about an increa.se 
in half life of active hormone.
(iv) The drug may displace mineralocorticoids from non-specif
binding sites in the plasma and other tissues, raising the 
concentrations of active unbound steroid and hence making 
more available for action at target sites.
(v)'” Carbenoxolone may potentiate the action of
mineralocorticoid hormones at receptor sites by an 
allosteric-like effect.
One or more of these possible mechanisms may contribute to 
the mineralocorticoid action of carbenoxolone and there may be 
other as yet unknown possibilities.
The mixed function oxidase enzymes of the hepatic endoplasmic 
reticulum,responsible for a large proportion of drug metabolism, 
were discussed briefly in chapter two, section 1 (a). The 
enzymes responsible for deactivating steroids include hydroxylases 
reductases, isomerases and transferases and these enzymes are very 
similar to those responsible for metabolising drugs. Thus 
carbenoxolone may exert its steroid sparing effect by stimulation 
of enzymes concerned with biosynthesis in the adrenals or 
inhibition of enzymes in the liver responsible for deactivation. 
The mineralocorticoid-like action of glycyrrhizin was attributed
to the inhibition of the metabolic degradation of steroid hormones 
1
in the liver by glycyrrhizin (Kumagai, et al, 1957), while 
glycyrrhetic acid has been found to inhibit the metabolism of 
progesterone and 11-deoxycorticosterone by a 10% rat liver 
homogenate (Atherden, 1998)* Glycyrrhetic acid also inhibited 
progesterone metabolism in the presence of NADH in a dialysed 
29,000 g supernatant (Atherden, 1958).
(c) Microsomal Drug-Metabolising Enzymes and- Methods of
Investigation.
The oxidative reactions of microsomal enzymes which were 
mentioned in chapter two can all be ascribed to a common mechanism, 
that of hydroxylation. This hydroxylating system has been shown 
to contain NADPH^, a flavoprotein,a non-haeme iron protein and a 
haemoprotein known as cytochrome P-A5 0, (see Parke, 1968a).
18 18Experiments with 0^ and 0 have shown that the oxygen of the
hydroxyl group introduced into foreign compounds is derived from 
molecular oxygen (Mason, 1957; Hayaishi, 1962) and hence 
Mason (1957, 196 5) called these enzymes ’mixed function oxidases5. 
There is now considerable evidence to indicate that NADPH^-dependeh 
enzymes in liver microsomes metabolise not only foreign compounds 
but also a variety of endogenous physiological substrates such as 
steroid hormones, fatty acids, thyroxine and-various amines 
(Conney, 1967; Orrenius, Gnosspelius, Das & Ernster, 1968). The 
similarities between drug and steroid hydroxylases in the liver 
first led Kuntzman, et. al, (196^ -) to suggest that drugs and steroid 
are substrates for the same hydroxylating enzymes. Conney (1967) 
discusses the evidence to support this view and more supporting
experimental evidence has since been obtained. (Conney, Levin,
/
Ikeda, Kuntzman, Cooper■& Rosenthal, 1968; Jacobson &
Kuntzman, 1969; Kato, Takahashi & Omori, 19 6 8; Tephlv & ' 
Mannering, 1968; Wada, Shimakawa, Takasugi, Kotake & Sakamoto,
1968). Work on these microsomal enzyme systems has been •'
hampered by lack of a suitable pure preparation but since the 
original method of Omura & Sato (196*1-), Lu & Coon (1968) have: 
obtained a partially purified active preparation of cytochrome
P-45O.
Workers from Conney’s laboratory (Alvares, Schilling,
Levin, Kuntzman, Brand & Mark, 1969) have since demonstra.ted 
the presence of cytochrome P-450 and cytochrome bc in human 
liver microsomes and the stimulcitory effects of drugs and other 
foreign chemicals on steroid and drug metabolism found in animal 
experiments have been reproduced in man. -Phenobarbital (Burstein 
& Klaiber, 1965) diphenylhydantoin (Werk, Maclyce, Sholiton,
1964) and phenylbutazone (Kuntzman, Jacobson & Conney, 1966) 
are examples of drugs that increase, the metabolism of cortisol 
in man via the hydroxylase pathway to several polar compounds 
one of which is 6[3~hydroxycortisol. Gaylor & Mason (196 8) 
however have presented evidence to show that cytochrome P-450 
does not participate in the mechanism of oxidative demethylation 
of sterols in liver microsomes, although Skinner & Akhtar (1969) 
ha\e &h.own that in the human placenta in the oxidative removal 
of 19-CK7 and aromatisation of ring A, occurring in the conversion 
of androgens to restrogens, three consecutive hydroxylations occur 
which are all NADPI^ and 0^ dependent.
Cytochr'ome P-450 is also present in bovine adrenocortical 
microsomes (Estabrook, Cooper 8c Rosenthal, 19&3) anc* Harding,
Wong 8c Nelson (1964) demonstrated the presence of this cytochrome 
in rat adrenal mitochondria. It is now considered that 
cytochrome P-450 is involved in corticoidogenesis (Inano, Inano 8c 
Tamaoki, 1969)® The biosynthetic pathway of aldosterone has not 
been completely elucidated but it is thought that corticosterone 
is involved in the pathway (Kahnt 8< Neher, 1965) and evidence 
has been presented that mitochrondrial cytochrome P-450 is 
involved in the C^g~hydroxylation of corticosterone and that 
18-hydroxycorticosterone is the immediate precursor of aldosterone 
(Greengard, Psychoyos, Tallan, Cooper, Rosenthal 8c Estabrook, 1967)*
Take sue 8c Sato (1968) found that cytochrome P-450 was 
present in rabbit intestinal microsomes at about one tenth or 
one fifth of the concentration in rabbit liver microsomes. . As:- 
well as exerting an effect on the kidney aldosterone is thought 
to control electrolyte balance in the intestine. Carbenoxolone 
may therefore exert an effect on aldosterone action and metabolism 
in the intestine as well as kidney, adrenal 8c liver.
Following a ’phase I’ reaction, such as hydroxylation, drugs 
and hormones may undergo conjugation (phase II) reactions. The 
most 'important conjugations are with glucuronic acid and these 
reactions may be affected in a manner similar to mixed function 
oxidase reactions by pretreatment with various drugs and foreign
compounds. Pretreatment of rats with phenobarbitone increases 
the UDP glucuronyl-transferase activity of rat liver microsomes 
using bilirubin (De Leon, Gartner & Arias, 1967) or p-nitrophenol 
(Zeidenberg, Orrhenius & Ernster, 1967) as substrate. Following 
the observations of Crigler & Gold (1966) and Yaffe, ejt al, (1966) 
that phenobarbitone administration caused a decrease in serum 
bilirubin concentration in cases of hyperbilirubinaeraia, treatment 
of pregnant women with phenobarbitone for several days just prior 
to delivery was found to reduce the concentration of neonatal 
serum bilirubin (Maurer, Wolff, Finster, Poppers, Pantuck,
Kuntzman & Conney, 19 6 8j Trolle, 1968). Phenobarbitone therapy 
reduced serum bilirubin concentration in two adults suffering 
from hyperbilirubinaeraia (Kreek & Sleisenger, 1968). In all of 
these cases the hypothesis was put forward that phenobarbitone 
was stimulating the glucuronyl transferase responsible for 
conjugating bilirubin.
Thus it can be seen that any effect of carbenoxolone, either 
stimulation or inhibition, on the microsomal enzymes of the liver 
or intestine or the mitochondrial enzymes of the adrenal cortex 
may bring about alterations in the metabolism of steroid hormones. 
In this way carbenoxolone may exert mineralocorticoid effects 
since both stimulation of biosynthetic pathways and inhibition of 
degradative or co.njugative routes v/ould lead to an increase in 
concentration of active steroid.
It is v/ell known that steroids such as cortisone when 
administered orally cause erosions and ulceration of the gastric 
mucosa and this is a serious limitation on their-therapeutic 
use. Murray (1967) studied the binding of endogenous cortisol 
to plasma proteins in man in health, stress and at death and 
concluded that stressful situations in man are associated with 
increased plasma concentrations of biologically active (i.e. 
non-protein bound) cortisol* Shenkin & Feldman (1968) found that 
patients with gastrointestinal bleeding of stress origin all had 
elevated plasma cortisol concentrations and abnormally low plasma 
transcortin binding capacities. It was postulated that the 
amount of unbound (active) cortisol would be unusually high and 
that any effect concerning erosion and bleeding that endogenous 
corticosteroids have on the gastrointestinal mucosa would be 
potentiated by a low plasma content of transcortin. None of the 
patients studied by Shenkin & Feldman (1968) had gastric or 
duodenal ulcers, and no data appears to be available, but it 
seems reasonable to suppose that ulcer patients may also have low 
plasma transcortin concentrations. Thus the possibility arises:, 
that increased amounts of active steroid reaching the gastro­
intestinal mucosa either after oral administration or through the 
blood stream may be involved in the process of ulceration. This 
may be a possible locus of action for the therapeutic effect of 
carbenoxolone. Hence the interaction of carbenoxolone and 
steroid hormones may result in both the mineralocorticoid 
"side effects" and the ulcer healing action.
It is also important to know the effect of a drug on 
drug metabolsing enzymes from the viewpoint of drug interactions 
(Drug Research Board, 1969) since an alteration in the metabolism 
of a drug may result in an undesirable change in the duration and 
intensity of its action. Induction of microsomal drug metabolising 
enzymes can result in increased metabolism of another concomitantly 
administered drug (Conney, 1967)* Barbiturates stimulate the 
hydroxylation of coumarin anticoagulants in man (Cucinell.j Conney, 
Sansur & Burns, 1965; MacDonald, Robinson, Sylvester & Jaffe,
1969; O’Reilly 8: Aggeler, 1969) bringing about a reduced 
anticoagulant action and consequent increased risk of thrombosis. 
Conversely, inhibition of warfarin metabolism may occur when a 
drug such as disulfiram (Rothstein, 1968) is also given and this 
can result in serious haemorrhagic complications. The increasing 
practice of administering several drugs to one patient is likely 
to result in an increased incidence of drug interactions and 
Prescott (1969) has recently surveyed pharmacokinetic drug 
interactions including a number arising from altered metabolism.
The microsomal drug metabolising enzymes are present in the 
endoplasmic reticulum which is a.tubular network extending through 
the cytoplasm of the cell. One part of this network has a. rough 
appearance (rough endoplasmic reticulum) owing to the presence of 
ribosomes which are sites of protein synthesis, while the other 
part lacking ribosomes has a smooth appearance and is called the 
smooth endoplasmic reticulum. The smooth endoplasmic reticulum 
appears to contain the higher drug metabolising enzyme activity
(Orrenius 8c Ernster, 196^5 Gram 8: Fouts, 196?) although this 
may depend upon the methods of cell fractionation used,, (Fouts 8: 
Gram, 19^9)• Dallner 8c Ernster (1968) have reviewed the 
subfraction and composition of microsomal mernbra.nes, but studies 
on drug metabolising enzymes have been hampered by the lack of 
a suitably solubilised preparation necessary for a detailed 
investigation,, So far most studies have been made using crude 
subcellular fractions of liver obtained.by centrifugation after, 
homogenisation in an isotomic medium. Centrifugation of a liver 
homogenate at 10 ,000 g for 10-20 rnin. deposits cell debris, 
mitochondria and nuclei, leaving a microsomal supernatant which' 
contains the ruptured endoplasmic reticulum which has formed into 
vesicles often called ’microsomes1» Further centrifugation at
100 ,000  g and above deposits these microsomes leaving a supernatan 
called the soluble fraction (Mitoma, ejb al, 1956)* Various 
refinements in this technique, e.g. zonal centrifugation using 
carefully selected density gradients have yielded fractions that 
are much purer than those obtained by the scheme already outlined* 
However, at the present time these techniques are rather, lengthy 
and have not been-widely used for studying drug metabolising 
enzymes which are unstable, but it is likely that data obtained 
using the total microsomal fraction may need-re-evaluation in 
the future.
(d) Metabolism of Cortisol in the Hat.
The metabolism of cortisol and other steroid hormones in
rat and other common experimental animals does not appear to have
been extensively studied but some experimental findings have been
reported. The metabolism and biliary excretion of
hydrocortisone-4-C (cortisol) in the male ra.t has been studied
by Wyngaarden, Petersen & Wolff (1955) who found that after
subcutaneous injection 85% of the dose axopeared in the bile in
33 hours when the excretion reached a plateau and by 6 hours only
a further 1-2% of the dose was excreted. It was found that
glucuronic acid was not involved in the' conjugation of cortisol
metabolites. Hyde & Williams (1957) also showed the rapid
elimination of radiocarbon in the bile after intravenous and
1 Z|.
intramuscular injection of C-cortisol, 68/b and 75^ respectively
in the first k hours, but contrary to the findings of Wyngaarden,
et al, (1955) cortisol metabolites were found conjugated with
glucuronic acid amounting to 5*8 - 9*8/0 of the pooled bile after
hydrolysis with liver (3-glucuronidase. Ulrich & Long (1956)
1studied the effects of stress on serum C levels in rats
1following administration of hydrocortisone-^f-C and
. 1 /f
corticosterone-^f-C but found no significant effect and were, 
unable to decide whether or not increased peripheral utilization 
of adrenocortical hormones occurred during stress®
Taylor and co-workers have studied the biliary and urinary
excretion of radiometabolites following administration of 
1
C-labelled steroid m  a single injection or as an infusion©
The biliary ’and urinary excretion by the rabbit of metabolites 
of progesterone (Taylor & Scratcherd, 1965)* testosterone 
(Taylor & Scratcherd, 19&7) and cortisone (Taylor, 1970) has 
been studied and metabolites of these steroids are excreted in 
both the bile and urine with greater amounts in the bile. 
Metabolites of progesterone (Taylor & Scratcherd, 1961), 
corticosterone (Taylor & Scratcherd, 19&3) and oe.stradiol 
(Karim & Taylor, 1970) are excreted largely in the bile with only 
about 1% of the radioactivity appearing in the urine in 6 hours* 
The chemical identity of these various metabolites was .not 
established but glucuronide conjugates were present.
(e ) Anti-inflammatory Drugs and the Plasma Protein Binding of
Corticosteroids.
Brodie (1965) first put forward the interesting idea that 
non-steroidal antirheumatic drugs may exert their therapeutic 
action indirectly by displacing endogenous steroids from plasma 
protein binding sites and that it was in fact increased 
concentrations of unbound steroid that exerted the anti-inflammato 
effect. He presented some preliminary evidence showing that the 
antirheumatic activity of a number of acidic drugs was correlated 
with their ability to displace corticosterone in rat plasma, 
indomethacin being the most potent in this respect and raising 
the unbound corticosterone from about 10% to k0%. Other workers 
have not reported this phenomenon. Winter, Risley & Silber (1968) 
stimulated by Brodie’s report found that indomethacin in 
concentrations exceeding those occurring therapeutically did not
affect the plasma binding of corticosterone in the rat#
Acetylsalicylic acid, phenylbutazone and indomethacin given in 
recommended therapeutic doses for one v/eek to patients with 
rheumatoid arthritis were found to have no significant effect 
on plasma protein binding of 11-hydroxysteroids (Stenlake,
Davidson, Jasani & Williams, 1968). The previously mentioned 
three drugs together with ibufenac and oxyphenbutazone were 
investigated for their effect on the protein binding of 
11-hydroxysteroids in human plasma in vitro at higher total 
steroid concentrations than normal (Stenlake, Williams, Davidson, 
Downie & Whaley, 1969) and only oxyphenbutazone and acetylsalicylic 
acid had a significant effect. Oxyphenbutazone produced a decrease 
in the proportion of unbound 11-hydroxysteroids and acetylsalicylic 
acid produced an increase in unbound 11-hydroxysteroids.- 
Jansen & Schou (1967) found, pretreatment of guinea pigs for three 
days with either phenylbutazone, sodium salicylate or indomethacin 
did not seem to influence the protein binding of cortisol in 
plasma. The steroidal anti-inflammatory drugs betamethasone and 
dexamethasone did not alter the binding of cortisol in human 
plasma in vitro (Peets, Staub & Symchowicz, 1969)* Since 
carbenoxolone has anti-inflammatory properties it was of interest 
to investigate the effect of carbenoxolone on the plasma protein 
binding of cortisol.
(f) Investigations with Carbenoxolone.
In relation to the above discussion the effect of carbenoxolone 
pretreatment on hepatic microsomal enzymes has therefore been 
studied. Biphenyl-*!—hydroxylase (Creaven, Parke 8c Williams, 1965) 
modified for use with rat liver microsomal preparations by 
Franklin (1969) .and Neale (197.0) was used as a model for 
measurement of general mixed function oxidase activity. Previous 
work (Creaven 8c Parke, 1966) has shown that this enzyme system is 
affected by a number of well established inducers and inhibitors 
in a manner characteristic of mixed function oxidases. The 
*f-methylurnbelliferone glucuronyl transferase assay developed by 
Neale (1970) from that described by Arias, et al, (1958) was- used, 
to measure glucuronyl transferase activity. Cytochrome P-A-50 
content of the rat liver 'microsomal fraction' has been determined 
and the effect of pretreatment with enoxolone and carbenoxolone 
on hexobarbitone sleeping time investigated.
Rats pretreated'with carbenoxolone have been fitted -with a
biliary cannula under surgical anaesthesia, and the rate of
3excretion of radiometabolites of H-cortisol measured following 
intraperitoneal injection of ^H-cortisol.
3
The effect of carbenoxolone on the binding of K-cortisol 111 
human plasma has been studied by ultrafiltration to discover if ■ 
carbenoxolone has any displacing action on plasma protein bound 
cortisol. In conjunction with this work the effect of carbenoxolone 
pretreatment on the concentration of aldosterone at various sites' 
in the kidney and gastrointestinal mucosa is being studied in this 
laboratory.
2. EXPERIMENTAL
(a) Materials
Solutions used for enzyme assays.
(i) Tris buffer: 0.05M tris (2-amino~2-hydroxymethylpropane-1,
3-diol) (6.055 g/l-) adjusted to pH = 8.1 with. dil. HC1.
(ii) Mg Cl^  soln: 10.15 g/l- kn water.
(iii) Biphenyl: m.p. 70°C purified as described by Bridges, Creaven 
& Williams (1965) and the solution made up as described by 
Creaven, Parke & Williams (1965)*- biphenyl (185 mg.) was 
dissolved in Tween 80 (2 g.) and diluted to 100 ml. with aq.
1.15% W/v KC1. On standing the solution deposited crystals of 
biphenyl which were redissolved by warming before use.
(iv) Nicotinamide adenine dinucleotide phosphate monosodium salt 
(Sigma Chemical Co.) 5«0*f mg. NADP/ml. dissolved in 1.15% U/v 
KC1. 1.5 umole NADP per incubation.
(v) Potassium chloride: B.D.H. 'Analar' grade was used.
(vi) *t--Hydroxybiphenyl soln.: m.p. 167°C purified as described by
Bridges, Creaven & Williams (1965) and the solution made up as 
described by Creaven, Parke & Williams (1965):- *f-hydroxybiphenyl 
(7*5 mg.) dissolved in ethanol (12.5 ml.) and made up to 250 ml. 
with water to give a final concentration of 30 ug/ml.
(vii) Tris buffer: tris (12.11 g.) dissolved in water, adjusted to 
pH = 7-6 with dil. HC1 and made up to 11.
(viii) *f-Methylumbelliferone: Koch-Light Ltd., was re-crystallised as
described by Mead, Smith & Williams (1955)- The substrate 
solution was prepared by dissolving *f-methylumbelliferone (7-92 mg.) 
in water, 0 .6 pinole per incubation.
(ix) Uridine-5'-diphosphoglucuronic acid ammonium salt (Sigma Chemical 
Co.) was dissolved in 1.15% KC1 to give a concentration of 6.5^ 
mg/ml., 0 .6 pmole per incubation.
(x) 0.2M Acetate buffer: prepared by mixing *f90 ml. of 0.2M sodium
acetate with 5^0 ml. of 0.2M CH^  COOH.
(xi) (3-Glucuronidase solution: "Ketodase" (W.R. Warner, Ltd.) diluted
to 1,000 units/ml. with 0.2M acetate buffer (pH *f.6).
Other Materials
Folin 8c Ciocalteu's reagent (B.D.H.) used as supplied.
Phosphate buffer, 0.2M was prepared as described by Dav/son, et al., 
(1959) from ’Analar’ grade sodium dihydrogen phosphate and disodium 
hydrogen phosphate.
Urethane (B.D.H.) used as supplied.
Carbon monoxide was supplied by the British Oxygen Company, 
but in the majority of cytochrome P-A50 determinations coal gas v/as 
used as the source of CO.
Centre, Amersham. A solution (0.5 nil. = 0.5 m Ci) in benzene-ethanol 
(50:50) was supplied and this was diluted to 200 ml. with the same solvent 
mixture to form a standard solution.
Tween 80, polyoxyethylene sorbitan mono-oleate (Koch-Light) used 
as supplied.
Crystalline Bovine Serum Albumin: supplied by Koch Light,
Hexobarbitone sodium: supplied by May & Baker.
Cannulation tubing: Portex PP25, O.^ f mm. internal diam., 0 .8 mm.
external diameter.
cortisol-1,2-T, 2,000 m Ci/m.mol, .Radiochemi'cal
Suture: Black Braided Silk B.P.C., Ethicon Ltd., 'Mersilk1
R 820 5/0.
Solvents
All solvents were obtained from B.D.H. and used as supplied.
(b) Animal Procedure^
V/istar albino rats were bred in the University Animal Unit, at 
ground floor level under controlled heating and lighting conditions.
The rats were littered on wood chippings and the young were reared until 
weaning at h- weeks on the same bedding before being transferred to pastic 
cages where they were kept six to eight per cage on 'Steralit1 bedding 
material. The rats were fed on Spiller’s autoclaved small animal diet 
and water ad. libitum, and housed in a room exclusively for rats. For 
experimental purposes the rats were randomly allotted to their treatment 
group and.groups of test and control rats were kept in separate cages.
The weight of the rats used was routinely recorded.
Hexobarbitone H y p n o s i s  time
36 male V/istar albino rats weighing 210-^ -00 g. were randomly 
allotted to one of six treatment groups and each group was housed in a 
separate cage. Groups 1 and 2 were injected intraperitoneally with the 
vehicle ethyl oleate at a dose level of 2 ml ./kg. of body weight on each 
of three successive days. Groups 3 and A- were injected similarly with 
enoxolone suspended in the vehicle at dose levels of 10 mg ./kg. and 
20 mg./kg. respectively. Groups 5 and 6 were injected with carbenoxolone 
also at the dose levels of 10 mg./kg. and 20 mg./kg. respectively.
Enoxolone and carbenoxolone were suspended in the vehicle such that all 
treatment groups received the same dosage of ethyl oleate. On the 
fourth day, 2.k hours after the last injection each rat was injected 
intraperitoneally with a freshly prepared solution of hexobarbitone 
sodium (200 mg./kg.) in water for injection and the length of time after 
injection required for the rat to regain its righting reflex measured 
(hexobarbitone sleeping time). A rat was considered to have regained its 
righting reflex when it could right itself each time after being turned 
onto its back three times consecutively. A second similar experiment was 
performed using 12 female V/istar albino rats and the test group of six 
rats were pretreated with carbenoxolone (20 mg./kg.) in propylene glycol 
and the control group received the vehicle. For this experiment the dose 
level of hexobarbitone was 100 mg./kg. because the duration of action of 
hexobarbitone is much longer in adult female rats than in adult male rats 
(Quinn, Axelrod & Brodie, 1958).
Biliary cannulation of the ra.t
The rat was anaesthetised with urethane (0ol8 g/kg; subcutaneously) 
and after shaving a suitable area on the rats ventral surface a vertical 
midline incision was made and the common bile duct cannulated with a 
polythene cannula (internal diameter « 0 .^- mm., external diameter = 0 .8 mm.). 
The cannula was exteriorised through an incision in the abdominal wall 
and bile collected in graduated tubes (5 ml.) cooled in an ice-water mixture.
These cannulated rats were subsequently used for experiments
3
on the biliary excretion of H-cortisol. For each series of cannulation
experiments an appropriate volume of an ethanol-benzcne stock 
r 3 Isolution of [ H Jcortisol was evaporated to dryness under nitrogen*
r?)
the ['H Jcortisol was taken up into solution in a volume of. ethanol 
such that when the solution v/as made up with aq. 0.9% '*/v NaCl the 
final ethanol concentration was 2*5% V/v. Aliquots of bile. (0*2 ml) 
were counted in the fgel? scintillator as described in chapter two, 
section 2 (b)«
Collection of rat urine
The rat was maintained in a metabolism cage with a floor 
consisting of small diameter glass rods spaced approximately 1, cm 
apart* Underneath this floor a glass collecting vessel was placed 
to allow the separate collection of urine and faeces* Water was 
given ad* lib0 and food v/as given in small amounts as required- to 
avoid contamination of the urine with gross amounts of uneaten food*
Control, rats were pretreated for 4 days with the vehicle and 
test rats with carbenoxolone (20 mg/kg) in propylene glycol*
T.
Approximately 2k hours-following the last dose of drug, [ HJcortisol 
solution was injected intraperitoneally and the biliary or urinary 
excretion of tritium measured.
Statistical evaluation
Where appropriate results are expressed as the mean +_ standard 
error of the mean (S.E.M.)* Tests for statistical significance of the 
results were performed using the Student-t test or the Wilcoxoh Two- 
Sample Test (Laurence & Bacharach, 19^ +).
(c) 'Enzymatic Methods
Preparation of Rat Liver Subcellular Fractions
Rats were killed by a blow on the head at approximately the same 
time of day, i.e. 10 a.m. + 1 hour to minimise differences arising .
«t *
from diurnal variaton (Radzialowski & Bousquet, 1968). The livers were
rapidly removed, cut up, cooled in ice-cold 1.15$? potassium chloride
solution and then weighed. The liver was then homogenised with ice-cold
1.15$ WA  KOI using a glass -homogeniser fitted with a teflon pestle
(Potter & Elvehjem, 193&). The pestle was driven by a Black 8c Decker
electric drill at maximum velocity and three up and three down strokes
were used to homogenise each liverc The liver homogenate was diluted
with ice-cold 1.15$ W/v potassium chloride to 1 g. of liver per A ml.,
i.e. 1 ml. of the resulting homogenate contained the equivalent of
230 mg. of fresh weight liver. It v/as fractionated by using standard
omethods by centrifuging in 50 ml. plastic centrifuge tubes at 0 -5 C to 
give a '10,000 g« supernatant' (10,000 x g. for 10 min., M.S.E. ’High 
Speed 18’ refrigerated centrifuge). The '10,000 g. supernatant' was 
carefully decanted and used in the enzyme assays.
A 'microsomal suspension' was prepared by centrifuging an 
aliquot of the 10,000 g. supernatant at 105,000 g. av. for 1 hr. in a 
10 x 10 ml. angle head using an M.S.E. 'Superspeed 50' refrigerated 
centrifuge at 0-5°C. The supernatant fraction ('soluble fraction') v/as 
carefully decanted, the pellet was carefully rinsed with a few drops of 
ice-cold 1.155^  KOI to remove residual supernatant fraction and resuspended 
in the original volume of 1.15$ KOI by gentle homogenisation. This was
termed the ’microsomal suspension1. The homogenates were kept cool at
i,,
all times in ice-water during the foregoing procedures.
Aromatic hydroxylation: biphenyl-^ --hydroxylase
The assay procedure for rat liver was that of Creaven, Parke & 
Williams (19&5) as modified by Franklin (1969) and Neale (1970) for 
rat liver microsomal preparations.
The incubation mixtures for the in vitro determination of 
biphenyl-A-hydroxylase activity were as follows
Blank Standard Test
i) 0.05M Tris buffer (pH 8.1) 0 .50 ml 0.50 ml. 0 .50 ml
ii) Mg Cl^  soln. (10 nmoles) 0 .20 0.20 0 .20
iii) Biphenyl soln. (3 p-moles) f ^‘^5% 0.25* 0.25* 0.25
I KC1iv) NADP soln. (1.5 limoles) J 0.00 0 .00 0.25
v) 1.15# KC1 0.55 0.55 0.30
vi) 23% W/v liver homogenate
(10,000 g. supernatant) 0.50 0.50 0.50
vii) A-hydroxybiphenyl soln. • 0.00 1.00** 0 .00
2 .00 ml. 3-00 ml. 2 .00 ml
* The substrate solution was added after the incubation had been carried
out.
** The standard A-hydroxybiphenyl solution was added.after the incubation 
had been carried out. •
The incubation procedure was carried out in open 20 ml. 
ground-glass stoppered tubes shaken for 20 min. at 37°C in a Mickle 
Shaking Incubator. To terminate the reaction the tubes were placed in 
an ice water mixture and 2N-HC1 (0.5 ml.) added to each tube. The 
biphenyl substrate solution and ^ f-hydroxybiphenyl solution were then 
added to the blank and standard tubes as required. The contents of 
each tube was then extracted with n~heptane (10 ml.) by mechanical' shakin 
of the stoppered tubes for 5 min. The tubes were centrifuged at
2,000 rev./min. for 15 min. (M.S.E. ’Magnum’ refrigerated centrifuge, 
head no. 69167) and a portion (2 ml.) of the heptane layer in each tube 
was shaken for 5 min. in similar tubes with O.IN-NaOH (10 ml.) made up 
in all-glass distilled water. The mixture v/as then centrifuged as 
before for 10 min. The fluorescence intensity of the lower alkaline 
layer (3-^  ml.) in quartz cuvettes (1 cm. light path) v/as then determined 
at A00 nm with excitation at 311 rm using a Baird Atomic Fluorescence 
Spectrophotometer Model SF1. Estimations were performed in triplicate.
Conjugation: A-methylumbelliferone_glucuronyl transferase
The method used v/as developed by Neale (1970) from that 
described by Arias, et al., (1958).
The first incubation mixture was as follows:-
Volume
viii) Tris-HCl buffer (0.1M; pH = 7-6) 0.3 ml.
ix) A-Methylurnbelliferone, 0.6 p,moles (in) 0.3 ml.
x) UDPGA 3 ixmoles (in) 0.2 ml.
xi) Liver homogenate (1 g./80 ml.) 0.2 ml.
1.0 ml.
The MO,000 g. supernatant1 obtained by the method outlined
above (in section (c)) v/as diluted 1:20 with ice-cold 1.15# KC1 for
use in this assay. The incubation procedure was carried out in open
20 ml. ground-glass stoppered tubes for 30 min. at 37°C. using a Mickle
Shaking Incubator. To stop the reaction the tubes were placed in
ice-cold water and then ice-cold water (2.0 ml.) was added followed by
chloroform (10 ml.). The tubes were then shaken for 10 min. in a
✓
mechanical shaker when the chloroform denatured the protein and removed 
unconjugated A-methylumbelliferone. The tubes were centrifuged at 
2,000 rev./min. for 10 min. (M.S.E. 'Magnum1 refrigerated centrifuge, 
head no. 69167) at room temperature. The aqueous layer was then shaken 
a second time with chloroform (10 ml.) and re-centrifuged as before. 
Aliquots (0.5 ml.) of the aqueous layer from each tube were incubated in 
10 ml. glass test tubes for 30 min. at 37°0 using the shaking incubator. 
This second incubation mixture v/as:-
Volume
xii) Acetate buffer (0.1M; pH=A.6) • 1.0 ml.
xiii) P-glucuronidase; 500 units 0.5 ml*
xiv) Aqueous layer 0.5 ml.
2.0 ml.
Similar, aliquots were carried through the same procedure 
without p-glucuronidase* After incubation the tubes were placed in 
ice-cold water and 0,5M glycine buffer (5 ml; pH - 10©*f) v/as added
to each tube. The fluorescence intensity was then measured in
2 r 
quartz cuvettes (1 cm ) at k^O nm with excitation at 3&5 nm using
a Baird Atomic Fluorescence Spectrophotometer (Model SF1) • A.
standard curve for the fluorescence of A-rnethylumbel.life.rone.
(fig, IV.-2) under the same conditions v/as produced by measuring- the.
fluorescence:- of 0«001~0,0f moles dissolved in acetate buffer-
(2,0 ml) and diluted with glycine buffer (3-0 ml.). The. wavelengths-
were instrumental values and uncorrected.
The increase in fluorescence following incubation with 
P-glucuronidase; was considered to. indicate the amount of 
4-methylumbclliferone that was conjugated with' glucuronic acid in 
the first incubation.
Blanks, consisting of substrate added after the first incubation 
and standards of A - rn e t h y 1 u mb ell :L f e r o n e and A-me t hylumb e 111 f e r one 
glucuronide were, run through the same procedure. Be terminations 
were carried out in triplicate.
Cytochrome P-A^O Determination
The. cytochrome P-hffjO content of the rat liver- ’microsomal 
fraction’ was determined by a method similar to that of Sladek & 
Mannering (1966). The ’10,000 g supernatant1 (7*0 ml.) v/a„s 
centrifuged in an M,i5,2S* ’Superspeed refrigerated centrifuge 
as described in (c) above to obtain the 'microsomal suspension'*
Microsomal suspension (6.0 ml:
1.0 ml. was retained for protein estimation) v/as pipetted into a conical 
flask and 0.2M phosphate buffer (12.0 ml; pH = 7-^ ) was added and mixed. 
Sodium dithionite (a few mg.) was then added and allowed to dissolve. 
Duplicate aliquots (3 ml.) v/ere taken'in silica cuvettes (1 cm. light path) 
and carbon monoxide or coal gas v/as bubbled through the suspension in 
one cuvette (the sample) for 30 seconds. The second, ungassed cell, 
was used as the reference. The difference spectrum betv/een 380 and 
330 nm. v/as then measured in a Pye Unicam SP800 dual beam spectrophotometer, 
using the gas treated sample as the test and the untreated as reference.
The difference in absorption between ^ 30 um. and--A90 nm. v/as used as 
the estimate of cytochrome P-A30. A typical trace is shown in F i g . 3 •
No difference was detected between the spectrum produced using either 
coal gas or carbon monoxide.
Protein estimation
Protein concentrations were determined by the method of 
Lowry, et al., (193*1 )• With the 10,000 g. supernatant an aliquot 
(0.2 ml.) was diluted to 10 ml. v/ith distilled water, while with the 
microsomal suspension 0.3 ml. was diluted to 10 ml. The diluted solution 
(1.0 ml.) was then taken for protein determinations. Four reagents v/ere 
used:-
A) 2.0# WA  Na2 CO^  in 0.1N. NaOH.
B) 2.0# W/v WaK tartrate.
C) 1.0# WA  Cu SO^ . 3H20. •
D) Folin & Ciocalteu's reagent.
1,0 ml each of B and C v/ere mixed just before use with 100 ml 
of A, and 10 ml of this mixture was added to 1.0 ml of the diluted 
protein solution, mixed and allowed to stand for 13 min. Folin & 
Ciocalteu’s reagent (0.3 ml) was then added and the solutions mixed 
immediately and after ^0 min. the optical, density at 730 nm was 
measured in a silica cell (l cm light path) using a: Pye-Unicam SPpOO 
series 2 spectrophotometer. The -blank v/as distilled water and 
standards: (1,0 ml) of bovine serum albumin (B.S,A.) containing 
30-300 p, g of BSA were used. The., standard curve for BSA is shown 
in fig., IV-1,
3(d) Protein Binding of [ HJCortisol in Human Plasma
3
The effect of carbenoxolone on the binding of [ Kjcortisol in
human plasma- at 20° v/as studied by ultrafiltration. Human plasma
(3 ml) v/as diluted v/ith 3 rnl 0.1 M Tris buffer (pH 7*^) containing
carbenoxolone (10-^0 pg/ml) end trace amounts (325?000 d..p.m, -
373*9 n,mo3.s) of ["10 cortisol (2-000 mCi/m.mol). The mixture v/as 
allowed to equilibrate, for 1 hour at 20° and then ultrafiltration 
v/as carried out as described, in chapter two. The endogenous 
11-hydroxysteroid, concentration of the human plasma, used was 
measured by Mattingly’s (19&2) method and found to be 1A ; g/100 ml, 
i.e. within the normal range. The % of unbound [yHlcortisol v/as. 
calculated from:
„/ , , d©p.m./ml filtrate.% unbound = -A V-r-— -^-------x 100,d.p.m./ml plasma
Fig.IV-1. Standard Curve for Protein Determinations
Protein: bovine serum albumin (crystalline)
0.7
0.6
0.5
0.1
0.30.20.1
Albumin concentration (mg/ml.)
Fig.IV-2. Standard Curve for the Fluorescence of 4-Methylumbelliferone
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4-0 Discussion and Conclusions
The influence of carbenoxolone pretreatment on the activities; 
of drug-metabolising enzymes has been investigated both by ini vitro 
enzyme measurements and by measurement of hexobarbitone hypnosis, 
time in vivo. Certain steroid hormones may share, common metabolic 
pathways with drugs (Conney, 19&-7; Conney, et al, 1968; Jacobson 8c 
Kuntzman, 19&9; Kato, et al, 1968; Tephly & Mannering, 1968;
Wada, ejt aIS: 1968). In view of this and of the steroid-lille actions 
of carbenoxolone the effect of carbenoxolone on the in vivo excretion 
of 8. typical, endogenous steroid has been studied* The results of 
these investigations are discussed here®
Carbenoxolone and Drug Metabolism
The effect of carbenoxolone pretreatment on the. body-weight 
of rats is shown in table lY-l, and as can be seen, three days 
pre treatment caused a slight decrease in weight ga.in while after 
14- days oral treatment the treated group had gained slightly more 
weight* The body weight changes were not statistically significant* 
The slightly greater gain in body weight in rats pretreated orally 
for 14- days may represent an antidiuretic effect with retention of 
water and sodium since this has been observed in rats receiving 
carbenoxolone (Khan 8c Sullivan, 1968).
Table IV-2 shows that carbenoxolone treatment results in no 
change in the liver weights of rats either on an absolute basis 
or v/hen expressed, as a percentage of body weight. The microsomal
protein content was higher in groups of older rats but no significant 
effects of carbenoxolone were apparent (table IV-3)* With many 
other drugs an increase in liver weight is accompanied by an 
increase in the microsomal drug-metabolising enzymes (Conney, 196?) 
however some compounds increase liver growth without enhancing • 
liver microsomal enzyme activity (Conney, 19o7)c Conversely-liver- 
microsomal enzyme activity can increase without concomitant 
increase in liver weight (Platt 8c Cockrill, 19b9)«- The significance. 
of. changes in liver size, protein content and enzyme activity 
following pretreatment with drugs and hormones is however- still 
obscure*
The effect of carbenoxolone pretreatment in vivo on the ability 
of rat liver 10 ,000 x g supernatant to carry out aromatic 
hydroxylation was investigated using biphenyl as a model substrate. 
The results in table IV-4- show that carbenoxolone pretreatment had 
no appreciable effect on biphenyl-4—hydroxylase, activity* In one 
experiment only, after 3 days pretreatment, a increase in
biphenyl-4—hydroxylase activity-was observed but this was not 
repeatable* Leibman (1971) has. found a. weak inhibitory effect of 
glycyrrhetic acid on the hepatic microsomal hydroxylation of aniline 
and acetanilide and the dernethylation of aminopyrine when added 
in vitro to the incubation mixture. No significant effect on these 
enzyme activities was found after pretreatment of rats with 
glycyrrhetic acid (Dr* K.C. Leibman, personal communication).
The influence of carbenoxolone pretreatment on the glucuronyl 
transferase activity of the diluted 10 ,000 x g rat liver supernatant, 
using 4—methylurabelliferone as substrate., is shown in table IV-5* 
Carbenoxolone caused a consistent slight increase in glucuronyl 
transferase activity, which however was not statistically significant. 
Since, carbenoxolone is metabolised by glucuronide conjugation it 
might have been expected that the drug would have, enhanced the 
activity- of this enzyme. In summary, carbenoxolone pretreatment 
had no significant stimulatory effect on the liver drug metabolising 
enzymes. This is surprising as> carbenoxolone has surfactant 
properties and substances of this nature, e.g. Triton X-100 are 
known to act on microsomal membranes activating the microsomal 
enzymes, includiiig glucuronyl transferase when added in vitro
v
(Mulder, 1970).
The role of the microsomal carbon monoxide binding pigment 
cytochrome P-450 in the oxidative metabolism of both drugs and 
endogenous compounds such as steroid hormones was, discussed in the 
introduction to this chapter. The effect of carbenoxolone 
pre treatment on the cytochrome P-4-50. content of rat liver microso.mes 
is shown in table 1V-6. There was no statistically significant 
difference under- the various conditions of pretreatment. Also, 
as can be seen from the representative spectra (fig. IV-3)j 
carbenoxolone pretreatment had no detectable effect on the carbon 
monoxide difference spectrum of reduced cytochrome P-4-pO.
The liexobarbitone hypnosis times of male and female rats 
pretreated with cither enoxolone or- carbenoxolone were, measured 
(tables IV- 7  and. X.V-8 )* Neither compound had a. statistically 
significant effect 011 the duration of hypnosis. These in vivo 
experiments support the. results from the in vitro enzyme 
measurements showing that carbenoxolone has no effect on drug.; 
hydroxylation or on glucuronide. conjugation.
The properties which a compound should possess in order* for it 
to- be a potent inducer of drug-metabolising enzymes; are not fully 
understood- but several suggestions have been made. Remmer (1969) 
has- put forward three, requirements for compounds inducing 
hydroxylation; i) high lipid solubility; ii) high concentration in 
liver and iii) long duration of action. Prescott (19&9) has made 
three., somewhat similar suggestions indicating that as a general 
rule a. compound may induce, if it is (i) very lipid soluble at 
physiological pH; (ii) not normally rapidly metabolised (i.e. 
probably, has.a long duration of action) and (iii) moderately to 
strongly bound to plasma proteins. Carbenoxolone complies with 
certain of these suggestions, it is highly plasma protein bound, 
reaches a fair concentration in the liver and the unionised moiety 
is highly lipid soluble. However carbenoxolone does hot meet the, 
requirement of being slowly metabolised and as Remmer (19&9) has; 
pointed out the most efficient inducers such as phenobarbitone and 
D.D.T. are slowly metabolised. The fact that carbenoxolone is not. 
a significant inducer of hepatic drug-metabolising enzymes can be 
considered indirect evidence that the drug itself does not undergo
any form of hydroxylation in the liver and this is in agreement
with, the metabolism studies.
The fact that carbenoxolone does not appear to cause* 
significant induction or inhibition is important from the 
toxic-ological and- therapeutic'; viewpoint. Any drug which influences* 
the activity of the microsomal enzymes is a potential cause of drug 
interactions•(Prescott, 19&9) and the experimental results reported 
here indicate that carbenoxolone is unlikely to be a cause; of drug 
interactions arising from altered hepatic metabolism* Since, 
carbenoxolone does not inhibit glucuronyl transferase., inhibition 
of bilirubin conjugation, jaundice and consequent liver damage are; 
unlikely* This;appears to. be the situation in patients treated with 
carbenoxolone since no increased incidence of liver disease has been 
attributed to use of the drug. If it is the case that drugs and 
endogenous steroid hormones share coram on metabolic pathways it seems 
unlikely that carbenoxolone exerts its steroid-like actions through 
an affect on the metabolic pathways in the liver* Since the anti- 
inf3„ammato.ry activity of carbenoxolone is at least partially 
dependent upon the presence .of intact adrenals it would seem that 
carbenoxolone exerts some of its actions through an effect on 
corticosteroids* '
3Carbenoxolone and [ H] Cortisol Excretion
The effect of carbenoxolone on the metabolism of steroids was; 
investigated by measuring the biliary and urinary excretion of 
radioactivity after intraperitcneal administration of trace amounts 
of [ H jcortisol to rats: pretreated-with carbenoxolone for 4 days*
3It was hoped'1 that the use of [ H Cortisol in trace amounts would 
reveal any action of carbenoxolone on steroid-metabolising enzymes, 
particularly those in extrahepatic tissues*
3The rate of excretion of [ H.jcortisol and its metabolites in 
the bile is shown in table IV- 9  for male rats and in table IV-10 
for female rats* The cumulative excretion of radioac.tivity for male 
and female rats is given in table IV-1T* Carbenoxolone pretreatment 
caused an increase in the mean rate of excretion of total 
radioactivity which v/as most marked at two hours in male, rats and 
at three hours in female rats, however these increases were not 
significant* There was considerable variability in the results but 
the* reasons for this wore not determined* Liver function can be 
depressed after surgery and other forms of stress and a relatively 
small, effect of carbenoxolone 011 the biliary excretion of cortisol 
may therefore have been obscured by the operative procedure0 A 
barbiturate anaesthetic was not used since an acute dose inhibits 
microsomal enzymes*
The urinary excretion of radioactivity after injection ox
3[ HJcortisol is given in table IV-12 for male rats and table VI-13 
for female rats* Radioactivity v/as excreted more rapidly in the 
urine of carbenoxolone treated rats of both sexes but the differences 
were not significantly different*
Thus carbenoxolone does not have a significant influence on 
the excretion of cortisol and its metabolites in the urine and bile 
although there was a tendency to increased excretion in both urine
and bile* There is considerable evidence to suggest that 
carbenoxolone either possesses intrinsic steroid-like biological 
activity or that it produces this activity by some secondary effect* 
It has been found that six days intraperitoneal administration of 
glycyrrhetic acid to rats caused a lowering of plasma corticosterone 
when measured on the seventh day, but had no effect on the mean 
adrenal weight (Gupta, Gupta, Tangri & Bhargava,. 1969)0 This is in 
contrast to the observation that an acute rise in the 'plasma.
1T-hydroxycorticoid concentration occurred in duodenal ulcer patient 
between 20 and 60 minutes after receiving a. single dose of. 
carbenoxolone (Mattingly, Tyler & Biiton, 1970)* It was suggested, 
that carbenoxolone increased endogenous steroid production by a 
direct action on the adrenal cortex, since no such .rise in 
11-hydroxycorticoids v/as seen in patients.suffering from adrenal 
insufficiency (Mattingly, ert al, 1970)* One explanation for the 
findings in the rat is that after six days pretreatment a negative 
feedback mechanism operated to reduce the plasma corticosterone 
concentration* There would be insufficient time for this to occur 
in the patients and so it is possible that carbenoxolone, during 
the process, of absorption, displaced steroids from binding sites:, 
in the gastrointestinal mucosa into the blood stream.
Carbenoxolone and the Binding of [~K]Cortisol.
The possibility that carbenoxolone may have an effect on the
plasma protein binding of cortisol v/as investigated, by measuring
3the percentage binding of trace amounts of [II] cortisol in human 
pla sma. The results (table IV-l^ f) indicated that carbenoxolone at 
therapeutic plasma concentrations and slightly above had no
appreciable effect on the binding of ['I I ]cortisol* It is therefore 
unlikely that the anti-inflammatory activity of c3.rbenoxolone is 
mediated through a displacement effect on plasma cortisol*
The results of the experiments in this chapter were, somewhat 
surprising in that no significant changes in steroid ?L.evels or 
drug-metabolising enzyme activity were brought about by carbenoxo3.ones 
However, certain trends were observed and an effect of carbenoxolone 
on steroid metabolism, particularly in extrahepatic tissues, cannot 
be completely excluded*. In a negative sense the lack of influence:' 
of carbenoxolone. on hepatic microsomal enzymes can be a useful 
feature of a drug since a number, of undesirable drug interactions 
are knovm to result from changes in hepatic microsomal enzyme activity 
The findings are in agreement with those of Lee., Parke 8: Whitehouse. 
(1965) who showed that, intraduodenal infusion of sodium glycyrrhetatc. 
had no significant in vivo effect on the excretion of [ H]cholesterol. 
and its metabolites in the bile of rats. Carbenoxolone did not 
displace cortisol, and. so it appears that it is one of a group of 
drugs, discussed earlier, which do not appear to exert anti­
inflammatory activity through displacement of endogenous 
corticosteroids. Carbenoxolone, unlike certain other anti­
inflammatory and uricosuric drugs has been shown to have no 
displacement effect on the binding of urate to human serum albumin 
(Bluestone, Kippcn, Klincnberg & Y/hitehouse, 1970)*
/
Five possible ways in v/hich carbenoxolone could interact with 
hormones were considered at the beginning of this chapter and in 
the light of the present findings, two of these seem unlikely,
namely that carbenoxolone has no effect on metabolic deactivation 
in the liiver or on plasma binding of corticosteroids. Carbenoxolone 
probably possesses a certain degree of intrinsic mineralocorticoid 
activity and it may potentiate the action of mineralocorticoid 
hormones at receptor sites by an allosterie-liko. effect, since the 
drug has the ability to affect protein conformation.
CHAPTER FIVE
■j
This last chapter is a brief review of the main experimental 
findings together with a final discussion.
Absorption and Metabolism of Carbenoxolone in Man
*'1 A
Experiments with [ Clsuccinate in man formed a necessary
preliminary to the investigation of [ C]- and [ li]carbenoxolone
1Zf
metabolism in man since the [ C] radioactive: label v/as in the.
1 f^succinate side chain. It has been shown that [ C]succinate is 
rapidly metabolised in man after oral administration and that the
14radioactive label as excreted almost completely as respiratory OO^ ,*
Previous workers have shown that C C Jsuccinate v/as rapidly and
"1almost completely excreted as CO^ in the rat (Gould, et al, 19-9)^
If.
The experiments with [ C]succinate established that any hydrolysis
1 h- 'ih-of [ CJcarbenoxolone in man to release [ CJsuccinate would be
Zj. ' j Zj.
revealed by rapid excretion of respiratory ^ 2*  ^ C]Carbenoxolone
v/as-known to be rapidly and extensively hydrolysed to enoxolone
1 1and [ C]succinate after administration to rats, the [ C] succinate:
1 -^then being rapidly metabolised to respiratory CO^*
pf] f J- _3 -iOral, administration of L CJ LHJcarbenoxolone to human
volunteers established that in man extensive hydrolysis, of the drug
/ 1^ 1 did not occur with the result that less than 10/o of the dose of C
"1 A-v/as excreted as respiratory CO^ in days. Measurement of plasma 
concentrations of radioactivity revealed that at leas/t $0% of the 
drug had been absorbed. Most of the administered radioactivity 
was recovered in the faeces with very little being excreted in the 
urine (<0.1/o in 8 hours). In view of the extensive absorption of
the drug it v/as concluded that carbenoxolone and its conjugates
-i
were excreted in the bile as shown by Downer, et al, (1970) iu 
patients with biliary drainage T-tubes* Over &0% of the radioactivity 
in the faeces was present as carbenoxolone with the remainder
_ 1 4 - -rpresent as carbenoxolone-30-glucuronidee The fate, of [ CJ- and
3 • •'[ H]carbenoxolone in human subjects is summarised in table 11-13*
1 if
The absorption of [ Cj carbenoxolone v/as studied in duodenal 
ulcer patients a£ter administration in a novel positioned-release- 
capsule and found to be readily absorbed.* The preparation was 
designed to release the drug in the region of the pyloric 
sphincter so that quantities sufficient to exert a therapeutic action 
on duodenal ulcers would reach the small intestinec It seems likely 
that this did occur in two; of the patients and clinical trials are. 
still in progress^ to test the efficacy of this-preparation.
Since the drug is readily absorbed when administered in capsule 
form, side-effects similar to those observed with tablets may occur, 
and so physicians should be alert for mineralocorticoid side-effects 
in older duodenal, ulcer patients*.
Comparative Metabolism of Carbenoxolone. . •
1The metabolic fate of l C ]carbenoxolone in intact and 
biliary-cannulated squirrel monkeys has been investigated (see 
table II-l6and table. 11-19) &ud the overall, pattern of metabolism 
found to be very similar to that in man. Very little hydrolysis 
of the drug occurred after administration to squirrel monkeys and 
the drug v/as excreted in the bile as carbenoxolone-30-glucuronide
with possible traces of a diglucuronide. The reason for the 
difference in metabolism between primates and the rat was; 
investigated* Experiments with rats pretreated with antibacterial 
compounds ini vivo and' also jln vitro incubation experiments have 
established that the gut microflora of the rat are responsible for-- 
hydrolysis, of carbenoxolone and the resultant species difference* 
Because; of the species difference the rat is therefore an 
unsuitable animal for investigating the biological actions of 
carbenoxolone and it.is suggested that the squirrel, monkey, when 
available, may be a more suitable laboratory species*
One aspect of the excretion of the drug common to man, 
monkey and rat was. the very small percentage of the dose excreted 
in the -urine. In view of the high affinity of carbenoxolone for * 
plasma proteins and its high molecular weight it seems likely that 
extensive biliary excretion-would occur in all common laboratory 
species. •
Enteroliepatic circulation of the drug occurs in man 
(Downer, ejb al, 1970) and the small amounts of carbenoxolone still 
I>resent in the plasma of intact squirrel monkeys four days after­
oral dosing was indicative of re-circulation in the squirrel monkey 
also. This enterohepatic circulation has; several consequences, for. 
the therapeutic use of the drug. It provides an opportunity for 
accumulation of the drug to occur, possibly resulting in side-effects, 
and this would be exacerbated in older patients with reduced gut 
motility. The formation of hydroxylated metabolites of carbenoxolone
as a result of bacterial metabolism may be responsible for the 
adverse: side-effects, and although no: such metabolites, have been 
detected, prolonged exposure of gastrointestinal micro-organisms 
to-the drug may result in induction of bacterial hydroxylases* 
Microbial oxidation of glycyrrhetic acid to 7 P~hyd.roxyglyc2frrhetic 
acid and the 3-keto derivative has> been observed (J.M. de Bueren- 
Pelizzoni. & Francesca, 1970) hut the organism v/as not a normal 
inhabitant of the gastrointestinal tract*
Plasma Protein Binding of Carbenoxolone.
The experiments in chapter three have provided answers to;
some of the questions originally proposed by Scatchard (19V9) and
reiterated in the introduction to that chapter. Human plasma
albumin has tv/o primary high affinity binding sites for carbenoxolon
n
with an apparent association constant greater than 10 l/mol.e, and 
a second, class of four sites v/ith an apparent association constant 
of 10^ l/mole. The nature of the binding site on albumin was not 
elucidated but it is at least partially hydrophobic, in character 
and. tryptophan and tyrosine may be involved . In whole plasma, 
carbenoxolone was found to be bound principally to albumin, but 
binding to: the globulin proteins also occurred. Ansvrers; have, 
therefore been provided to. the questions: How many binding sites? 
How tightly bound? and to what proteins is the drug bound? The 
question ‘Why? 1 can be answered only in terms of the attractive fore 
responsible, namely ionic bonds, hydrogen bonds, hydrophobic bonds, 
and in addition van der V/aql’s forces. The consequences of the 
protein binding of carbenoxolone (i.e. the answer to ’V/hat of it?1)
are several absorption of the drug is probably facilitated, 
distribution is limited largely to the plasma, liver and 
gastrointestinal tract, and urinary excretion of the drug is 
strictly limited. The protein binding probably, also serves, to limit 
the toxic potential of the drug to haemolyse. erythrocytes, uncouple 
oxidative phosphorylation and exert any intrinsic, mineralocorticoid. 
effects.
The plasma protein binding studies have another consequence; 
in that they offer an explanation for the occurrence of side efficts 
in certain patients, particularly the elderly. Since it is highly 
bound, carbenoxolone is probably one of a group of drugs which 
have ax critically narrow therapeutic, dose 3?snge in certain patients, 
particularly the elderly. If this; dose range is exceeded then a . 
large increase in unbound drug occurs. Several, conditions, acting 
singly, or together, may cause; an increase, in unbound drug concentration 
lowered plasma, protein concentration, impaired conjugation and 
excretion by the liver causing accumulation, with enterohepatic 
circulation and reduced gut motility also contributing to. 
accumulation. It is significant that these conditions are most 
likely to. prevail collectively in the elderly. The hypothesis 
advanced here is supported by the recent report of Lewis, jet al,
(1971) which attributed the side effects of prednisone to lowered 
plasma protein levels, and hence an increase in unbound drug, in 
the patients concerned. The ability of carbenoxolone to cause 
conformational changes in albumin and its previously shown in vitro 
ability to uncouple oxidative phosphorylation supports the 
hypothesis of Weinbach 8c Garbus (19&9) that uncouplers act through
evoking a.cohformational change in mitochondrial proteins* The 
liver distribution study revealed that carbenoxolone does have the. 
potential to interact with mitochondria, but perhaps more 
significantly this investigation indicated the likelihood that 
carbenoxolone is bound by the anion binding proteins described by 
Levi, et. al, (1969)* During absorption carbenoxolone may interact 
with mucoproteins, producing a conformational change and thereby- 
improving their protective qualities* The distribution of
r-1^-L CJ carbenoxolone v/as studied, by autoradiography and found to oe 
limited to the liver, gastrointestinal tract and plasma. The
S\ Zj.
[ C]carbenoxolone used was of too low a specific activity (51 pCi/m
1^-mol.) for satisfactory results and since synthesis of C-l&belled, 
material of sufficiently high specific activity is difficult it 
is suggested that [ *yHJoarbenoxolone (5-10 Gi/m.mol) should be used 
for future studios.
Carbenoxolone and Metabolism of Drugs and Steroids
Carbenoxolone did. not have a significant effect on various 
factors involved in the hepatic microsomal metabolism of drugs: and 
steroid hormones and from the therapeutic point of view this is 
probably advantageous. Carbenoxolone also had no effect on the 
biliary and urinary excretion of cortisol in the rat and it is also 
unlikely that the anti-inflammatory action of carbenoxolone is 
mediated through displacement of cortisol from its plasma proteiii 
binding sites.
A. large number of questions remain unanswered and so finally
a few suggestions for future lines of inquiry will be made* An
investigation into the possibility of interaction between
carbenoxolonc and the mine.ralocorticoids should give an indication
of the reason for these side effectSe Measurement of the plasma
protein concentration and liver function of patients may establish
vdiether these- are correlated in any way with the incidence of side.
effects*- If there is such a. relationship, then measurement of
these, two parameters may serve to identify patients at risk from
sodium and. water:- retention an&. hypokalemia* The dose:, of drug
could then be adjusted to; a suitable regimen or alternative therapy
instituted* An investigation of the effect of carbencxolone on
gastrointestinal mucus should be carried out to determine any
3quantitative, or qualitative changes* The use of [ EQcarbenoxolone. 
of high specific radioactivity, would enable the intracellular 
distribution to, be investigated by techniques such as micro­
autoradiography. These, investigations, may give- ah insight into the 
mode'Of action of carbenoxolone and enable the design of improved 
anti-ulcer drugs*
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